

0001437749-25-00375210-Q cbdMD, Inc. 2025021320250213160547160548160548 0 0001437749-25-003752 10-Q 73 20241231 20250213 20250213 cbdMD, Inc. 0001644903 2844 473414576 NC 0930 10-Q 34 001-38299 256201813 8845 RED OAK BOULEVARD CHARLOTTE NC 28217 704-445-3060 8845 RED OAK BOULEVARD CHARLOTTE NC 28217 Level Brands, Inc. 20170202 LEVEL BEAUTY GROUP, INC. 201506111 10-Q 1 ycbd20241231 10q.htm FORM 10-Q ycbd20241231 10q.htm 0001644903 cbdMD, Inc. false --09-30 Q1 2025 50,000,000 50,000,000 0.001 0.001 5,000,000 5,000,000 5,000,000 5,000,000 150,000,000 150,000,000 0.001 0.001 5,543,124 5,543,124 3,939,057 3,939,057 5 3 0 8.0 5,000,000 5,000,000 5,000,000 5,543,124 3,939,057 719,911 185,223 0 0 false false false 00016449032024-10-012024-12-31 0001644903us-gaap:CommonStockMember2024-10-012024-12-31 0001644903ycbd:SeriesACumulativeConvertiblePreferredStockMember2024-10-012024-12-31 xbrli:shares 00016449032025-02-12 thunderdemo:item iso4217:USD 00016449032024-12-31 00016449032024-09-30 iso4217:USDXbrli:shares 00016449032023-10-012023-12-31 00016449032023-09-30 00016449032023-12-31 0001644903us-gaap:CommonStockMember2024-09-30 0001644903us-gaap:PreferredStockMember2024-09-30 0001644903us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-30 0001644903us-gaap:AdditionalPaidInCapitalMember2024-09-30 0001644903us-gaap:RetainedEarningsMember2024-09-30 0001644903us-gaap:CommonStockMember2024-10-012024-12-31 0001644903us-gaap:PreferredStockMember2024-10-012024-12-31 0001644903us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-31 0001644903us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-31 0001644903us-gaap:RetainedEarningsMember2024-10-012024-12-31 0001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-gaap:CommonStockMember2024-10-012024-12-31 0001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-gaap:PreferredStockMember2024-10-012024-12-31 0001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-31 0001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-31 0001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-gaap:RetainedEarningsMember2024-10-012024-12-31 0001644903ycbd:ConversionOfNotesIntoCommonStockMember2024-10-012024-12-31 0001644903us-gaap:CommonStockMemberycbd:GssAgreementMember2024-10-012024-12-31 0001644903us-gaap:PreferredStockMemberycbd:GssAgreementMember2024-10-012024-12-31 0001644903us-gaap:AccumulatedOtherComprehensiveIncomeMemberycbd:GssAgreementMember2024-10-012024-12-31 0001644903us-gaap:AdditionalPaidInCapitalMemberycbd:GssAgreementMember2024-10-012024-12-31 0001644903us-gaap:RetainedEarningsMemberycbd:GssAgreementMember2024-10-012024-12-31 0001644903ycbd:GssAgreementMember2024-10-012024-12-31 0001644903us-gaap:CommonStockMember2024-12-31 0001644903us-gaap:PreferredStockMember2024-12-31 0001644903us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31 0001644903us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001644903us-gaap:RetainedEarningsMember2024-12-31 0001644903us-gaap:CommonStockMember2023-09-30 0001644903us-gaap:PreferredStockMember2023-09-30 0001644903us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001644903us-gaap:RetainedEarningsMember2023-09-30 0001644903us-gaap:CommonStockMember2023-10-012023-12-31 0001644903us-gaap:PreferredStockMember2023-10-012023-12-31 0001644903us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-31 0001644903us-gaap:RetainedEarningsMember2023-10-012023-12-31 0001644903us-gaap:EmployeeStockOptionMemberus-gaap:CommonStockMember2023-10-012023-12-31 0001644903us-gaap:EmployeeStockOptionMemberus-gaap:PreferredStockMember2023-10-012023-12-31 0001644903us-gaap:EmployeeStockOptionMemberus-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-31 0001644903us-gaap:EmployeeStockOptionMemberus-gaap:RetainedEarningsMember2023-10-012023-12-31 0001644903us-gaap:EmployeeStockOptionMember2023-10-012023-12-31 0001644903us-gaap:EmployeeStockOptionMember2023-10-012023-12-31 0001644903us-gaap:CommonStockMember2023-12-31 0001644903us-gaap:PreferredStockMember2023-12-31 0001644903us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001644903us-gaap:RetainedEarningsMember2023-12-31 xbrli:pure 0001644903srt:MinimumMember2024-12-31 0001644903srt:MaximumMember2024-12-31 utr:Y 0001644903ycbd:ManufacturingEquipmentMember2024-12-31 0001644903ycbd:SoftwareMember2024-12-31 0001644903us-gaap:SalesChannelDirectlyToConsumerMember2024-10-012024-12-31 0001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMemberus-gaap:SalesChannelDirectlyToConsumerMember2024-10-012024-12-31 0001644903us-gaap:SalesChannelDirectlyToConsumerMember2023-10-012023-12-31 0001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMemberus-gaap:SalesChannelDirectlyToConsumerMember2023-10-012023-12-31 0001644903us-gaap:SalesChannelThroughIntermediaryMember2024-10-012024-12-31 0001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMemberus-gaap:SalesChannelThroughIntermediaryMember2024-10-012024-12-31 0001644903us-gaap:SalesChannelThroughIntermediaryMember2023-10-012023-12-31 0001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMemberus-gaap:SalesChannelThroughIntermediaryMember2023-10-012023-12-31 0001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMember2024-10-012024-12-31 0001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMember2023-10-012023-12-31 0001644903us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-10-012024-12-31 0001644903ycbd:Investors8SeniorSecuredOriginalIssue20DiscountConvertiblePromissoryNoteMember2024-01-302024-01-30 0001644903ycbd:Investors8SeniorSecuredOriginalIssue20DiscountConvertiblePromissoryNoteMember2024-01-30 0001644903us-gaap:FairValueInputsLevel1Member2024-09-30 0001644903us-gaap:FairValueInputsLevel2Member2024-09-30 0001644903us-gaap:FairValueInputsLevel3Member2024-09-30 0001644903us-gaap:FairValueInputsLevel1Member2024-10-012024-12-31 0001644903us-gaap:FairValueInputsLevel2Member2024-10-012024-12-31 0001644903us-gaap:FairValueInputsLevel3Member2024-10-012024-12-31 0001644903us-gaap:FairValueInputsLevel1Member2024-12-31 0001644903us-gaap:FairValueInputsLevel2Member2024-12-31 0001644903us-gaap:FairValueInputsLevel3Member2024-12-31 0001644903ycbd:SteadyStateLlcMember2022-04-072022-04-07 0001644903ycbd:SteadyStateLlcMember2022-04-07 0001644903ycbd:SteadyStateLlcMember2023-09-302023-09-30 0001644903ycbd:ComputersFurnitureAndEquipmentMember2024-12-31 0001644903ycbd:ComputersFurnitureAndEquipmentMember2024-09-30 0001644903ycbd:ManufacturingEquipmentMember2024-09-30 0001644903us-gaap:LeaseholdImprovementsMember2024-12-31 0001644903us-gaap:LeaseholdImprovementsMember2024-09-30 0001644903ycbd:TrademarkRelatedToCbdmdMember2024-12-31 0001644903ycbd:TrademarkRelatedToCbdmdMember2024-09-30 0001644903ycbd:TrademarkRelatedToHempMdMember2024-12-31 0001644903ycbd:TrademarkRelatedToHempMdMember

[illegible]

and their entire share of taxable income or loss is included in the tax return of the Company and as of March 15, 2021, Therapeutics is also a wholly owned subsidiary and is a disregarded entity for tax purposes and its entire share of taxable income or loss is included in the tax return of the Company. Â The Company accounts for income taxes pursuant to the provisions of the Accounting for Income Taxes topic of ASC 740 which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company uses the inside basis approach to determine deferred tax assets and liabilities associated with its investment in a consolidated pass-through entity. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. Â Concentrations

Â Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities. Â The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (â€œFDICâ€) covers \$250,000 for substantially all depository accounts. The Company from time to time may have amounts on deposit in excess of the insured limits. Â Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not have any customers that represented a significant amount of our sales for the three months ended December 31, 2024. Â Stock-Based Compensation Â The Company accounts for its stock compensation under the ASC 718-10-30,Â Compensation - Stock CompensationÂ using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or thatÂ mayÂ be settled by the issuance of those equity instruments. Â The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. The Company recognizes forfeitures when they occur. Â Earnings (Loss) Per Share Â The Company uses ASC 260-10, Earnings Per Share for calculating the basic and diluted lossÂ per share. The Company computes basic loss per share by dividing net loss and net loss attributable to common shareholders, after deducting preferred stock dividends, by the weighted average number of common shares outstanding. Common equivalent shares are excluded from the computation of net loss per share if their effect is anti-dilutive. Â Liquidity and Going Concern Considerations Â The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company experienced income of \$15,095 for the three months ended December 31, 2024, resulting in a working capital deficit of \$2,809,100 at December 31, 2024. Â 15 Table of Contents Â While the Company is taking strong action, believes in the viability of its strategyÂ andÂ path to profitability, and in its ability to raise additional funds, there can beÂ noÂ assurances to that effect.Â Â The Companyâ€™s working capital positionÂ mayÂ notÂ be sufficient to support the Companyâ€™s daily operations for theÂ twelveÂ months subsequent to the issuance of these annual financial statements.Â The Companyâ€™s ability to continue as a going concern is dependent upon its ability to improve profitability and the ability to acquire additional funding. These and other factors raise substantial doubt about the Companyâ€™s ability to continue as a going concern withinÂ twelveÂ months after the date that the annual financial statements are issued. These financial statements doÂ notÂ include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities thatÂ mayÂ result in the CompanyÂ notÂ being able to continue as a going concern. Â Convertible Notes Â Effective February 1, 2024, the Company entered into a Securities Purchase Agreement dated January 30, 2024 (the â€œPurchase Agreementâ€) with five institutional investors (the â€œInvestorsâ€) whereby the Investors advanced the Company an aggregate of \$1,250,000 gross proceeds and the Company issued each Investor an 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note, in the aggregate principal amount of \$1,541,666 (the â€œNotesâ€). The Company is using the proceeds from the issuance of the Notes for working capital and general corporate purposes. The table below represents the change in fair value of the convertible notes as of December 31, 2024. Â Â Â Â In Active Â Â Â Â Â Â Â Â Markets forÂ Â Significant OtherÂ Â SignificantÂ Â Â Â Â Identical AssetsÂ Â ObservableÂ Â UnobservableÂ Â Â Â Â and LiabilitiesÂ Â InputsÂ Â InputsÂ Â Â Â (Level 1)Â Â (Level 2)Â Â (Level 3)Â Â Balance at September 30, 2024Â Â Â - Â - Â 1,171,308Â Â Change in fair value of convertible notesÂ Â Â - Â - Â - Â - Â (809,287)Â Â Balance at December 31, 2024Â Â Â - Â - Â \$362,021Â Â Â New Accounting Standards Â The Company adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Measurement. This standard went into effect for fiscal years beginning after December 13, 2023Â This standard enhances segment reporting under Topic 280 by expanding the breadth and frequency of segment disclosures. The Company is currently evaluatingÂ the impacts of this standardÂ on the consolidated financial statements.Â Â NOTE 2 â€œMARKETABLE SECURITIES AND INVESTMENT OTHER SECURITIES Â The Company has, from time to time, entered into contracts where a portion of the consideration provided by the counterparty in exchange for the Companyâ€™s services was common stock, options or warrants (an equity position). In these situations, upon invoicing the customer for the stock or other instruments, the Company recorded the receivable as accounts receivable other, and used the value of the stock or other instrument upon invoicing to determine the value. In determining fair value of marketable securities and investment other securities, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in our assessment of fair value. The Company determines the fair value of marketable securities and investment other securities based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the fair value hierarchy distinguishes between observable and unobservable inputs. Â On April 7, 2022, CBD Industries, LLC entered into an asset sale agreement to sell substantially all its manufacturing assets to a subsidiary of Steady State, LLC (â€œSteady Stateâ€). The equipment sale is initially valued at approximately \$1.8 million for accounting purposes, the sale price consisting of products to be provided to the Company under the manufacturing and supply agreement and \$1.4 million of which the Company invested into Steady State in the form of an equity investment consistent with the terms of Steady State's completed series C financing. In September of 2023, the CompanyÂ impaired this investment by \$700,000. The Company has classified this investment as Level 3 for fair value measurement purposes as there are no observable inputs and has included it in non-current assets on the accompanying condensed consolidated balance sheets as the Company plans to holdÂ this investment. Â In valuing theÂ investments, the Company used the value paid, which was the price offered to all third-party investors. Â 16 Table of Contents Â Â NOTE 3 - INVENTORY Â Inventory at December 31, 2024 and September 30, 2024 consists of the following: Â Â Â Â December 31, Â Â Â September 30, Â Â Â 2024 Â Â 2024 Â Finished Goods Â \$1,302,911Â Â \$1,534,718Â Inventory Components Â \$851,002Â Â \$830,469Â Inventory Reserve Â \$ (37,777)Â Â Â - Â - Â Inventory prepaid Â \$356,819Â Â \$159,006Â Total Inventory Â \$2,472,955Â Â \$2,524,193Â Â Abnormal amounts of idle facility expense, freight, handling costs, scrap and wasted material (spillage) are expensed in the period they are in incurred and no material expenses related to these items occurred in the three months ended December 31, 2024. Â Â NOTE 4 â€œPROPERTY AND EQUIPMENT Â Property and equipment at December 31, 2024 and September 30, 2024 consisted of the following: Â Â Â Â December 31, Â Â Â September 30, Â Â Â 2024 Â Â 2024 Â Computers, furniture and equipment Â \$1,751,798Â Â \$1,587,411Â Manufacturing equipment Â \$284,275Â Â \$284,275Â Leasehold improvements Â \$487,081Â Â \$487,081Â Â Â 2,523,154Â Â 2,358,767Â Less accumulated depreciation Â \$ (2,011,239)Â Â \$ (1,904,499)Â Property and equipment, net Â \$511,915Â Â \$454,268Â Â Depreciation expense related to property and equipment was \$106,740Â and \$110,864Â for the three months ended December 31, 2024 and 2023, respectively. Â Â NOTE 5 â€œÂ INTANGIBLE ASSETS Â Intangible Assets Â Intangible assets as of December 31, 2024 and September 30, 2024 consisted of the following: Â Â Â Â December 31, Â Â Â September 30, Â Â Â 2024 Â Â 2024 Â Trademark related to cbdMD Â \$21,585,000Â Â \$21,585,000Â Trademark for HempMD Â \$4,500,000Â Â \$4,500,000Â Technology Relief from Royalty related to DirectCBDOnline.com Â \$667,844Â Â \$667,844Â Tradename related to CBD MD limited markÂ \$368,000Â Â Â 368,000Â Â Tradename related to DirectCBDOnline.com Â \$749,567Â Â \$749,567Â Impairment of intangible assets Â \$ (17,504,000)Â Â \$ (17,504,000)Â Amortization of definite lived intangible assets Â \$ (3,218,098)Â Â \$ (3,026,831)Â Total Â \$2,698,313Â Â \$2,889,580Â Â AmortizationÂ expense related to definite lived intangible assets was \$191,267 and \$172,842Â for the three months ended December 31, 2024 and 2023.Â Â 17 Table of Contents Â Â NOTE 6A â€œRELATED PARTY TRANSACTIONS Â None.Â Â Â NOTE 7A â€œ SHAREHOLDERSÂ€ EQUITY Â Preferred Stock â€œ The Company is authorized to issue 50,000,000 shares of preferred stock, par value \$0.001 per share. In October 2019, the Company designated 5,000,000 of these shares as 8.0% Series A Cumulative Convertible Preferred Stock. Our 8.0% Series A Cumulative Convertible Preferred Stock ranks senior to our common stock for liquidation or dividend provisions and holders are entitled to receive cumulative cash dividends at an annual rate of 8.0% payable monthly in arrears for the prior month. The Company reviewed ASC 480 â€œÂ Distinguishing Liabilities from Equity in order to determine the appropriate accounting treatment for the preferred stock and determined that the preferred stock should be treated as equity. There were 5,000,000 shares of 8.0% Series A Cumulative Convertible Preferred Stock issued and outstanding at December 31, 2024 and September 30, 2024. Â The total amount of preferred dividends declared and accrued wereÂ \$1,006,500 for the three months ended December 31, 2024, respectively,Â and the total amount of preferred dividends declared and accrued were \$1,000,501 for the three months ended December 31, 2023. Â Common Stock â€œ The Company is authorized to issue 150,000,000 shares of common stock, par value \$0.001 per share. There were 5,543,124 and 3,939,057 shares of common stock issued and outstanding at December 31, 2024 and September 30, 2024, respectively. Â 18 Table of Contents Â Stock Options Â The Company currently has awards outstanding with service conditions and graded-vesting features. We recognize compensation cost on a straight-line basis over the requisite service period. Â Preferred stock transactions: Â The Company had no preferred stock transactions in the three months ended December 31, 2024 and 2023. Â Common stock transactions: Â In the three months ended December 31, 2024: Â During the quarter the Company issued 1,421,067 shares of common stock for conversion of the Notes. Â In November 2024, the Company issuedÂ 175,000 shares of common stock to a consultant for advisory services. Â In the three months ended December 31, 2023: Â None. Â Â 19 Table of Contents Â NOTE 8A â€œ STOCK BASED COMPENSATION Â The fair value of each time-based award is estimated on the date of grant using the Black-Scholes option valuation model. Our weighted-average assumptions used in the Black-Scholes valuation model for equity awards with time-based vesting provisions granted during the year. Â The following table summarizes stock option activity under both plans for the three months ended December 31, 2024: Â Â Â Number of shares Â Â Weighted-average exercise price Â Â Weighted-average remaining contractual term (in years) Â Â Â Aggregate intrinsic value (in thousands) Â Â Outstanding at September 30, 2024 Â Â 44,035Â Â \$123.58Â Â 3.14Â Â Â Granted Â Â Â - Â Â - Â - Â Â - Â - Â Exercised Â Â - Â Â - Â - Â - Â Forfeited Â Â (112)Â Â 10.35Â Â - Â - Â - Â Outstanding at December 31, 2024 Â Â 43,923Â Â Â 123.83Â Â Â 2.89Â Â Â - Â - Â - Â - Â - Â - Â Exercisable at December 31, 2024 Â Â 43,923Â Â Â 123.87Â Â Â 2.89Â Â Â - Â - Â As of December 31, 2024, there was approximately \$3,925Â of total unrecognized compensation cost related to non-vested stock options which vest over a period of approximately 0.75Â years. Â Restricted Stock Award transactions: Â The Company had 8,000 shares of previously issued restricted stock vest during theÂ three months ended December 31, 2024. Â 20 Table of Contents Â Â NOTE 9A - WARRANTS Â Transactions involving the Company equity-classified warrants for theÂ three months ended December 31, 2024 are summarized as follows: Â Â Â Number of shares Â Â Weighted-average exercise price Â Â Weighted-average remaining contractual term (in years) Â Â Â Aggregate intrinsic value (in thousands) Â Â Outstanding at September 30, 2024 Â Â 48,957Â Â \$29.48Â Â 3.42Â Â Â - Â - Â - Â - Â - Â - Â Exercised Â Â - Â - Â - Â - Â Forfeited Â Â (1,079)Â Â 176.06Â Â - Â - Â - Â Outstanding at December 31, 2024 Â Â 47,878Â Â Â 26.17Â Â Â 2.98Â Â Â - Â - Â - Â - Â - Â - Â Exercisable at December 31, 2024 Â Â 47,878Â Â Â 26.17Â Â Â - Â - Â - Â The

(*æœenakend creditsæœ*). The Company has determined that using the general methodology for calculating income taxes during an interim period for the quarters ending December 31, 2019, March 31, 2020, and June 30, 2020, provided for a wide range of potential annual effective rates.Â At September 30, 2023 the Company recorded a net deferred tax asset of zero as the cumulative net deferred tax asset had a full valuation on it and there was not enough positive evidence that would warrant recognizing the benefit of the net deferred tax asset. In addition, the net indefinite lived deferred tax items were a deferred tax asset so there was not any recognition of a deferred tax liability related to indefinite lived deferred tax liabilities. At December 31, 2024, the Company determined the same circumstances to be true and therefore recorded a net deferred tax asset of zero. Â NOTE 15Â *æœ* SUBSEQUENT EVENTS Â During January 2025, the Company issued an aggregate of 719,709 shares of common stock upon the conversion of the Notes to satisfy the remaining balance of principal and accrued interest on the Notes. Â 25 Table of Contents Â ITEM 2. MANAGEMENTÂ *æœ* S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. Â The following discussion of our financial condition and results of operations for the three months ended December 31, 2024 and the three months ended December 31, 2023 should be read in conjunction with the unaudited condensed consolidated financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties such as our plans, objectives, expectations and intentions. Â Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements because of several factors, including those set forth under the Part I, Item 1A, Risk Factors and Business sections in our 2024Â 10-K, this report, and our other filings with the Securities and Exchange Commission. We use words such as *æœ* anticipate, *æœ* estimate, *æœ* *æœ* plan, *æœ* *æœ* project, *æœ* *æœ* continue, *æœ* *æœ* ongoing, *æœ* *æœ* expect, *æœ* *æœ* believe, *æœ* *æœ* intend, *æœ* *æœ* may, *æœ* *æœ* will, *æœ* *æœ* should, *æœ* *æœ* could, *æœ* and similar expressions to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements. Such statements are based on our current expectations and could be affected by the uncertainties and risk factors described throughout this report. Â Our Company Â General Â We own and operate the nationally recognized CBD (cannabidiol) brands cbdMD, Paw CBD and functional mushroom brand ATRx Labs. We believe that we are an industry leader producing and distributing hemp derived solutions including broad spectrum CBD products and full spectrum CBD products. Our mission is to enhance our customerÂ *æœ* s overall quality of life while bringing cannabinoid and mushroom education, awareness and accessibility of high quality and effective products to all. We source cannabinoids, including CBD, which are extracted from non-GMO hemp grown on farms in the United States. Our innovative broad spectrum formula utilizes one of the purest hemp extracts, containing CBD, CBG and CBN, while eliminating the presence of tetrahydrocannabinol (THC). Non-THC is defined as below the level of detection using validated scientific analytical methods. Our full spectrum and Delta 9 products contain a variety of cannabinoids and terpenes in addition to CBD while maintaining small amounts of THC that fall below the level of detection and are within the limits set in the 2018 Farm Act. In addition to our core brands, we also operate cbdMD Therapeutics, LLC to capture the CompanyÂ *æœ* s ongoing investments in science related to its existing and future products, including research and development activities for therapeutic applications and Proline Global that houses some of our newer brands. Â Our cbdMD brand of products includes an array of high-grade, premium every day and functional CBD products, including tinctures; gummies; topicals; capsules; and sleep, focus and calming aids.Â In addition, we have clinical based claims and industry leading strength and concentrations to drive product efficacy. Â Â Â 26 Table of Contents Â Our Paw CBD brand of products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths and formulas. Paw CBD products have undergone the National Animal Safety CouncilÂ *æœ* s rigorous audit and meet their Quality Seal standard. Â Our ATRx brand was developed using the power of functional mushrooms to provide consumers a complementary natural ingredient solution for immunity, focus, digestive health, cognitive and mood benefits. Â Our cbdMD, Paw CBD and ATRxÂ products are distributed through our e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.Â Recent DevelopmentsÂ Management continues to be very focused on our goal of delivering positive earnings through a combination of optimizing our product portfolio, right-sizing our cost structure and investing in marketing that will provide positive return on customer acquisition.Â During fiscal 2024 we continue to make sweeping changes that have had a very positive impact to the business.Â The first quarter of fiscal 2025 is the first quarter in CompanyÂ *æœ* s history as a public company that revenues increased from a prior sequential quarter, the Company achievedÂ Net Income (before the preferred dividend accrual) and the Company achieved positive EBITDA on a Non GAAP basis.Â During the first fiscal quarter cbdMD took a bigger step into the beverage category and launched our line of hemp derived, ready-to-drink beverages under the Herbal Oasis (*æœ*Oasis*æœ*) line.Â We see this as currently the fastest growing category in the hemp industry. Â We remain focused on growing the Company in a smart, profitable manner along with appropriate cost controls. Â 27 Table of Contents Â Growth Strategies Â We continued to pursue many strategies to grow our revenues and expand the scope of our business in fiscal 2025 and beyond: Â Â Product Innovation: Our goal is to provide our customers superior functional based products with greater efficacy claims and absorption. We constantly assess and evaluate our product portfolio, and devote resources to ongoing research and development processes with the goal of improving our product offerings. During the first quarter of fiscal 2025, we launched reformulations on several sleep products to enhance their effectiveness and improve taste.Â In addition, we launched ready-to-drink beverage product under our new Oasis brand.Â We have a pipeline of cannabinoid and non-cannabinoid products and formulation upgrades that are in the queue for ongoing innovation and product portfolio improvement. Â Â Expand our revenue channels:Â We continued to pursue relationships with traditional retail accounts and distributorsÂ and believe our top brand awareness and effective marketing position us as a preferred CBD partner for key traditional retail accounts as this channel has continued to normalize. During the first quarter of fiscal 2024 we launched several SKUs into Sprouts retail footprint. In April 2024 we added Door Dash as a customer. We expanded our ATRx Labs product in GNC during 2024.Â In 2025 we began developing relationships with beer and alcohol distributors for our Oasis beverage line. Â Â International Expansion: We continue to explore sales in markets outside of the United States. We generally partner with local wholesalers and local legal counsel who can help navigate the laws and regulatory requirements within their jurisdiction. We continue to pursue key wholesale accounts in a number of international markets and are gaining market share in Central and South America through our sanitary registration approvals. We are also continuing to expand our E-commerce business to consumers in the United Kingdom (UK) which was expanded onto AmazonÂ *æœ* s platform during fiscal year 2023 and are continuing to grow this channel quarterly. Â Â Cultivate Additional Brands: We continue to operate and attempt to grow the Paw CBD business. During fiscal 2024 we have launched our nootropic mushroom line under the ATRx brand.Â During the first quarter of fiscal 2025 we launched a new line of hemp derived and nootropic beverages under the Oasis brand. We believe there are ongoing opportunities with these brands to focus on education, cross-selling and customer retention. Â 28 Table of Contents Â Acquisitions:Â We evaluate acquisitions (M&A) where we believe (i) there is an accretive customer base that can lower our cost of customer acquisitions through either a complementary direct to consumer base or wholesale channels, or (ii) the target has a profitable business or easily attainable cost synergies that can quickly help contribute and accelerate profitability of our Company. While the Company continues to evaluate M&A opportunities, as of the date of this report we currently do not have any pending or potential acquisitions. There have been opportunities, however, our current capital structure, specifically the overhang of our Series A Preferred stock, has to this point stalled prospects. Â Results of operations Â The following tables provide certain selected consolidated financial information for the periods presented: Â Â Three Months Ended December 31, Â Â 2024 Â 2023 Â Change Â Total net sales Â \$ 5,113,476 Â \$ 5,375,405 Â \$ (261,929) Cost of sales Â \$ 1,712,867 Â \$ 1,817,907 Â \$ (105,040) Gross profit as a percentage of net sales Â 66.5 % Â 66.2 % Â 0.3 % Operating expenses Â \$ 3,486,881 Â \$ 4,623,333 Â \$ (1,136,452) Operating loss from operations Â \$ (86,272) Â \$ (1,065,835) Â \$ 979,563 Decrease on contingent liability Â - Â - Â 69,752 Â \$ (69,752) Net Income (loss) before taxes Â \$ 15,095 Â \$ (996,501) Â \$ 970,840 Net loss attributable to cbdMD Inc. common shareholders Â \$ (1,011,596) Â \$ (1,997,002) Â \$ 985,406 Â We record product sales primarily through two main delivery channels, direct to consumers via our E-commerce sales and direct to wholesalers utilizing our internal sales team. The following table provides information on the contribution of net sales by type of sale to our total net sales. Â Â Three Months Â Â Â Three Months Â Â Â Three Months Â Â Â Ended Â Â Â Ended Â Â Â December 31, Â Â Â December 31, Â Â Â Â Â Â Â % of total Â Â 2023 Â Â % of total Â E-commerce sales Â \$ 3,952,729 Â \$ 77.3 % Â \$ 4,424,006 Â \$ 82.3 % Wholesale sales Â \$ 1,160,747 Â \$ 22.7 % Â \$ 951,399 Â \$ 17.7 % Total Net Sales Â \$ 5,113,476 Â \$ 100 % Â \$ 5,375,405 Â \$ 100 % Â 29 Table of Contents Â Net Sales Â We had total net sales of \$5.1 million and \$5.4 million for the three months ended December 31, 2024 and 2023, respectively, resulting in a decrease in net sales of \$0.3 million or 4.9% quarter over quarter. This decrease is partially attributable to a decrease of \$0.5 million in e-commerce sales year over year while wholesale sales increased by \$0.2 million. The decrease was primarily due to a reduction in marketing spend and ongoing market changes. However, wholesale sales have recentlyÂ seen a positive impact related to changes in our team and product portfolio year over year. Sequentially, revenue grew by 12%. Our team continues to focus on all areas of driving revenue improvement. Despite the overall category facing challenges, we remain optimistic about our market positioning in fiscal 2025. Â Cost of sales Â Our cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, third party providers, and freight for our product sales. Our cost of sales as a percentage of net sales was 33.5% and 33.8% for three months ended December 31, 2024 and 2023, respectively. This slight decrease in cost of sales is mostly attributed to ongoing cost saving initiatives.Â Operating expenses Â Our principal operating expenses include staff related expenses, advertising (which includes expenses related to industry distribution and trade shows), sponsorships, affiliate commissions, merchant fees, technology, travel, rent, professional service fees, and business insurance expenses. Â Consolidated Operating Expenses Â The following tables provide information on our operating expenses for the three months ended December 31, 2024 and 2023: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended December 31, Â Â Â 2024 Â Â 2023 Â Â Change Â Staff related expense Â \$ 1,241,879 Â \$ 1,386,866 Â \$ (144,987) Accounting/legal expense Â \$ 207,925 Â \$ 272,045 Â \$ (64,120) Professional outside services Â \$ 137,485 Â \$ 181,178 Â \$ (43,693) Advertising/marketing/social media/events/tradeshows/sponsorships/affiliate commissions Â \$ 1,001,242 Â \$ 1,392,996 Â \$ (391,754) Merchant fees Â \$ 148,639 Â \$ 175,875 Â \$ (27,236) R&D and regulatory Â \$ 2,947 Â \$ 4,629 Â \$ (1,682) Rent and utilities Â \$ 139,245 Â \$ 139,310 Â \$ (256,065) Non-cash stock compensation Â \$ 3,082 Â \$ 16,542 Â \$ (13,460) Intangibles Amortization Â \$ 191,267 Â \$ 172,842 Â \$ 18,425 Depreciation Â \$ 106,740 Â \$ 110,864 Â \$ (4,124) All other expenses Â \$ 306,430 Â \$ 514,187 Â \$ (207,757) Totals Â \$ 3,486,881 Â \$ 4,623,334 Â \$ (1,136,453) Â 30 Table of Contents Â Our overall operating expenses decreased by approximately \$1.2 million or 26% for the three months ended December 31, 2024 as compared to the three months ended December 31, 2023. The year over year decrease was primarily driven by management's continued ongoing efforts to reduce our cost structure including decreases in staff related expenses, marketing expenses, and professional, accounting and legal expenses. Our team continues to pursue cost saving initiatives, however after significant progress in 2023 and 2024, larger saving opportunities are harder to identify and implement.Â We are closely watching marketing expenses and anticipate seeing some increases in future quarters with the goal of positively impacting (increasing) revenues.Â Corporate overhead and allocation of management fees to our segments Â Included in our consolidated operating expenses are expenses associated with our corporate overhead which are not allocated to the operating business unit, including (i) staff related expenses; (ii) accounting and legal expenses; (iii) professional outside services; (iv) travel and entertainment expenses; (v) rent; (vi) business insurance; and (vii) non-cash stock compensation expense. Â Liquidity and Capital Resources Â We had cash and cash equivalents on hand of approximately \$2.0A million and a working capital deficit of \$2.8A million. Our working capital is reduced by approximately \$5.7 million of accrued dividend payments as of December 31, 2024. At September 30, 2024 we had cash and cash equivalents of Â \$2.4 million and working capital of negative \$1.1 million.Â Our working capital was reduced by approximately \$4.7 million for accrued dividends payments as of September 30, 2024. Excluding the accrued dividend payments, we had adjusted working capital of \$2.8 million as of December 31, 2024 and \$2.4 million as of September 30, 2024. See non GAAP Adjusted EBITDA disclosure below. Â 31 Table of Contents Â We do not have any commitments for material capital expenditures. We have a commitment for cumulative dividends at an annual rate of 8% payable monthly in arrears for the prior month to our preferred shareholders. As of August 2023, we suspended paying the dividend in cash and are accruing this dividend on a monthly basis. Â While the Company is taking strong action and believes that it can execute its strategy and path to profitability, and in its ability to raise additional funds, there can be no assurances to that effect. The CompanyÂ *æœ* s working capital position may not be sufficient to support the CompanyÂ *æœ* s daily operations for the twelve months subsequent to the filing ofÂ this quarterly report. The CompanyÂ *æœ* s ability to continue as a going concern is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding. These and other factors raise substantial doubtÂ about the CompanyÂ *æœ* s ability to continue as a going concern within twelve months after the date that theseÂ financial statements are issued. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result in the Company not being able to continue as a going concern. Â On December 31, 2024, we received notification (the *æœ*Notice*æœ*) from the NYSE American NYSE American that the Company is no longer in compliance with an additional NYSE American continued listing standard. Specifically, the letter states that the Company is not in compliance with the continued listing standard set forth in Section 1003(a)(i) of the NYSE American Company Guide (the *æœ*Company Guide*æœ*). Section 1003(a)(i) requires a listed company to have stockholdersÂ *æœ* equity of \$2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years then ended. The Company reported stockholders equity of \$1,963,417 as of September 30, 2024, and losses from continuing operations and/or net losses in four of its five most recent fiscal years then ended. The Notice further provided that the Company remains subject to the conditions set forth in the NYSE AmericanÂ *æœ* s initial non compliance notification dated June 5, 2024 and its compliance plan that was accepted by the NYSE American on August 20, 2024 for noncompliance under Section 1003(a)(ii) of the Company Guide due to stockholdersÂ *æœ* equity under \$4 million which addressed how the Company intends to regain compliance with the continued listing standards by December 5, 2025 (the *æœ*Plan*æœ*). If the Company is not in compliance with the continued listing standards by December 5, 2025 or if the Company does not make progress consistent with the Plan during the Plan period, the Company will be subject to delisting procedures as set forth in the Company Guide. Â As previously disclosed, the Company is committed to undertaking a transaction or transactions in the future to achieve compliance with the NYSE AmericanÂ *æœ* s requirements, including but not limited to seeking shareholder approval to convert its outstanding Series A Preferred Stock and accrued dividends, a liability totaling \$5.7 million on December 31, 2024, into shares of Common Stock.Â Under certain Series A Preferred Stock conversion proposals, the accrued dividend would move to equity and increase the CompanyÂ *æœ* s stockholder equity. However, there can be no assurance that the Company will be able to achieve compliance with the NYSE AmericanÂ *æœ* s continued listing standards within the required timeframe. Â While the Notice has no immediate impact on the listing of the CompanyÂ *æœ* s shares of common stock or Series A Preferred Stock, which will continue to be listed and traded on the NYSE American during this period, subject to the CompanyÂ *æœ* s compliance with the other listing requirements of the NYSE American, if the Common Stock and Series A Preferred Stock ultimately were to be delisted for any reason, it could negatively impact the Company by (i) reducing the liquidity and market price of the CompanyÂ *æœ* s Common Stock and Series A Preferred Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock and Series A Preferred Stock, which could negatively impact the CompanyÂ *æœ* s ability to raise equity financing; and (iii) limiting the CompanyÂ *æœ* s ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets. Â Our goal from a liquidity perspective is to use operating cash flows to fund day to day operations. We continue to improve the CompanyÂ *æœ* s operating performance, we have been able to stabilize our cash position over the last few quarters, and we believe we are getting closer to long-term sustainable cash flow production.Â The conversion of the Notes provides the Company additional cash for working purposes during fiscal 2025. Management continues to focus on profitability growing the Company in order to strengthen its balance sheet. Â Adjusted EBITDA Â To supplement the Company's unaudited interim consolidated financial statements presented in accordance with USÂ GAAP, the Company uses certain non-GAAP measures of financial performance. Non-GAAP financial measures are not prepared in accordance with, or as an alternative to USÂ GAAP. Generally, a non-GAAP financial measure is a numerical measure of a company's performance that either excludes or includes amounts, or is subject to adjustment that have such an effect, that are not normally excluded or included in the most directly comparable financial measure that is calculated and presented in accordance with USÂ GAAP. Adjusted EBITDA as presented below is a non-GAAP measure. Â cbdMD defines Adjusted EBITDA as Earnings Before Interest, Taxes, Depreciation and Amortization excludingÂ stock based compensation and mergers and acquisitions and financing transaction expenses. Â Our management uses and relies on Adjusted EBITDA, which is a non-GAAP financial measure. We believe that management, analysts and shareholders benefit from referring to the following non-GAAP financial measure to evaluate and assess our core operating results from period-to-period after removing the impact of items that affect comparability. Our management recognizes that the non-GAAP

financial measures have inherent limitations because of the excluded items described above.Â We have included a reconciliation of our non-GAAP financial measure to the most comparable financial measures calculated in accordance with GAAP. We believe that providing the non-GAAP financial measures, together with the reconciliation to GAAP, helps investors make comparisons between cbdMD and other companies. In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance. Investors should pay close attention to the specific definition being used and to the reconciliation between such measure and the corresponding GAAP measure provided by each company under applicable rules of the Securities and Exchange Commission.Â A 32 Table of Contents Â Adjusted EBITDA for the three months ended December 31, 2024 and December 31, 2023 is as follows: Â A 32 Table of Contents Â Three Months Ended December 31, 2024 Â 2023 Â (Unaudited) Â A 32 Table of Contents Â GAAP (loss) from operations Â \$(86,272) Â A \$(1,065,835) Adjustments: Â A 32 Table of Contents Â Depreciation & Amortization (1) Â A 298,007 Â A 283,706 Â Employee and director stock compensation (2) Â A 3,082 Â A 16,542 Â Mergers and Acquisitions and financing transaction expense (3) Â A - Â A 67,599 Â Non-GAAP adjusted EBITDA Â \$ 214,817 Â A \$(697,988) Â (1) Represents depreciation of property, plant and equipment and amortization of the Company's intangible assets. (2) Represents non-cash expense related to options, warrants, restricted stock expenses that have been amortized during the period. (3) Represents expenses incurred in relation to M&A and financing activities during the quarter ended December 31, 2023.Â Critical accounting policies Â The preparation of financial statements and related disclosures in conformity with US GAAP and our discussion and analysis of our financial condition and operating results require our management to make judgments, assumptions and estimates that affect the amounts reported in our consolidated financial statements and accompanying notes. Note 1, "Organization and Summary of Significant Accounting Policies," of the Notes to our consolidated financial statements appearing elsewhere in this report describes the significant accounting policies and methods used in the preparation of our consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.Â Please see Part II, Item 7 "Critical Accounting Policies" appearing in our 2024A 10-K for the critical accounting policies we believe involve the more significant judgments and estimates used in the preparation of our consolidated financial statements and are the most critical to aid you in fully understanding and evaluating our reported financial results. Management considers these policies critical because they are both important to the portrayal of our financial condition and operating results, and they require management to make judgments and estimates about inherently uncertain matters.Â 33 Table of Contents Â Recent accounting pronouncements Â Please see Note 1 "Organization and Summary of Significant Accounting Policies" appearing in the consolidated financial statements included in this report for information on accounting pronouncements.Â Off balance sheet arrangements Â As of the date of this report, we have no undisclosed off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.Â Not applicable for a smaller reporting company.Â ITEM 4. CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures. We maintain "disclosure controls and procedures" as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Based on their evaluation as of the end of the period covered by this report, our principal executive officer and principal accounting officer has concluded that our disclosure controls and procedures were effective to ensure that the information relating to our company, required to be disclosed in our SEC reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive officer and principal accounting officer, to allow timely decisions regarding required disclosure.Â Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.Â 34 Table of Contents Â PART II - OTHER INFORMATION Â ITEM 1. LEGAL PROCEEDINGS.Â None.Â ITEM 1A. RISK FACTORS.Â We desire to take advantage of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Accordingly, in addition to the disclosure below, we incorporate by reference the risk factors disclosed in Part I, Item 1A of our 2024A 10-K. See also "Liquidity and Capital Resources" above.Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.Â Except for those unregistered securities previously disclosed in reports filed with the SEC, we have not sold any securities without registration under the Securities Act during the period covered by this report.Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES.Â None.Â ITEM 4. MINE SAFETY DISCLOSURES.Â Not applicable to our Company's operations.Â 35 Table of Contents Â ITEM 5. OTHER INFORMATION.Â The Auditor Firm ID for our external auditors,Â Cherry Bekaert LLP, isÂ 677.Â A 36 Table of Contents Â EXHIBITS.Â A 36 Table of Contents Â Incorporated by Reference Â Filed or Furnished No. Â Exhibit Description Â Form Â Date Filed Â Number Â Herewith Â 2.1 Â Merger Agreement dated December 3, 2018 by and among Level Brands, Inc.,Â AcqCo, LLC, cbdMD LLC and Cure Based Development, LLC Â 8-K Â 12/31/18 Â 2.1 Â A 2.2 Â Articles of Incorporation of Merger dated December 20, 2018 as filed with the Secretary of State of Nevada merging AcqCo, LLC with and into Cure Based Development, LLC Â 10-Q Â 2/14/19 Â 2.2 Â A 2.3 Â Articles of Amendment to the Articles of Incorporation of Merger dated December 20, 2018 as filed with the Secretary of State of North Carolina merging AcqCo, LLC with and into Cure Based Development, LLC Â 10-Q Â 2/14/19 Â 2.3 Â A 2.4 Â Articles of Amendment to the Articles of Incorporation of Merger dated December 20, 2018 as filed with the Secretary of State of Nevada merging Cure Based Development, LLC with an into cbdMD LLC Â 10-Q Â 2/14/19 Â 2.4 Â A 2.5 Â Articles of Amendment to the Articles of Incorporation of Merger dated December 20, 2018 as filed with the Secretary of State of North Carolina merging Cure Based Development, LLC with an into cbdMD LLC Â 10-Q Â 2/14/19 Â 2.5 Â A 2.6 Â Addendum No. 1 to Agreement and Plan of Merger dated March 31, 2021 Â 8-K Â 4/1/21 Â 10.1 Â A 3.1 Â Articles of Incorporation of 1-A Â 9/18/17 Â 2.1 Â A 3.2 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.2 Â A 3.3 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.3 Â A 3.4 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.4 Â A 3.5 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.5 Â A 3.6 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.6 Â A 3.7 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.7 Â A 3.8 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.8 Â A 3.9 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 2.9 Â A 3.10 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.0 Â A 3.11 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.1 Â A 3.12 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.2 Â A 3.13 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.3 Â A 3.14 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.4 Â A 3.15 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.5 Â A 3.16 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.6 Â A 3.17 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.7 Â A 3.18 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.8 Â A 3.19 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.9 Â A 3.20 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.21 Â A 3.22 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.23 Â A 3.24 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.25 Â A 3.26 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.27 Â A 3.28 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.29 Â A 3.30 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.31 Â A 3.32 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.33 Â A 3.34 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.35 Â A 3.36 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.37 Â A 3.38 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.39 Â A 3.40 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.41 Â A 3.42 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.43 Â A 3.44 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.45 Â A 3.46 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.47 Â A 3.48 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.49 Â A 3.50 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.51 Â A 3.52 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.53 Â A 3.54 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.55 Â A 3.56 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.57 Â A 3.58 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.59 Â A 3.60 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.61 Â A 3.62 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.63 Â A 3.64 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.65 Â A 3.66 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.67 Â A 3.68 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.69 Â A 3.70 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.71 Â A 3.72 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.73 Â A 3.74 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.75 Â A 3.76 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.77 Â A 3.78 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.79 Â A 3.80 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.81 Â A 3.82 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.83 Â A 3.84 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.85 Â A 3.86 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.87 Â A 3.88 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.89 Â A 3.90 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.91 Â A 3.92 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.93 Â A 3.94 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.95 Â A 3.96 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.97 Â A 3.98 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.99 Â A 3.100 Â Articles of Amendment to the Articles of Incorporation of 1-A Â 9/18/17 Â 3.101 Â A 3.102 Â Articles

Disclosure - Note 4 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 4 - Property and Equipment - Major Classes of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 5 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 7 - Shareholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 8 - Stock Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 8 - Stock Based Compensation - Summary of Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 9 - Warrants - Schedule of Equity-Classified Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 9 - Warrants - Summary of Outstanding Common Stock Purchase Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 11 - Note Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 12 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 12 - Leases - Operating Lease Costs and Supplemental Cash Flow Information (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 12 - Leases - Future Minimum Aggregate Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 13 - Loss Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 14 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 15 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 5 ycbd-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 ycbd-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 ycbd-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value Measurement, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies 2026 Note 1 - Organization and Summary of Significant Accounting Policies Note 3 - Inventory Note 4 - Property and Equipment Note 5 - Intangible Assets Note 8 - Stock Based Compensation Note 9 - Warrants Long term liabilities: Note 12 - Leases Issuance of stock for services Note 1 - Organization and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Income Tax Disclosure [Text Block] Note 1 - Organization and Summary of Significant Accounting Policies - Summary of Convertible Notes (Details) Note 3 - Inventory - Schedule of Inventory (Details) Stock based compensation Note 4 - Property and Equipment - Major Classes of Property and Equipment (Details) Restricted stock expense Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) us-gaap DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) Note 8 - Stock Based Compensation - Summary of Stock Option Activity (Details) 2025 us-gaap LiabilitiesCurrent Total current liabilities Note 9 - Warrants - Schedule of Equity-Classified Warrants (Details) Note 9 - Warrants - Summary of Outstanding Common Stock Purchase Warrants (Details) Convertible Debt [Table Text Block] Note 12 - Leases - Operating Lease Costs and Supplemental Cash Flow Information (Details) Note 12 - Leases - Future Minimum Aggregate Lease Payments (Details) Earnings Per Share, Policy [Policy Text Block] Notes To Financial Statements Notes To Financial Statements [Abstract] Debt Conversion Description [Axis] us-gaap Revenues Total Net Sales Revenues, Total Debt Conversion, Name [Domain] Income Tax, Policy [Policy Text Block] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercisable, warrants (in shares) Number of warrants or rights that are exercisable.

ycbd_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice Outstanding, warrant, weighted average exercise price (in dollars per share) Outstanding, warrant, weighted average exercise price (in dollars per share) Weighted average exercise price of warrants or rights outstanding. Exercisable, warrant, weighted average exercise price (in dollars per share) Weighted average exercise price of warrants or rights that are exercisable. Outstanding, warrant, contractual term (Year) Weighted average remaining contractual term for warrants and rights outstanding. us-gaap DepreciationExcludingLessorAssetUnderOperatingLease Depreciation, Excluding Lessor Asset under Operating Lease Commitment Shares [Member] Represents commitment shares. Depreciation us-gaap ConversionOfStockSharesIssued1 Conversion of Stock, Shares Issued (in shares) Equity Classified Warrants [Member] Represents equity classified warrants. Intangible Assets Disclosure [Text Block] Common Stock Purchase Warrants [Member] Represents common stock purchase warrants. Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Exercisable, weighted average exercise price (in dollars per share) us-gaap AssetsCurrent Total current assets us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Exercisable (Year) Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] Warrants Expiring May 2024 [Member] Represents Warrants expiring in May, 2024. us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Exercisable (in shares) us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Outstanding, weighted average remaining contractual term (Year) Increase (decrease) in contingent liability Decrease of contingent liability Series A Cumulative Convertible Preferred Stock [Member] Represents Series A Cumulative Convertible Preferred Stock. Common Stock Adjustments to reconcile net loss to net cash used by operating activities: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Convertible notes, at fair value Common Stock, authorized (in shares) Common Stock, Shares Authorized (in shares) Forfeited, weighted average exercise price (in dollars per share) Common Stock, issued (in shares) Common Stock, Shares, Issued (in shares) Deferred revenue Common Stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) us-gaap AccruedLiabilitiesCurrent Accrued expenses Statistical Measurement [Domain] Cash paid for amounts included in the measurement of operating lease liabilities Maximum [Member] Conversion of Notes into Common Stock [Member] Represents conversion of notes into common stock. Minimum [Member] Lessee, Operating Leases [Text Block] Accrued dividends Accounts payable us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding (in shares) Outstanding (in shares) Statistical Measurement [Axis] Debt, Policy [Policy Text Block] Preferred Stock us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Preferred Stock, Shares Issued (in shares) Preferred Stock, Shares Issued (in shares) us-gaap InterestPaidNet Interest expense us-gaap PolicyTextBlockAbstract Accounting Policies Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred Stock, Shares Authorized (in shares) Preferred Stock, Shares Authorized (in shares) us-gaap InventoryNet Total Inventory Issuance of shares for services Preferred Stock, Par or Stated Value Per Share (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Inventory Components Indefinite-Lived Intangible Assets [Axis] Gross Sales us-gaap InventoryValuationReserves Inventory Reserve Indefinite-Lived Intangible Assets, Major Class Name [Domain] Fair Value, Inputs, Level 3 [Member] us-gaap PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Finished Goods Non-cash financing/investing activities: Fair Value Hierarchy and NAV [Domain] us-gaap InventoryGross Inventory Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Current liabilities: Operating lease liability Cash Payments for: us-gaap Assets Total assets us-gaap PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Deferred revenue / customer deposits Interest expense us-gaap PreferredStockDividendRatePercentage Preferred Stock, Dividend Rate, Percentage us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Cash flows from operating activities: us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Loss attributable to cbdMD, Inc. common shareholders Revenue [Policy Text Block] Statement [Line Items] Accounts receivable us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current Additional paid in capital Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] AOCI Attributable to Parent [Member] cbdMD, Inc. shareholders' equity: Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] CBD MD Limited Mark [Member] Represents CBD MD Limited Mark. Long-Lived Tangible Asset [Axis] us-gaap OtherAssets Total other assets Long-Lived Tangible Asset [Domain] Award Type [Domain] Preferred dividends Preferred dividends ycbd_FinitelivedIntangibleAssetAccumulatedImpairment Impairment of intangible assets Amount of accumulated impairment of finite-lived intangible assets. Current assets: Net Loss Net Income (Loss) Attributable to Parent Net Income (loss) Award Type [Axis] us-gaap FinitelivedIntangibleAssetsAccumulatedAmortization Amortization of definite lived intangible assets Intangible assets us-gaap IntangibleAssetsNetExcludingGoodwill Intangible Assets, Net (Excluding Goodwill), Total us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Inventory, Policy [Policy Text Block] GSS Agreement [Member] Represents GSS Agreement. Definite lived intangible assets us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash flows from financing activities Other assets: us-gaap Liabilities Total liabilities us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Net increase (decrease) in cash Operating expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Excludes impairment of assets. Commitments and Contingencies (Note 10) Sale of Stock [Axis]

ycbd_ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments Comprehensive Income (loss) Amount after tax before income adjustments of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Sale of Stock [Domain] us-gaap OperatingIncomeLoss Loss from operations Share-Based Payment Arrangement, Option [Member] us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash flows from investing activities Prepaid expenses and other current assets Antidilutive Securities [Axis] Cost of sales Antidilutive Securities, Name [Domain] us-gaap GrossProfit Gross Profit Indefinite lived trademark Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Inventory prepaid Amount of consideration paid in advance for inventory that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid sponsorship Amount of consideration paid in advance for sponsorships. Commitments and Contingencies Disclosure [Text Block] us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net Property and equipment, gross ycbd_IssuanceOfSharesForConversionOfDebtAndAccruedInterest Issuance of shares for conversion of debt and accrued interest The proceeds from the issuance of shares for the conversion of debt and accrued interest us-gaap EquityMethodInvestmentOtherThanTemporaryImpairment Equity Method Investment, Other-than-Temporary Impairment ycbd_PrincipleAdjustmentsOfDebt Principle Adjustments of Debt The change in the principle value of debt. Concentration Risk, Credit Risk, Policy [Policy Text Block] ycbd_SalesAllowances Allowances Amount of sales allowance. us-gaap PaymentsOfDividends Payments of Dividends ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable Net cash flows from operating activities Represents the amount of accounts receivable collected from discontinued operations. us-gaap Investments Investments, Total ycbd_IncreaseDecreaseInPrepaidInventoryTotal Prepaid inventory Represents the increase (decrease) in prepaid inventory. Cash flows from investing activities: Cost of Goods and Service [Policy Text Block] Retained Earnings [Member] Net Loss per share: Investment in other securities, noncurrent Earnings Per Share [Text Block] Title and Position [Domain] Title and Position [Axis]

ycbd_StockIssuedDuringPeriodValueNewIssuesRetainedEarningsImpact Issuance of Common Stock, GSS Agreement Represents the value of the retained earnings impact due to the issuance of new issues of stock. Issuance of Common Stock, Convertible Notes Issuance of Common Stock, Convertible Notes Represents the amount of treasury stock that is issued at a lower than repurchase price due to the conversion of convertible securities. Accounts payable and accrued expenses Additional Paid-in Capital [Member] Common Stock [Member] Decrease (increase) in fair value of convertible debt Increase (decrease) in fair value of convertible debt Amount of addition (reduction) to the amount of debt. Related Party Transactions Disclosure [Text Block] Preferred Stock [Member] ycbd_OtherComprehensiveIncomeLossChangesInFairValueOfDebtRelatedToCreditRisk Change in fair value of debt related to credit risk Amount of equity impact on other comprehensive income loss due to changes in fair value of debt related to credit risk. Equity Components [Axis] Equity Component [Domain] Manufacturing Equipment [Member] Represents manufacturing equipment. Software [Member] Represents software. us-gaap RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap NotesPayable Notes Payable Merchant Receivable and Reserve [Policy Text Block] Disclosure of accounting policy for merchant receivables and reserve. ycbd_Merchantprocessingfee MerchantProcessingFee Represents agreed percentage for merchant processing fees. us-gaap ClassOfWarrantOrRightOutstanding Outstanding, warrants (in shares) Outstanding, warrants (in shares) us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (loss) before provision for income taxes ycbd_NumberOfMajorCustomers Number of Major Customers Represents number of major customers. Sales Channel [Member] Represents type of sales channel. us-gaap ConvertibleDebt Balance at September 30, 2024 Balance at December 31, 2024 Cash and cash equivalents us-gaap DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) Disaggregation of Revenue [Table Text Block] Accounts Receivable [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap ComprehensiveIncomeNetOfTax Comprehensive Loss attributable to cbdMD, Inc. common shareholders Document Transition Report City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current us-gaap SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common Stock, shares outstanding (in shares) Common Stock, Shares, Outstanding (in shares) Preferred Stock, Shares Outstanding, Ending Balance (in shares) Preferred Stock, Shares Outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_ProceedsFromConvertibleDebt Proceeds from Convertible Debt us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent Computers, Furniture, and Equipment [Member] Represents Computers, furniture, equipment. Document Fiscal Period Focus us-gaap_IncreaseDecreaseInDepositOtherAssets Deposits Total Operating Lease Costs Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Lease, Cost [Table Text Block] Document Period End Date Change in lease asset ycbd_StockIssuedDuringPeriodSharesRestrictedStockAwardVested Vesting of Restricted stock (in shares) The number of restricted stock that has vested. us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating Lease, Weighted Average Remaining Lease Term (Year) ycbd_StockIssuedDuringPeriodValueRestrictedStockAwardVested Vesting of Restricted stock The value of the restricted stock that has vested. Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business us-gaap_ProceedsFromRepaymentsOfNotesPayable Note payable Entity Shell Company Trademark Related to Hemp MD [Member] Represents the trademark "HempMD". Trademark Related to cbdMD [Member] Represents the trademark "cbdMD". us-gaap_DividendsPreferredStockCash Preferred dividend declared, not paid Document Information [Line Items] Document Information [Table] Entity Filer Category Debt Instrument [Axis] Preferred dividends accrued but not paid Represents the value of dividends accrued but not paid for the period. Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Statement [Table] Entity Address,

[illegible]

[illegible]

[illegible]

XML-16-R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD (\$)	Dec. 31, 2024	Sep. 30, 2024
---	---------------	---------------

Current assets:		
Cash and cash equivalents	\$ 1,970,217	\$ 2,452,553
Accounts receivable	1,272,846	983,910
Inventory	2,116,136	2,365,187
Inventory prepaid	356,819	159,006
Prepaid sponsorship	7,126	21,754
Prepaid expenses and other current assets	637,559	406,674
Total current assets	6,360,703	6,389,084
Other assets:		
Property and equipment, net	511,915	454,268
Operating lease assets	1,209,338	85,817
Deposits for facilities	62,708	62,708
Intangible assets	2,698,313	2,889,580
Investment in other securities, noncurrent	700,000	700,000
Total other assets	5,182,274	4,192,373
Total assets	11,542,977	10,581,457
Current liabilities:		
Accounts payable	1,161,133	1,541,108
Accrued expenses	775,946	632,674
Accrued dividends	5,671,500	4,671,000
Deferred revenue	527,438	503,254
Operating leases - current portion	671,765	98,696
Convertible notes, at fair value	362,021	1,171,308
Total current liabilities	9,169,803	8,618,040
Long term liabilities:		
Operating leases - long term portion	591,583	0
Total long term liabilities	591,583	0
Total liabilities	9,761,386	8,618,040
Commitments and Contingencies (Note 10)		
cbdMD, Inc. shareholders' equity:		
Preferred Stock	5,000	5,000
Common Stock	5,543	3,939
Additional paid in capital	184,832,130	184,029,565
Comprehensive other expense	(7,777)	(7,189)
Accumulated deficit	(183,053,305)	(182,067,898)
Total cbdMD, Inc. shareholders' equity	1,781,591	1,963,417
Total liabilities and shareholders' equity	\$ 11,542,977	\$ 10,581,457

XML-17-R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - \$ / shares	Dec. 31, 2024	Sep. 30, 2024
---	---------------	---------------

Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	\$ 0.001	\$ 0.001
Preferred Stock, Shares Issued (in shares)	5,000,000	5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	5,000,000	5,000,000
Common Stock, authorized (in shares)	150,000,000	150,000,000
Common Stock, par value (in dollars per share)	\$ 0.001	\$ 0.001
Common Stock, issued (in shares)	5,543,124	3,939,057
Common Stock, shares outstanding (in shares)	5,543,124	3,939,057

XML-18-R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD (\$)	3 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023

Gross Sales	\$ 5,113,476	\$ 5,375,630
Allowances	0	(225)
Total Net Sales	5,113,476	5,375,405
Cost of sales	1,712,867	1,817,907
Gross Profit	3,400,609	3,557,498
Operating expenses	3,486,881	4,623,333
Loss from operations	(86,272)	(1,065,835)
Decrease of contingent liability	0	69,752
Decrease (increase) in fair value of convertible debt	89,963	0
Interest expense	11,404	(418)
Income (loss) before provision for income taxes	15,095	(996,501)
Net Income (loss)	15,095	(996,501)
Preferred dividends	1,000,501	1,000,501
Net Loss attributable to cbdMD, Inc. common shareholders	\$ (985,406)	\$ (1,997,002)
Net Loss per share:		
Basic and Diluted earnings per share (in dollars per share)	\$ (0.22)	\$ (0.67)
Weighted average number of shares Basic and Diluted: (in shares)	4,552,067	2,960,945

XML-19-R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD (\$)	3 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023

Net Loss	\$ 15,095	\$ (996,501)
Comprehensive Income (loss)	15,095	(996,501)
Other Comprehensive income	0	0
Preferred dividends	(1,000,501)	(1,000,501)
Comprehensive Loss attributable to cbdMD, Inc. common shareholders	\$ (985,406)	\$ (1,997,002)

XML-20-R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD (\$)	3 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023

Cash flows from operating activities:		
---------------------------------------	--	--

Note 1 - Organization and Summary of Significant Accounting Policies

3 Months Ended

Dec. 31, 2024

Notes to Financial Statements

Significant Accounting Policies [Text Block]

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

cbdMD, Inc. (“cbdMD”, “we”, “us”, “our”, or the “Company”) is a North Carolina corporation formed on March 17, 2015 as Level Beauty Group, Inc. In November 2016 we changed the name of the Company the name of our Company to cbdMD, Inc. We operate from offices located in Charlotte, North Carolina. Our fiscal year end is established as September 30.

There have been no material changes in the Company's significant accounting policies from those previously disclosed in the Annual Report as of and for the fiscal year ended September 30, 2024 as filed on Form 10-K.

The accompanying unaudited interim condensed consolidated financial statements of cbdMD have been prepared in accordance with accounting principles generally accepted in the United States of America. These statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the 2024 10-K. In the opinion of management, all adjustments necessary for a fair presentation of consolidated financial position and the consolidated results of operations for the interim periods presented have been reflected herein.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CBDI, Paw CBD, Proline and Therapeutics. All material intercompany transactions and balances have been eliminated.

Use of Estimates

The Company's condensed consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect the amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of changes in estimates in the period they are determined to be necessary. Significant estimates made in the accompanying condensed consolidated financial statements include, but are not limited to, allowances for credit losses and allowances, certain assumptions related to the valuation of investments other securities, acquired intangibles and long-lived assets and the recoverability of intangible and long-lived assets and income tax reserves for estimated tax liabilities is a material estimate. Actual results could differ from these estimates. The Company continues to monitor macroeconomic conditions to remain flexible and to optimize its operating performance.

Cash and Cash Equivalents

For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three months when purchased to be cash equivalents.

Accounts Receivable

Accounts receivable are stated at cost less an allowance for credit losses, if applicable. Credit is extended to customers after an evaluation of the customer's financial condition, and generally collateralized by the customer's creditworthiness. Management's determination of the allowance for credit losses is based on an evaluation of the receivables, past experience, current economic conditions, and other risks inherent in the receivables portfolio. The allowance for credit losses was \$310,712 and \$346,197 December 31, 2024 and September 30, 2024, respectively.

Merchant Receivable and Reserve

The Company primarily sells its products through the internet and has an arrangement to process customer payments with third-party payment processors and negotiate the fee based on the market. The arrangement requires the Company pay a fee between 2.5% and 4.0% of the transaction amounts processed. Pursuant to this agreement, there can be a waiting period between 2 to 5 days prior to reimbursement to the Company payment processors hold back. Fees and reserves can change periodically with notice from the processors. At December 31, 2024 and September 30, 2024, the receivable from payment processors included approximately \$1,100,000 and \$1,000,000, respectively, and the reserve for payment processors was \$100,000 and \$100,000, respectively. The reserve for payment processors is recorded as a contra asset to the merchant receivable and is recorded as accounts receivable in the accompanying condensed consolidated balance sheet.

Inventory

Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and manufacturing overhead. Write-offs of potentially slow moving or damaged inventory are recorded based on management's analysis of inventory levels, forecasted future sales volume and pricing and through special inventory counts. Inventory is assessed quarterly for slow moving products and potential impairments and at a minimum perform a physical inventory count annually near fiscal year end.

Property and Equipment

Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense on a straight-line method. Generally, the useful lives are five years for manufacturing equipment and automobiles and three years for software, computer, and furniture and equipment. The useful life for leasehold improvements is the remaining economic life of the asset, whichever is shorter. The cost and accumulated depreciation of property are eliminated from the accounts upon disposal, and any resulting gain or loss is included in the consolidated statement of operations. Long-lived assets held and used by the Company are reviewed for impairment whenever changes in circumstance indicate the carrying value of an asset may not be recoverable.

Fair Value Accounting

The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is the price that would be received from the sale of an asset or the settlement of a liability in an orderly market between willing market participants. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participants, the Company establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Level 1 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 of the hierarchy. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability. Level 3 inputs are unobservable inputs for the fair value measurement. In instances where the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy that is most significant to the overall fair value measurement is the level in the hierarchy that is most significant to the overall fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety is based on the lowest level input that is significant to the fair value measurement in its entirety.

When the Company records an investment in marketable securities the carrying value is assigned at fair value. Any changes in fair value for marketable securities during a given period will be recorded as an increase or decrease in net income. For investment other securities without a readily determinable fair value, the Company may elect to estimate its fair value at cost less impairment plus or minus changes resulting from observable market changes.

The Company elected the fair value option under ASC 825 *Fair Value Measurements* for its Convertible notes. The convertible notes were initially recognized at fair value on the balance sheet. All subsequent changes in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income.

Intangible Assets

The Company accounts for its trademarks in accordance with Accounting Standards Codification (ASC) Topic 360, Property, Plant and Equipment and are amortized over 5-10 years. The Company performs impairment testing should be completed whenever events or changes in circumstances indicate that the asset group's carrying value may not be recoverable.

Revenue Recognition

Under ASC 606, *Revenue from Contracts with Customers*, the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the customer is expected to provide in exchange for the goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

Performance Obligations

Contract liabilities represent unearned revenues and are presented as deferred revenue or customer deposits on the condensed consolidated balance sheets.

Other than account receivable, the Company has no material contract assets nor contract liabilities at December 31, 2024.

The following tables represent a disaggregation of revenue by sales channel:

	Three Months Ended December 31, 2024			
	2024	% of total		
E-commerce sales	\$ 3,952,729	77.3%		\$
Wholesale sales	1,160,747	22.7%		
Total Net Sales	\$ 5,113,476	100.0%		\$

Cost of Sales

The Company's cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, third-party providers, and outbound freight for the Company's products. The Company's cost of sales also includes the cost of refurbishing products returned by customers that will be offered for resale, if any, and the cost of inventory write-downs associated with adjustments of held inventories to their net realizable value. The Company's consolidated statements of operations when the product is sold and net sales revenues are recognized or, in the case of inventory write-downs, when circumstances indicate that the carrying value of the inventory is not recoverable.

Income Taxes

The Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. CBDI, Therapeutics, and Paw CBD are wholly owned subsidiaries and are disregarded entities for federal income tax purposes. The Company's taxable income or loss is included in the tax return of the Company and as of March 15, 2021, Therapeutics is also a wholly owned subsidiary and is a disregarded entity for tax purposes and its entire share of income or loss is included in the tax return of the Company.

The Company accounts for income taxes pursuant to the provisions of the *Accounting for Income Taxes* topic of ASC 740 which requires, among other things, an asset and liability approach to calculating deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The deferred tax assets and liabilities associated with its investment in a consolidated pass-through entity. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is not probable that they will be realized.

Concentrations

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.

The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers \$250,000 for substantially all deposit amounts on deposit in excess of the insured limits.

Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivable not have any customers that represented a significant amount of our sales for the three months ended December 31, 2024.

Stock-Based Compensation

The Company accounts for its stock compensation under the ASC 718-10-30, Compensation - Stock Compensation using the fair value-based method. Under this method, compensation cost is measured at the recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments.

The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance and is recognized over the vesting periods. The Company recognizes forfeitures when they occur.

Earnings (Loss) Per Share

The Company uses ASC 260-10, Earnings Per Share for calculating the basic and diluted loss per share. The Company computes basic loss per share by dividing net loss and net loss attributable to common stock by the weighted average number of common shares outstanding. Common equivalent shares are excluded from the computation of net loss per share if their effect is anti-dilutive.

Liquidity and Going Concern Considerations

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company experienced income of \$15,095 for the three months ended December 31, 2024.

While the Company is taking strong action, believes in the viability of its strategy and path to profitability, and in its ability to raise additional funds, there can be no assurances to that effect. The Company support the Company's daily operations for the twelve months subsequent to the issuance of these annual financial statements. The Company's ability to continue as a going concern is dependent upon its additional funding. These and other factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the annual financial statements are adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result in the Company not being able to continue as a going concern.

Convertible Notes

Effective February 1, 2024, the Company entered into a Securities Purchase Agreement dated January 30, 2024 (the "Purchase Agreement") with five institutional investors (the "Investors") whereby the Company issued \$1,250,000 gross proceeds and the Company issued each Investor an 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note, in the aggregate principal amount of \$1,541,666 (the "Notes") for working capital and general corporate purposes. The table below represents the change in fair value of the convertible notes as of December 31, 2024.

	In Active Markets for Identical Assets and Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)
Balance at September 30, 2024	-	-
Change in fair value of convertible notes	-	-
Balance at December 31, 2024	\$ -	\$ -

New Accounting Standards

The Company adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Measurement. This standard went into effect for fiscal years beginning after December 15, 2023, under Topic 280 by expanding the breadth and frequency of segment disclosures. The Company is currently evaluating the impacts of this standard on the consolidated financial statements.

XML 23 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Marketable
Securities and
Investment Other
Securities

Notes to Financial
Statements

Investments in Debt and
Marketable Equity
Securities (and Certain
Trading Assets)
Disclosure [Text Block]

NOTE 2 - MARKETABLE SECURITIES AND INVESTMENT OTHER SECURITIES

The Company has, from time to time, entered into contracts where a portion of the consideration provided by the counterparty in exchange for the Company's services was common stock, options or warrants (an equity position). In these situations, upon invoicing the customer for the stock or other instruments, the Company recorded the receivable as accounts receivable other, and used the value of the stock or other instrument upon invoicing to determine the value. In determining fair value of marketable securities and investment other securities, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in our assessment of fair value. The Company determines the fair value of marketable securities and investment other securities based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the fair value hierarchy distinguishes between observable and unobservable inputs.

On April 7, 2022, CBD Industries, LLC entered into an asset sale agreement to sell substantially all its manufacturing assets to a subsidiary of Steady State, LLC ("Steady State"). The equipment sale is initially valued at approximately \$1.8 million for accounting purposes, the sale price consisting of products to be provided to the Company under the manufacturing and supply agreement and \$1.4 million of which the Company invested into Steady State in the form of an equity investment consistent with the terms of Steady State's completed series C financing. In September of 2023, the Company impaired this investment by \$700,000. The Company has classified this investment as Level 3 for fair value measurement purposes as there are no observable inputs and has included it in non-current assets on the accompanying condensed consolidated balance sheets as the Company plans to hold this investment.

In valuing the investments, the Company used the value paid, which was the price offered to all third-party investors.

XML 24 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Inventory

Notes to Financial
Statements

Inventory Disclosure [Text
Block]

NOTE 3 - INVENTORY

Inventory at December 31, 2024 and September 30, 2024 consists of the following:

	December 31, 2024	September 30, 2024
Finished Goods	\$ 1,302,911	\$ 1,534,718
Inventory Components	851,002	830,469
Inventory Reserve	(37,777)	-
Inventory prepaid	356,819	159,006
Total Inventory	\$ 2,472,955	\$ 2,524,193

Abnormal amounts of idle facility expense, freight, handling costs, scrap and wasted material (spoilage) are expensed in the period they are incurred and no material expenses related to these items occurred in the three months ended December 31, 2024.

XML 25 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Property and
Equipment

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

NOTE 4 - PROPERTY AND EQUIPMENT

Property and equipment at December 31, 2024 and September 30, 2024 consisted of the following:

	December 31, 2024	September 30, 2024
Computers, furniture and equipment	\$ 1,751,798	\$ 1,587,411
Manufacturing equipment	284,275	284,275
Leasehold improvements	487,081	487,081
	2,523,154	2,358,767
Less accumulated depreciation	(2,011,239)	(1,904,499)
Property and equipment, net	\$ 511,915	\$ 454,268

Depreciation expense related to property and equipment was \$106,740 and \$110,864 for the three months ended December 31, 2024 and 2023, respectively.

XML 26 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible
Assets

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

NOTE 5 - INTANGIBLE ASSETS

Intangible Assets

Intangible assets as of December 31, 2024 and September 30, 2024 consisted of the following:

	December 31, 2024	September 30, 2024
Trademark related to cbdMD	\$ 21,585,000	\$ 21,585,000

Trademark for HempMD	50,000	50,000
Technology Relief from Royalty related to DirectCBDOnline.com	667,844	667,844
Tradename related to CBD MD limited mark	368,000	368,000
Tradename related to DirectCBDOnline.com	749,567	749,567
Impairment of intangible assets	(17,504,000)	(17,504,000)
Amortization of definite lived intangible assets	(3,218,098)	(3,026,831)
Total	\$ 2,698,313	\$ 2,889,580

Amortization expense related to definite lived intangible assets was \$191,267 and \$172,842 for the three months ended December 31, 2024 and 2023.

XML 27 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Related Party Transactions

3 Months Ended
Dec. 31, 2024

Notes to Financial Statements

Related Party Transactions Disclosure [Text Block] NOTE 6 - RELATED PARTY TRANSACTIONS

None.

XML 28 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Shareholders' Equity

3 Months Ended
Dec. 31, 2024

Notes to Financial Statements

Equity [Text Block]

NOTE 7 - SHAREHOLDERS' EQUITY

Preferred Stock - The Company is authorized to issue 50,000,000 shares of preferred stock, par value \$0.001 per share. In October 2019, the Company designated 5,000,000 of these shares as 8.0% Series A Cumulative Convertible Preferred Stock. Our 8.0% Series A Cumulative Convertible Preferred Stock ranks senior to our common stock for liquidation or dividend provisions and holders are entitled to receive cumulative cash dividends at an annual rate of 8.0% payable monthly in arrears for the prior month. The Company reviewed ASC 480 - *Distinguishing Liabilities from Equity* in order to determine the appropriate accounting treatment for the preferred stock and determined that the preferred stock should be treated as equity. There were 5,000,000 shares of 8.0% Series A Cumulative Convertible Preferred Stock issued and outstanding at December 31, 2024 and September 30, 2024.

The total amount of preferred dividends declared and accrued were \$1,006,500 for the three months ended December 31, 2024, respectively, and the total amount of preferred dividends declared and accrued were \$1,000,501 for the three months ended December 31, 2023.

Common Stock - The Company is authorized to issue 150,000,000 shares of common stock, par value \$0.001 per share. There were 5,543,124 and 3,939,057 shares of common stock issued and outstanding at December 31, 2024 and September 30, 2024, respectively.

Stock Options - The Company currently has awards outstanding with service conditions and graded-vesting features. We recognize compensation cost on a straight-line basis over the requisite service period.

Preferred stock transactions:

The Company had no preferred stock transactions in the three months ended December 31, 2024 and 2023.

Common stock transactions:

In the three months ended December 31, 2024:

During the quarter the Company issued 1,421,067 shares of common stock for conversion of the Notes.

In November 2024, the Company issued 175,000 shares of common stock to a consultant for advisory services.

In the three months ended December 31, 2023:

None.

XML 29 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation

3 Months Ended
Dec. 31, 2024

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

NOTE 8 - STOCK BASED COMPENSATION

The fair value of each time-based award is estimated on the date of grant using the Black-Scholes option valuation model. Our weighted-average assumptions used in the Black-Scholes valuation model for equity awards with time-based vesting provisions granted during the year.

The following table summarizes stock option activity under both plans for the three months ended December 31, 2024:

	Number of shares	Weighted-average exercise price	Weighted-average remaining contractual term (in years)	Aggregate intrinsic value (in thousands)
Outstanding at September 30, 2024	44,035	\$ 123.58	3.14	\$ -
Granted	-	-	-	-
Exercised	-	-	-	-
Forfeited	(112)	10.35	-	-
Outstanding at December 31, 2024	43,923	123.83	2.89	-
Exercisable at December 31, 2024	43,923	\$ 123.87	2.89	\$ -

As of December 31, 2024, there was approximately \$3,925 of total unrecognized compensation cost related to non-vested stock options which vest over a period of approximately 0.75 years.

Restricted Stock Award transactions:

The Company had 8,000 shares of previously issued restricted stock vest during the three months ended December 31, 2024.

XML 30 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Warrants

3 Months Ended
Dec. 31, 2024

Notes to Financial Statements

Warrants Disclosure [Text Block]

NOTE 9 - WARRANTS

Transactions involving the Company equity-classified warrants for the three months ended December 31, 2024 are summarized as follows:

	Number of shares	Weighted-average exercise price	Weighted-average remaining contractual term (in years)	Aggregate intrinsic value (in thousands)
Outstanding at September 30, 2024	48,957	\$ 29.48	3.42	\$ -
Granted	-	-	-	-
Exercised	-	-	-	-
Forfeited	(1,079)	176.06	-	-
Outstanding at December 31, 2024	47,878	26.17	2.98	-
Exercisable at December 31, 2024	47,878	\$ 26.17	-	\$ -

The following table summarizes outstanding common stock purchase warrants as of December 31, 2024:

	Number of shares	Weighted-average exercise price	Expiration
Exercisable at \$56.25 per share	822	56.25	January 2025
Exercisable at \$168.30 per share	3,357	168.30	December 2025
Exercisable at \$168.75 per share	3,199	168.75	June 2026
Exercisable at \$2.52 per share	40,500	2.52	April 2028
	47,878	\$ 37.75	

XML 31 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Commitments and Contingencies

3 Months Ended
Dec. 31, 2024

Notes to Financial Statements

None.

XML 32 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Note Payable

Notes to Financial Statements

Debt Disclosure [Text Block]

NOTE 11 - NOTE PAYABLE

Effective February 1, 2024 (the “Effective Date”), the Company entered into a Securities Purchase Agreement dated January 30, 2024 (the “Purchase Agreement”) with five institutional investors (the “Investors”) whereby the Investors advanced the Company an aggregate of \$1,250,000 gross proceeds and the Company issued each Investor an 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note, in the aggregate principal amount of \$1,541,666 (the “Notes”). The Company intends to use the proceeds from the issuance of the Notes for working capital and general corporate purposes.

Each Note bears interest of 8% per annum and matures on July 30, 2025. The Note is convertible into shares of common stock at any time following the date of issuance at the Investor’s option at an initial conversion price of \$0.684 per share (the “Conversion Price”), subject to certain adjustments. If 30 calendar days, 60 calendar days, 90 calendar days, 120 calendar days, or 180 calendar days after the effective date of a registration statement registering the shares of common stock issuable upon conversion of the Notes (the “Registration Statement”) (the “Adjustment Dates”), the Conversion Price then in effect is higher than the Market Conversion Price then in effect on the Adjustment Date, the Conversion Price shall automatically decrease to the Market Conversion Price (as defined under the Note). The Conversion Price is subject to a \$0.30 floor price. As of the filing date of this report, the effective Conversion Price is \$0.5066.

The Company elected the fair value option under ASC 825 *Fair Value Measurements* for the Notes. The Notes were initially recognized at a fair value of \$2,702,000 on the balance sheet as of March 31, 2023. All subsequent changes in fair value, excluding the impact of the change in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income (loss).

The overall change in fair value of the Notes during the quarter ended December 31, 2024 was a decrease of \$809,287. The overall change in principal value related to the conversion of Notes to commons stock during the quarter ended December 31, 2024 was a decrease of \$719,911. As of December 31, 2024, total fair value of the Notes is \$362,021 of which \$363,798 represents the total principal outstanding.

Subsequent to the period covered by this report, the remaining principal and interest of the Notes were fully converted during January 2025. See Note 15 “Subsequent Events”.

XML 33 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Leases

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

NOTE 12 - LEASES

The Company has lease agreements for its warehouse and executive office with the lease period expiring in September 2026. ASC 842 requires the recognition of leasing arrangements on the consolidated balance sheet as right-of-use assets and liabilities pertaining to the rights and obligations created by the leased assets. The Company determines whether an arrangement is a lease at inception and classify it as finance or operating. All of the Company’s leases are classified as operating leases. The Company’s lease do not contain any residual value guarantees.

Right-of-use lease assets and corresponding lease liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since the interest rate implicit in our lease arrangements is not readily determinable, the Company determined an incremental borrowing rate for each lease based on the approximate interest rate on a collateralized basis with similar remaining terms and payments as of the lease commencement date to determine the present value of future lease payments. The Company’s lease terms may include options to extend or terminate the lease.

In addition to the monthly base amounts in the lease agreements, the Company is required to pay real estate taxes, insurance and common area maintenance expenses during the lease terms.

Lease costs on operating leases are recognized on a straight-line basis over the lease term and included as a selling, general and administrative expense in the condensed consolidated statements of operations.

Components of operating lease costs are summarized as follows:

	Three Months Ended December 31, 2024
Total Operating Lease Costs	\$ 180,974

Supplemental cash flow information related to operating leases is summarized as follows:

	Three Months Ended December 31, 2024
Cash paid for amounts included in the measurement of operating lease liabilities	\$ 100,452

As of December 31, 2024, our operating leases had a weighted average remaining lease term of 2.56 years and a weighted average discount rate of 4.66%.

Future minimum aggregate lease payments under operating leases as of December 31, 2024 are summarized as follows:

For the year ended December 31,	
2025	\$ 522,624
2026	798,200
Total future lease payments	1,320,824
Less interest	(57,476)
Total lease liabilities	\$ 1,263,348

XML 34 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Loss Per Share

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE 13 - LOSS PER SHARE

At December 31, 2024, 112,831 potential shares underlying options, unvested RSUs and warrants as well as 185,223 potential shares underlying series A preferred shares were excluded from the shares used to calculate diluted loss per share as their inclusion would be anti-dilutive. At December 31, 2023, 93,113 potential shares underlying options, unvested RSUs and warrants as well as 185,223 convertible preferred shares, as well as total of 283,593 available shares and remaining commitment share under the Keystone agreement were excluded from the shares used to calculate diluted loss per share as their inclusion would reduce net loss per share.

XML 35 R21.htm IDEA: XBRL DOCUMENT

Note 14 - Income Taxes

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE 14 - INCOME TAXES

The Company has a valuation allowance against the net deferred tax assets, with the exception of the deferred tax liabilities that result from indefinite-life intangibles (“naked credits”). The Company has determined that using the general methodology for calculating income taxes during an interim period for the quarters ending December 31, 2019, March 31, 2020, and June 30, 2020, provided for a wide range of potential annual effective rates. At September 30, 2023 the Company recorded a net deferred tax asset of zero as the cumulative net deferred tax asset had a full valuation on it and there was not enough positive evidence that would warrant recognizing the benefit of the net deferred tax asset. In addition, the net indefinite lived deferred tax items were a deferred tax asset so there was not any recognition of a deferred tax liability related to indefinite lived deferred tax liabilities. At December 31, 2024, the Company determined the same circumstances to be true and therefore recorded a net deferred tax asset of zero.

XML 36 R22.htm IDEA: XBRL DOCUMENT

Note 15 - Subsequent Events

Notes to Financial Statements

Subsequent Events [Text Block]

NOTE 15 - SUBSEQUENT EVENTS

During January 2025, the Company issued an aggregate of 719,709 shares of common stock upon the conversion of the Notes to satisfy the remaining balance of principal and accrued interest on the Notes.

XML 37 R23.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements

Insider Trading Arr Line Items

Rule 10b5-1 Arrangement Adopted [Flag]

Non-Rule 10b5-1 Arrangement Adopted [Flag]

3 Months Ended
Dec. 31, 2024

false

false

3 Months Ended
Dec. 31, 2024

Rule 10b5-1 Arrangement Terminated [Flag] false
Non-Rule 10b5-1 Arrangement Terminated [Flag] false
XML 38 R24.htm IDEA: XBRL DOCUMENT

Significant
Accounting Policies
(Policies)

Accounting Policies
[Abstract]

Consolidation Policy
[Policy Text Block]

Use of Estimates Policy
[Policy Text Block]

Cash and Cash
Equivalents Policy
[Policy Text Block]

Accounts Receivable
[Policy Text Block]

Merchant Receivable
and Reserve [Policy
Text Block]

Inventory Policy [Policy
Text Block]

Property, Plant and
Equipment Policy
[Policy Text Block]

Fair Value
Measurement Policy
[Policy Text Block]

Goodwill and Intangible
Assets, Intangible
Assets, Policy [Policy
Text Block]

Revenue [Policy Text
Block]

Cost of Goods and
Service [Policy Text
Block]

Income Tax Policy
[Policy Text Block]

Concentration Risk,
Credit Risk Policy
[Policy Text Block]

Share-Based Payment
Arrangement [Policy
Text Block]

3 Months Ended
Dec. 31, 2024

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CBDI, Paw CBD, Proline and Therapeutics. All material intercompany transactions and

Use of Estimates

The Company's condensed consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect the amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of changes in the period they are determined to be necessary. Significant estimates made in the accompanying condensed consolidated financial statements include, but are not limited to, allowances for credit losses and allowances, certain assumptions related to the valuation of investments in other securities, acquired intangibles and long-lived assets and the recoverability of intangible and long-lived assets and income and reserves for estimated tax liabilities is a material estimate. Actual results could differ from these estimates. The Company continues to monitor macroeconomic conditions to remain flexible and to optimize

Cash and Cash Equivalents

For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three months when purchased to be cash equivalents.

Accounts Receivable

Accounts receivable are stated at cost less an allowance for credit losses, if applicable. Credit is extended to customers after an evaluation of the customer's financial condition, and generally collateralized by the customer's creditworthiness. Management's determination of the allowance for credit losses is based on an evaluation of the receivables, past experience, current economic conditions, and other risks inherent in the receivables portfolio. The allowance for credit losses was \$310,712 and \$346,197 December 31, 2024 and September 30, 2024, respectively.

Merchant Receivable and Reserve

The Company primarily sells its products through the internet and has an arrangement to process customer payments with third-party payment processors and negotiate the fee based on the market. The arrangement requires the Company pay a fee between 2.5% and 4.0% of the transaction amounts processed. Pursuant to this agreement, there can be a waiting period between 2 to 5 days prior to reimbursement to the Company payment processors hold back. Fees and reserves can change periodically with notice from the processors. At December 31, 2024 and September 30, 2024, the receivable from payment processors included approximately \$100,000 and is recorded as accounts receivable in the accompanying condensed consolidated balance sheet.

Inventory

Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and manufacturers). Write-offs of potentially slow moving or damaged inventory are recorded based on management's analysis of inventory levels, forecasted future sales volume and pricing and through physical inventory counts quarterly for slow moving products and potential impairments and at a minimum perform a physical inventory count annually near fiscal year end.

Property and Equipment

Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense on a straight-line method. Generally, the useful lives are five years for manufacturing equipment and automobiles and three years for software, computer, and furniture and equipment. The useful life for leasehold improvements is based on the economic life of the asset, whichever is shorter. The cost and accumulated depreciation of property are eliminated from the accounts upon disposal, and any resulting gain or loss is included in the consolidated statement of operations. Long-lived assets held and used by the Company are reviewed for impairment whenever changes in circumstance indicate the carrying value of an asset may not be recoverable.

Fair Value Accounting

The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value measurements are made using the fair value hierarchy, which has three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are based on observable market data. Level 3 inputs are unobservable inputs for the fair value measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are based on observable market data. Level 3 inputs are unobservable inputs for the fair value measurement. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability. Level 3 inputs are unobservable inputs for the fair value measurement. As there is little, if any, observable market activity. In instances where the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy that is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety is based on the lowest level input that is significant to the fair value measurement in its entirety.

When the Company records an investment in marketable securities the carrying value is assigned at fair value. Any changes in fair value for marketable securities during a given period will be recorded as an increase or decrease in other comprehensive income. For investment other securities without a readily determinable fair value, the Company may elect to estimate its fair value at cost less impairment plus or minus changes resulting from observable inputs.

The Company elected the fair value option under ASC 825 *Fair Value Measurements* for its Convertible notes. The convertible notes were initially recognized at fair value on the balance sheet. All subsequent changes in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income related to the convertible notes.

Intangible Assets

The Company accounts for its trademarks in accordance with Accounting Standards Codification (ASC) Topic 360, Property, Plant and Equipment and are amortized over 5-10 years. The Company performs impairment testing should be completed whenever events or changes in circumstances indicate that the asset group's carrying value *may not be* recoverable.

Revenue Recognition

Under ASC 606, *Revenue from Contracts with Customers*, the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.

Performance Obligations

Contract liabilities represent unearned revenues and are presented as deferred revenue or customer deposits on the condensed consolidated balance sheets.

Other than accounts receivable, the Company has no material contract assets nor contract liabilities at December 31, 2024.

The following tables represent a disaggregation of revenue by sales channel:

	Three Months Ended Dec		
	2024	% of total	
E-commerce sales	\$ 3,952,729	77.3%	\$
Wholesale sales	1,160,747	22.7%	
Total Net Sales	\$ 5,113,476	100.0%	\$

Cost of Sales

The Company's cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, third-party providers, and outbound freight for the Company's products and services. The cost of refurbishing products returned by customers that will be offered for resale, if any, and the cost of inventory write-downs associated with adjustments of held inventories to their net realizable value are included in the cost of sales. The Company's consolidated statements of operations when the product is sold and net sales revenues are recognized or, in the case of inventory write-downs, when circumstances indicate that the carrying value of the inventory is not recoverable.

Income Taxes

The Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. CBDI, Therapeutics, and Paw CBD are wholly owned subsidiaries and are disregarded entities for federal income tax purposes. The Company's taxable income or loss is included in the tax return of the Company and as of March 15, 2021, Therapeutics is also a wholly owned subsidiary and is a disregarded entity for tax purposes and its entire share of income or loss is included in the tax return of the Company.

The Company accounts for income taxes pursuant to the provisions of the *Accounting for Income Taxes* topic of ASC 740 which requires, among other things, an asset and liability approach to calculating deferred income tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company recognizes deferred tax assets and liabilities associated with its investment in a consolidated pass-through entity. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is not probable that they will be realized.

Concentrations

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.

The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation ("FDIC") covers \$250,000 for substantially all deposits in excess of the insured limits.

Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to not have any customers that represented a significant amount of our sales for the three months ended December 31, 2024.

Stock-Based Compensation

The Company accounts for its stock compensation under the ASC 718-10-30, *Compensation - Stock Compensation* using the fair value-based method. Under this method, compensation cost is measured at the fair value of the equity instrument at the time of grant.

recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that *may* be settled by the issuance of those equity instruments.

The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the perf date) and is recognized over the vesting periods. The Company recognizes forfeitures when they occur.

[Earnings Per Share, Policy \[Policy Text Block\]](#)

Earnings (Loss) Per Share

The Company uses ASC 260-10, Earnings Per Share for calculating the basic and diluted loss per share. The Company computes basic loss per share by dividing net loss and net loss attributable to common st by the weighted average number of common shares outstanding. Common equivalent shares are excluded from the computation of net loss per share if their effect is anti-dilutive.

[Liquidity and Going Concern Considerations, Policy \[Policy Text Block\]](#)

Liquidity and Going Concern Considerations

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company experienced income of \$15,095 for the three months ended Decen \$2,809,100 at December 31, 2024.

While the Company is taking strong action, believes in the viability of its strategy and path to profitability, and in its ability to raise additional funds, there can be no assurances to that effect. The Compa support the Company's daily operations for the twelve months subsequent to the issuance of these annual financial statements. The Company's ability to continue as a going concern is dependent upon its a additional funding. These and other factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the annual financial statements are adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result in the Company not being able to continue as a c

[Debt, Policy \[Policy Text Block\]](#)

Convertible Notes

Effective February 1, 2024, the Company entered into a Securities Purchase Agreement dated January 30, 2024 (the "Purchase Agreement") with five institutional investors (the "Investors") whereby t \$1,250,000 gross proceeds and the Company issued each Investor an 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note, in the aggregate principal amount of \$1,541,666 (the " issuance of the Notes for working capital and general corporate purposes. The table below represents the change in fair value of the convertible notes as of December 31, 2024.

	In Active Markets for Identical Assets and Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)
Balance at September 30, 2024	-	-
Change in fair value of convertible notes	-	-
Balance at December 31, 2024	\$ -	\$ -

[New Accounting Pronouncements, Policy \[Policy Text Block\]](#)

New Accounting Standards

The Company adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures Measurement. This standard went into effect for fiscal years beginning after Decemb under Topic 280 by expanding the breadth and frequency of segment disclosures. The Company is currently evaluating the impacts of this standard on the consolidated financial statements.

XML 39 R25.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)

[Notes Tables Disaggregation of Revenue \[Table Text Block\]](#)

3 Months Ended

Dec. 31, 2024

	2024	Three Months Ended Dec % of total	
E-commerce sales	\$ 3,952,729	77.3%	\$
Wholesale sales	1,160,747	22.7%	
Total Net Sales	\$ 5,113,476	100.0%	\$

[Convertible Debt \[Table Text Block\]](#)

	In Active Markets for Identical Assets and Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)
Balance at September 30, 2024	-	-
Change in fair value of convertible notes	-	-
Balance at December 31, 2024	\$ -	\$ -

XML 40 R26.htm IDEA: XBRL DOCUMENT

Note 3 - Inventory (Tables)

[Notes Tables Schedule of Inventory, Current \[Table Text Block\]](#)

3 Months Ended Dec. 31, 2024

	December 31, 2024	September 30, 2024
Finished Goods	\$1,302,911	\$ 1,534,718
Inventory Components	851,002	830,469
Inventory Reserve	(37,777)	-
Inventory prepaid	356,819	159,006
Total Inventory	\$2,472,955	\$ 2,524,193

XML 41 R27.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Tables)

[Notes Tables Property, Plant and Equipment \[Table Text Block\]](#)

3 Months Ended Dec. 31, 2024

	December 31, 2024	September 30, 2024
Computers, furniture and equipment	\$ 1,751,798	\$ 1,587,411
Manufacturing equipment	284,275	284,275
Leasehold improvements	487,081	487,081
	2,523,154	2,358,767
Less accumulated depreciation	(2,011,239)	(1,904,499)
Property and equipment, net	\$ 511,915	\$ 454,268

XML 42 R28.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets (Tables)

[Notes Tables Schedule of Intangible Assets and Goodwill \[Table Text Block\]](#)

3 Months Ended Dec. 31, 2024

	December 31, 2024	September 30, 2024
Trademark related to cbdMD	\$ 21,585,000	\$ 21,585,000
Trademark for HempMD	50,000	50,000
Technology Relief from Royalty related to DirectCBDOnline.com	667,844	667,844
Tradename related to CBD MD limited mark	368,000	368,000
Tradename related to DirectCBDOnline.com	749,567	749,567
Impairment of intangible assets	(17,504,000)	(17,504,000)
Amortization of definite lived intangible assets	(3,218,098)	(3,026,831)
Total	\$ 2,698,313	\$ 2,889,580

XML 43 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation (Tables)

[Notes Tables Share-Based Payment Arrangement, Option, Activity \[Table Text Block\]](#)

3 Months Ended Dec. 31, 2024

	Number of shares	Weighted-average exercise price	Weighted-average remaining contractual term (in years)	Aggregate intrinsic value (in thousands)
Outstanding at September 30, 2024	44,035	\$ 123.58	3.14	\$ -
Granted	-	-	-	-
Exercised	-	-	-	-
Forfeited	(112)	10.35	-	-
Outstanding at December 31, 2024	43,923	123.83	2.89	-
Exercisable at December 31, 2024	43,923	\$ 123.87	2.89	\$ -

Note 9 - Warrants
(Tables)

[Common Stock Purchase Warrants \[Member\]](#)

Notes Tables

[Schedule of Stockholders' Equity Note, Warrants or Rights \[Table Text Block\]](#)

3 Months Ended Dec. 31, 2024			
	Number of shares	Weighted-average exercise price	Expiration
Exercisable at \$56.25 per share	822	56.25	January 2025
Exercisable at \$168.30 per share	3,357	168.30	December 2025
Exercisable at \$168.75 per share	3,199	168.75	June 2026
Exercisable at \$2.52 per share	40,500	2.52	April 2028
	47,878	\$ 37.75	

[Equity Classified Warrants \[Member\]](#)

Notes Tables

[Schedule of Stockholders' Equity Note, Warrants or Rights \[Table Text Block\]](#)

	Number of shares	Weighted-average exercise price	Weighted-average remaining contractual term (in years)	Aggregate intrinsic value (in thousands)
Outstanding at September 30, 2024	48,957	\$ 29.48	3.42	\$ -
Granted	-	-	-	-
Exercised	-	-	-	-
Forfeited	(1,079)	176.06	-	-
Outstanding at December 31, 2024	47,878	26.17	2.98	-
Exercisable at December 31, 2024	47,878	\$ 26.17	-	\$ -

Note 12 - Leases
(Tables)

Notes Tables

[Lease, Cost \[Table Text Block\]](#)

3 Months Ended Dec. 31, 2024			
	Three Months Ended December 31, 2024	Three Months Ended December 31, 2024	
Total Operating Lease Costs	\$ 180,974		
Cash paid for amounts included in the measurement of operating lease liabilities	\$ 100,452		
For the year ended December 31,			
2025	\$ 522,624		
2026	798,200		
Total future lease payments	1,320,824		
Less interest	(57,476)		
Total lease liabilities	\$ 1,263,348		

Note 1 - Organization
and Summary of
Significant
Accounting Policies
(Details Textual)

[Accounts Receivable, Allowance for Credit Loss](#)

[Accounts Receivable, after Allowance for Credit Loss, Current](#)

[Revenue, Remaining Performance Obligation, Amount](#)

[Net Income \(Loss\) Attributable to Parent](#)

[Working Capital](#)

[Investors 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note \[Member\]](#)

[Proceeds from Convertible Debt](#)

[Debt Instrument, Interest Rate, Stated Percentage](#)

[Debt Instrument Discounted Percentage](#)

[Debt Instrument, Face Amount](#)

[Customer Concentration Risk \[Member\] | Revenue Benchmark \[Member\]](#)

[Number of Major Customers](#)

[Manufacturing Equipment \[Member\]](#)

[Property, Plant and Equipment, Useful Life \(Year\)](#)

[Software \[Member\]](#)

[Property, Plant and Equipment, Useful Life \(Year\)](#)

[Minimum \[Member\]](#)

[MerchantProcessingFee](#)

[Maximum \[Member\]](#)

[MerchantProcessingFee](#)

Note 1 - Organization
and Summary of
Significant
Accounting Policies -
Disaggregation of
Revenue (Details) -
USD (\$)

[Revenues, Total](#)

[Sales Channel \[Member\] | Revenue Benchmark \[Member\]](#)

[Concentration Risk, Percentage](#)

[Sales Channel, Directly to Consumer \[Member\]](#)

[Revenues, Total](#)

[Sales Channel, Directly to Consumer \[Member\] | Sales Channel \[Member\] | Revenue Benchmark \[Member\]](#)

[Concentration Risk, Percentage](#)

[Sales Channel, Through Intermediary \[Member\]](#)

[Revenues, Total](#)

[Sales Channel, Through Intermediary \[Member\] | Sales Channel \[Member\] | Revenue Benchmark \[Member\]](#)

[Concentration Risk, Percentage](#)

Note 1 - Organization
and Summary of
Significant
Accounting Policies -
Summary of
Convertible Notes
(Details) - USD (\$)

[Decrease \(increase\) in fair value of convertible debt](#) \$ 89,963 \$ 0

[Fair Value, Inputs, Level 1 \[Member\]](#)

[Balance at September 30, 2024](#)

[Decrease \(increase\) in fair value of convertible debt](#)

[Balance at December 31, 2024](#)

[Fair Value, Inputs, Level 2 \[Member\]](#)

3 Months Ended

Dec. 31, 2024 Dec. 31, 2023

3 Months Ended
Jan. 30, 2024 Dec. 31, 2024 Dec. 31, 2023 Sep. 30, 2024
USD (\$) USD (\$) USD (\$) USD (\$)

\$ 310,712 \$ 346,197

631,033 \$ 621,678

0

15,095 \$ (996,501)

\$ (2,809,100)

\$ 1,250,000

8.00%

20.00%

\$ 1,541,666

0

5 years

3 years

2.50%

4.00%

3 Months Ended
Dec. 31, 2024 Dec. 31, 2023

\$ 5,113,476 \$ 5,375,405

100.00% 100.00%

\$ 3,952,729 \$ 4,424,006

77.30% 82.30%

\$ 1,160,747 \$ 951,399

22.70% 17.70%

Balance at September 30, 2024	
Decrease (increase) in fair value of convertible debt	
Balance at December 31, 2024	0
Fair Value, Inputs, Level 3 [Member]	
Balance at September 30, 2024	1,171,308,000
Decrease (increase) in fair value of convertible debt	(809,287,000)
Balance at December 31, 2024	\$ 362,021,000

XML 49 R35.htm IDEA: XBRL DOCUMENT

Note 2 - Marketable Securities and Investment Other Securities (Details Textual) - Steady State, LLC [Member] - USD (\$)	Sep. 30, 2023	Apr. 07, 2022
--	---------------	---------------

Equipment Sold Value	\$ 1,800,000
Investments, Total	\$ 1,400,000
Equity Method Investment, Other than Temporary Impairment	\$ 700,000

XML 50 R36.htm IDEA: XBRL DOCUMENT

Note 3 - Inventory - Schedule of Inventory Dec. 31, 2024	Sep. 30, 2024
(Details) - USD (\$)	

Finished Goods	\$ 1,302,911	\$ 1,534,718
Inventory Components	851,002	830,469
Inventory Reserve	(37,777)	0
Inventory prepaid	356,819	159,006
Total Inventory	\$ 2,472,955	\$ 2,524,193

XML 51 R37.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment (Details Textual) - USD (\$)	3 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023

Depreciation, Excluding Lessor Asset under Operating Lease	\$ 106,740	\$ 110,864
--	------------	------------

XML 52 R38.htm IDEA: XBRL DOCUMENT

Note 4 - Property and Equipment - Major Classes of Property and Equipment (Details) - USD (\$)	Dec. 31, 2024	Sep. 30, 2024
Property and equipment, gross	\$ 2,523,154	\$ 2,358,767
Less accumulated depreciation	(2,011,239)	(1,904,499)
Property and equipment, net	511,915	454,268
Computers, Furniture, and Equipment [Member]		
Property and equipment, gross	1,751,798	1,587,411
Manufacturing Equipment [Member]		
Property and equipment, gross	284,275	284,275
Leasehold Improvements [Member]		
Property and equipment, gross	\$ 487,081	\$ 487,081

XML 53 R39.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets (Details Textual) - USD (\$)	3 Months Ended	
	Dec. 31, 2024	Dec. 31, 2023

Amortization of Intangible Assets	\$ 191,267	\$ 172,842
-----------------------------------	------------	------------

XML 54 R40.htm IDEA: XBRL DOCUMENT

Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) - USD (\$)	Dec. 31, 2024	Sep. 30, 2024
Impairment of intangible assets	\$ (17,504,000)	\$ (17,504,000)
Amortization of definite lived intangible assets	(3,218,098)	(3,026,831)
Intangible Assets, Net (Excluding Goodwill), Total	2,698,313	2,889,580
Technology Relief From Royalty Related To Direct C B D Online Com Member		
Definite lived intangible assets	667,844	667,844
CBD MD Liminted Mark [Member]		
Definite lived intangible assets	368,000	368,000
Tradenname Related To Direct C B D Online Com Member		
Definite lived intangible assets	749,567	749,567
Trademark Related to cbdMD [Member]		
Indefinite lived trademark	21,585,000	21,585,000
Trademark Related to Hemp MD [Member]		
Indefinite lived trademark	\$ 50,000	\$ 50,000

XML 55 R41.htm IDEA: XBRL DOCUMENT

Note 7 - Shareholders' Equity (Details Textual) - USD (\$)	1 Months Ended	3 Months Ended	
	Nov. 30, 2024	Oct. 31, 2019	Dec. 31, 2024
			Dec. 31, 2023
			Sep. 30, 2024

Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	\$ 0.001	\$ 0.001
Preferred Stock, Shares Outstanding (in shares)	5,000,000	5,000,000
Payments of Dividends	\$ 1,006,500	\$ 1,000,501
Common Stock, Shares Authorized (in shares)	150,000,000	150,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	\$ 0.001	\$ 0.001
Common Stock, Shares, Issued (in shares)	5,543,124	3,939,057
Preferred Stock, Shares Issued (in shares)	5,000,000	5,000,000
Common Stock, Shares, Outstanding (in shares)	5,543,124	3,939,057
Consultant [Member]		
Stock Issued During Period, Shares, Issued for Services (in shares)	175,000	
Conversion of Notes into Common Stock [Member]		
Conversion of Stock, Shares Issued (in shares)	1,421,067	
Series A Cumulative Convertible Preferred Stock [Member]		
Preferred Stock, Shares Authorized (in shares)	5,000,000	
Preferred Stock, Dividend Rate, Percentage	8.00%	
Preferred Stock, Shares Outstanding (in shares)	5,000,000	5,000,000
Preferred Stock, Shares Issued (in shares)	5,000,000	5,000,000

XML 56 R42.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation (Details Textual) - Share-Based Payment Arrangement, Option [Member]	3 Months Ended	
	Dec. 31, 2024	
	USD (\$)	

Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	\$ 3,925
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	9 months

XML 57 R43.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation - Summary of Stock Option Activity (Details) - \$ / shares	3 Months Ended		12 Months Ended	
	Dec. 31, 2024		Sep. 30, 2024	
Outstanding (in shares)	44,035			
Outstanding, weighted average exercise price (in dollars per share)	\$ 123.58			
Outstanding, weighted average remaining contractual term (Year)	2 years 10 months 20 days		3 years 1 month 20 days	
Granted (in shares)	0			
Granted, weighted average exercise price (in dollars per share)	\$ 0			
Exercised (in shares)	0			
Exercised, weighted average exercise price (in dollars per share)	\$ 0			
Forfeited (in shares)	(112)			
Forfeited, weighted average exercise price (in dollars per share)	\$ 10.35			
Outstanding (in shares)	43,923		44,035	
Outstanding, weighted average exercise price (in dollars per share)	\$ 123.83		\$ 123.58	
Exercisable (in shares)	43,923			
Exercisable, weighted average exercise price (in dollars per share)	\$ 123.87			
Exercisable (Year)	2 years 10 months 20 days			

XML-58-R44.htm IDEA XBRL DOCUMENT

Note 9 - Warrants - Schedule of Equity-Classified Warrants (Details) - \$ / shares	3 Months Ended			
	Dec. 31, 2024		Oct. 01, 2024	
Granted, warrants (in shares)	0			
Granted, warrant, weighted average exercise price (in dollars per share)	\$ 0			
Exercised, warrants (in shares)	0			
Exercised, warrant, weighted average exercise price (in dollars per share)	\$ 0			
Forfeited, warrants (in shares)	(1,079)			
Forfeited, warrant, weighted average exercise price (in dollars per share)	\$ 176.06			
Exercisable, warrants (in shares)	47,878			
Exercisable, warrant, weighted average exercise price (in dollars per share)	\$ 37.75			
Warrants to Purchase Common Stock [Member]				
Outstanding, warrants (in shares)	48,957			
Outstanding, warrant, weighted average exercise price (in dollars per share)	\$ 29.48			
Outstanding, warrant, contractual term (Year)	2 years 11 months 23 days		3 years 5 months 1 day	
Outstanding, warrants (in shares)	47,878			
Outstanding, warrant, weighted average exercise price (in dollars per share)	\$ 26.17			
Exercisable, warrants (in shares)	47,878			
Exercisable, warrant, weighted average exercise price (in dollars per share)	\$ 26.17			

XML-59-R45.htm IDEA XBRL DOCUMENT

Note 9 - Warrants - Summary of Outstanding Common Stock Purchase Warrants (Details)	Dec. 31, 2024			
	\$ / shares		shares	
Exercisable, warrants (in shares) shares	47,878			
Exercisable, warrant, weighted average exercise price (in dollars per share) \$ / shares	\$ 37.75			
Warrants Expiring September 2023 [Member]				
Exercisable, warrants (in shares) shares	822			
Exercisable, warrant, weighted average exercise price (in dollars per share) \$ / shares	\$ 56.25			
Warrants Expiring May 2024 [Member]				
Exercisable, warrants (in shares) shares	3,357			
Exercisable, warrant, weighted average exercise price (in dollars per share) \$ / shares	\$ 168.3			
Warrants Expiring October 2024 [Member]				
Exercisable, warrants (in shares) shares	3,199			
Exercisable, warrant, weighted average exercise price (in dollars per share) \$ / shares	\$ 168.75			
Warrants Expiring January 2025 [Member]				
Exercisable, warrants (in shares) shares	40,500			
Exercisable, warrant, weighted average exercise price (in dollars per share) \$ / shares	\$ 2.52			

XML-60-R46.htm IDEA XBRL DOCUMENT

Note 11 - Note Payable (Details Textual) - Investors 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note [Member] - USD (\$)	3 Months Ended		
	Jan. 30, 2024	Dec. 31, 2024	Mar. 31, 2023
Proceeds from Convertible Debt	\$ 1,250,000		
Debt Instrument, Interest Rate, Stated Percentage	8.00%		
Debt Instrument Discounted Percentage	20.00%		
Debt Instrument, Face Amount	\$ 1,541,666		
Debt Instrument, Convertible, Conversion Price (in dollars per share)	\$ 0.684		\$ 0.5066
Notes Payable, Fair Value Disclosure			\$ 362,021
Principle Adjustments of Debt			\$ 2,702,000
Notes Payable			(719,911)
Minimum [Member]			\$ 363,798
Debt Instrument, Convertible, Conversion Price (in dollars per share)	\$ 0.3		

XML-61-R47.htm IDEA XBRL DOCUMENT

Note 12 - Leases (Details Textual)	Dec. 31, 2024	
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 6 months 21 days	
Operating Lease, Weighted Average Discount Rate, Percent	4.66%	

XML-62-R48.htm IDEA XBRL DOCUMENT

Note 12 - Leases - Operating Lease Costs and Supplemental Cash Flow Information (Details)	3 Months Ended	
	Dec. 31, 2024	
	USD (\$)	
Total Operating Lease Costs	\$ 180,974	
Cash paid for amounts included in the measurement of operating lease liabilities	\$ 100,452	

XML-63-R49.htm IDEA XBRL DOCUMENT

Note 12 - Leases - Future Minimum Aggregate Lease Payments (Details)	Dec. 31, 2024	
	USD (\$)	
2025	\$ 522,624	
2026	798,200	
Total future lease payments	1,320,824	
Less interest	(57,476)	
Total lease liabilities	\$ 1,263,348	

[The following text is extremely dense and appears to be a mix of random characters and symbols, likely representing a corrupted or encoded document. It contains no legible information.]

C.G.HJF.D.UZ#ISTG(10)3U3P4:~987Q2.2/RH1%\$<+MU.M.E.5@ZAZ.YB7%.*GB^H8WP5T(%)&+YRG>A^6.6W.TN^G3X.M&E.F+6^SFR.ZDPI.Z#810)55^K912Y-2Q%
(3.35F.161XW32.90)V1+510D1Q@#R0.MC9.%.#DQ2.\$P>.^PT.D3FX%<5.~+J5KM&B@81G/FV/LC7^I5^Y@D.K.C^/QHPQ:~74GWDV17^0UJL3JHYG)G^&QI0.EI2I0<~
<B.H&H/W614+0Q=83V5B(M@P7.I&.<#DQ37^IR.S00.M^7^1<?<BIC<~JL.Y1.5+^A&D&B&Z&E^I1^Q^X&G&HFRN&.<W04.QE3^
M^P+2+1=QY<C@7^F0T7+^RIEJL1^0VOVW1&.<#321^SQWT^/JM@A+4^5H18^7JG&SY8B@D.JX^L5+M.W=01P+BV^QCG61S&#RN1)9K)2VHJ1H-IC6E.F2
=MHS<P(Y^C)5T.M=4.%D&R5M^6Y.M\$V..I+WOPOA.^#7+1^JMP.U#B+E8W^8JG&W9+6WZ1A9.U#M^Q507<5.5(2.Y@>^IYVG<H1D5H.M\$R^FW.
DM0&B&87V0?>K3<+4YK6G@MOOV19\$DPI5.06U1.PLU4C<#%#N#>Q.M\$4<+4L15Q<N1.N#:=<I2BV5.=0041^<#Y6HT43A1NYK176G1A&^Q7F7VLP.M-D.NBY&4<+J^<#HV8
_5X<^C4X.DCGH.P+HY&KPC.EIS77W\$<KRRX.Y?>51V0B&1/QOTO#M.JNG<3JVAIPO>V^A1^H16<+^AKZEJYW+M.B-CJ<+6JVA4@GU1L^YU^SN41&GMD6^6T
@JHH^KE^M.E1+&1^XIN^MW24#>3.J1.(9L5^HXYNA.M..3W1+^#PXF=>@ZG.2461MBZV10MVC7^%>M^#032^W^X^%U01.DV0+1^UKSLT4^Y3.BHFPD2R.%SH^DWWT2.R.
MN5X^8B0HW3&2U12?>4E1/CHU&CD0@R1%<@J3851^<^60C.M^323U^Y50.M^VZ.T2.S5^R1FN2^1)YOP^@MA4K7UM^PALI^ML<+<^Q2^FEWBG3^&#R.M(PT^F^%4+YAB2
P1C4Q0U1^1102P.5%<4L1H6U6B>Y>P-BP<M-ID.IX^IW.W&K&ULC5M5.HLVS^AKRT^LP^Q^MWB.HLPWS28<L%<JL3M<+<^I^<MCG>20^D^TU3L-R8F(MA5J^W3K\$%
M^%>04YD^ZNL<JX..POLX<X0.MA1A.IR1^V18=<5D^V135^FMVX5J.U1.^UN4N5^TE1J.3#1+@Q1^3R1D@G^M^#VNY&DN8MV4^N8Q1+P5780.W=<#G3^
<M^<LZOYF5^Y2M.U^BOQH&AD^SA.MH.C14>BTZ0B^V1^16KUFIS^X^<C5.U16.ZRT13^2CKF=C2K1T.MG7^1L+1+66;=&H4^X1%1+<#%#^X.F1R^+MKU.OG1^<6BG\$H<^D80-
M.E5/101H16&WE3^%<^WIDP5&K&A&L\$&S^HVB.TVDS>#ZSR1^<1^J1<^M31.80FK1R^F1U^>F0^>3J1^GNZ8.M1T^SDXO<+34QO~
(V3N63J^2YXW&=<#H+XN9.PMY6EAK+1L(00GX71%G.MR^F^UI\$8P.PHUA030RX.40D5V5M5W&2^2YJ@QFH61^V>U29H0GKCFGY4.MOISJ^0JAO^F^B1.
^5HPK1+<^16Z13B@4.C39G&P7PW&DQ1&Q=VIR.V.H965T1V0<^G^V^M\$32E3.ON^<I^VW525^>22PHJZHF1^%>J4C&GF1N6Y^>MH0?16&K&SFHC65^<75B&DPP
M5^U^91L>Z0^Y1.6ONA2^>6H.F2RX@P\$A2.1^<^C\$V1^#2A5XZ>#5^M^#A..YUL72(P@VLP.HS^UJQ152.HBFC1H3D>Q<^<^9607M6R(Q16G
MOZM^U0MGZD^6D12=<55G>7^J1)(ID<+<FMR1T9C<+<6BM;B^F4M9Z^%W^XU3V0^N.M\$<+X^#7L\$9GBXA&H^F&HOPHT1.8.^0^>=F3A.V01W^F20E^768^6IRG
MAOWJPA=IR.HX27F9Q^%>H1^<1^ABX9J^H7Z^F60E7^H7Z=>P8^7K67^8D.MQ6XC&T^B>S0G<^@FA7^CFB+VWQ.79EKNM^D^>W1Y>A@NK5&Q^K&N1Q
M2=<210SA1Z^<CJ8X7^<^9ZPVM^PYK10>=WIY1K&B1GZ4<+<JPA2^>PDG\$+B1^MJS(1+V155N&DQ^CVC^XZ8S14B8)H^K^R^>6.64F8H^JCH^J^%J
M^#<1R1R3D0K6J.Y1A=1^YH^UGV089W1^J&B^W^%>#>4.EPB8.B&X&=<I(BC>V1^M\$5=ZBZ1U9ZK6)P@3H1^W7K1^W3Q1A&S6?>51+P04^>5\$U.UVH1(K)^M^#R0<60
^A1^W=>O2R<MGI0X14521>^<HKA9J75JYGDJ+1^<AZE7R4^<L1B&7^1+EU&M1%9841^1MH>1Q(95W.GF=FE1GH=>U^Q75E07>P^<#SGNP63N^>Q4VU^#2^<MVR+
MMZA.BMBGQD>R^%6#76^<41T.PCD51OB;Z1ZU8+X1.MA#7FVC.P6A1Q.NQ.\$)&A^X3&81P^W1A7V+5UR63.%Z+<176Z7^B1P5.NM6^7K&
H1BD>B>+1^W&W91^#Q\$C^<41T1@5-Q2N5/0WW1=<3<X0^<MK>1^<ORDFF65:78>3310&8.FZT^D1B^FZ+<DE7^+H(70^#<#<16D0D01^M^#
(P7Y1.Q.OYB7^7A1G.<UX+K4L5^1HXC>=<MY2@U^QZ&Z(27^F1^<@0NB^1^<^<P1GLS1D=05J1D=2J1^QX7HEG.5.MR.M7^C4^0KE(SK9AW1Q/11L1:HN/16Y^Z?
WKGCI1MU5^%>Y7N)1H^#X\$1M\$3>B91>9.TJD1P<^JXMI161^M76R8QEXX3>1^U^CE(NH&1^1H1L^F^M8B^<9W&3W22.W1A^A86Z41Y1.B6H4M3K>==T>84(M276G^H1
X^5T^<PW^MFL^>GD>+UG.U6UF&=<81.M.2B&C^T2^H1QX<1^XV.K^45L^H10<1^35H0.8\$1+<+&S.9^<D&P>VIR.V.H965T1V0L@9.<A&^5&DZ30KK.Z04Q5MH?
3&Y1^PP.TCS:794.M^LGL51L^\$>^WMKY^<EM16L^H46^K<L^A7H758G15V\$55^Q74.M^Z^#Q0Q3VLX1+0^9A^#TS^IND2ACO.@^<X6^OAN^IU^M0BU<+>^/HN
MIS5^T3@H+>F0Q.3F<^<KX.X^T1Z1>=>U7^MJUPQORQ8SK8Z@73.Q8EOU^>^>N4AZMFEU^+OX4UF\$?^P^MI(RN>^>7IM
M^#H1M^Z91>#>+1^4R^54^<4Z1C33Y1F^>RW1OX3=987XN1^<@.GU3N45/M^JZPNH1^2&C
T.P.759T67P1^<5\$73K1^QMKK1^DXYK1V3^>1D1N>+1W5Q.H&M1V1^#8K&3^<HC^P^<^<Y6C216ED)5.M3U^TCE;KP9.FH1^JCF3JB.LH1FZ@<UEK51^#Z^>ZG09K.\$H^#UW01^
MA#01^<4DC.AY^<108^1^#1^712^1U^6&U.FH1HW21H.XA.U6&3RH5R1L.MZVFO^>T^N&^<6JH16Q>5H17>^SS^A10TSLSOV.ZOZ41@5N^QA2320^Z.M1@NL^KUIK11EBS.3?
T34M\$F41B1)H\$K.RE%Q14&L\$1H10<1^<35H9V1@2201^%&8.9>+&PQ=VIR.V.H965T1V0L@9.<A&^5&DZ30KK.Z04Q5MH?
M54EDB045N1MXWH5.%XZXZ=F1GQ4-0ZYR7.^BZ^>C<3C\$7ZY^C.IN-1YFF.MVFRXXV^%4IRC.E1^>W>
MZ&SD31QD<C.GJ^#>51^<1^D.OECDRGH^N0&IN@<K146101F104FO1^>A.M^#PW@>2+2^PNIM.5N4MTVPE&C(TG@3F5^JYA9^XGA1F6N)9URPN0K=<M^C^7(OX1^:48
WHHJ51S>V1D32^H5H>NIG@<+&9^MH13&A^MI@#N^#E13.M1E^>D1Y1^<O^A@WB.R^G10>@H^<1^P.NB^WSA^OG0H14GDE79^>KE68^RMOYQ^>1^QK=8?
WODP7L>3V7^MN6@>W4W>8G^YCUF.SMIH&B&M

[illegible]

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet <http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals> Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003-
Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet <http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited> Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004- **Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Sheet** <http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited> Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Statements 5 false false R6.htm 005- **Statement - Condensed Consolidated Statement of Cash Flows (Unaudited) Sheet** <http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited> Condensed Consolidated Statement of Cash Flows (Unaudited) Statements 6 false false R7.htm 006- **Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet** <http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited> Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 7 false false R8.htm 007- **Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies Sheet** <http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies> Note 1 - Organization and Summary of Significant Accounting Policies Notes 8 false false R9.htm 008- **Disclosure - Note 2 - Marketable Securities and Investment Other Securities Sheet** <http://www.cbmdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities> Note 2 - Marketable Securities and Investment Other Securities Notes 9 false false R10.htm 009- **Disclosure - Note 3 - Inventory Sheet** <http://www.cbmdm.com/20241231/role/statement-note-3-inventory> Note 3 - Inventory Notes 10 false false R11.htm 010- **Disclosure - Note 4 - Property and Equipment Sheet** <http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment> Note 4 - Property and Equipment Notes 11 false false R12.htm 011- **Disclosure - Note 5 - Intangible Assets Sheet** <http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets> Note 5 - Intangible Assets Notes 12 false false R13.htm 012- **Disclosure - Note 6 - Related Party Transactions Sheet** <http://www.cbmdm.com/20241231/role/statement-note-6-related-party-transactions> Note 6 - Related Party Transactions Notes 13 false false R14.htm 013- **Disclosure - Note 7 - Shareholders' Equity Sheet** <http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity> Note 7 - Shareholders' Equity Notes 14 false false R15.htm 014- **Disclosure - Note 8 - Stock Based Compensation Sheet** <http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation> Note 8 - Stock Based Compensation Notes 15 false false R16.htm 015- **Disclosure - Note 9 - Warrants Sheet** <http://www.cbmdm.com/20241231/role/statement-note-9-warrants> Note 9 - Warrants Notes 16 false false R17.htm 016- **Disclosure - Note 10 - Commitments and Contingencies Sheet** <http://www.cbmdm.com/20241231/role/statement-note-10-commitments-and-contingencies> Note 10 - Commitments and Contingencies Notes 17 false false R18.htm 017- **Disclosure - Note 11 - Note Payable Sheet** <http://www.cbmdm.com/20241231/role/statement-note-11-note-payable> Note 11 - Note Payable Notes 18 false false R19.htm 018- **Disclosure - Note 12 - Leases Sheet** <http://www.cbmdm.com/20241231/role/statement-note-12-leases> Note 12 - Leases Notes 19 false false R20.htm 019- **Disclosure - Note 13 - Loss Per Share Sheet** <http://www.cbmdm.com/20241231/role/statement-note-13-loss-per-share> Note 13 - Loss Per Share Notes 20 false false R21.htm 020- **Disclosure - Note 14 - Income Taxes Sheet** <http://www.cbmdm.com/20241231/role/statement-note-14-income-taxes> Note 14 - Income Taxes Notes 21 false false R22.htm 021- **Disclosure - Note 15 - Subsequent Events Sheet** <http://www.cbmdm.com/20241231/role/statement-note-15-subsequent-events> Note 15 - Subsequent Events Notes 22 false false R23.htm 995445- **Disclosure - Insider Trading Arrangements Sheet** <http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements> Insider Trading Arrangements Notes 23 false false R24.htm 995468- **Disclosure - Significant Accounting Policies (Policies) Sheet** <http://www.cbmdm.com/20241231/role/statement-significant-accounting-policies-policies> Significant Accounting Policies (Policies) Policies 24 false false R25.htm 995469- **Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables> Note 1 - Organization and Summary of Significant Accounting Policies (Tables) Tables 25 false false R26.htm 995470- **Disclosure - Note 3 - Inventory (Tables) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-3-inventory-tables> Note 3 - Inventory (Tables) Tables 26 false false R27.htm 995471- **Disclosure - Note 4 - Property and Equipment (Tables) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-tables> Note 4 - Property and Equipment (Tables) Tables 27 false false R28.htm 995472- **Disclosure - Note 5 - Intangible Assets (Tables) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets-tables> Note 5 - Intangible Assets (Tables) Tables 28 false false R29.htm 995473- **Disclosure - Note 8 - Stock Based Compensation (Tables) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation-tables> Note 8 - Stock Based Compensation (Tables) Tables 29 false false R30.htm 995474- **Disclosure - Note 9 - Warrants (Tables) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-9-warrants-tables> Note 9 - Warrants (Tables) Tables 30 false false R31.htm 995475- **Disclosure - Note 12 - Leases (Tables) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-12-leases-tables> Note 12 - Leases (Tables) Tables 31 false false R32.htm 995476- **Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual> Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) Details 32 false false R33.htm 995477- **Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details> Note 1 - Organization and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) Details 33 false false R34.htm 995478- **Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Summary of Convertible Notes (Details) Notes** <http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details> Note 1 - Organization and Summary of Significant Accounting Policies - Summary of Convertible Notes (Details) Details 34 false false R35.htm 995479- **Disclosure - Note 2 - Marketable Securities and Investment Other Securities (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual> Note 2 - Marketable Securities and Investment Other Securities (Details Textual) Details 35 false false R36.htm 995480- **Disclosure - Note 3 - Inventory - Schedule of Inventory (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details> Note 3 - Inventory - Schedule of Inventory (Details) Details 36 false false R37.htm 995481- **Disclosure - Note 4 - Property and Equipment (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-details-textual> Note 4 - Property and Equipment (Details Textual) Details 37 false false R38.htm 995482- **Disclosure - Note 4 - Property and Equipment - Major Classes of Property and Equipment (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details> Note 4 - Property and Equipment - Major Classes of Property and Equipment (Details) Details 38 false false R39.htm 995483- **Disclosure - Note 5 - Intangible Assets (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets-details-textual> Note 5 - Intangible Assets (Details Textual) Details 39 false false R40.htm 995484- **Disclosure - Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details> Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) Details 40 false false R41.htm 995485- **Disclosure - Note 7 - Shareholders' Equity (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual> Note 7 - Shareholders' Equity (Details Textual) Details 41 false false R42.htm 995486- **Disclosure - Note 8 - Stock Based Compensation (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation-details-textual> Note 8 - Stock Based Compensation (Details Textual) Details 42 false false R43.htm 995487- **Disclosure - Note 8 - Stock Based Compensation - Summary of Stock Option Activity (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details> Note 8 - Stock Based Compensation - Summary of Stock Option Activity (Details) Details 43 false false R44.htm 995488- **Disclosure - Note 9 - Warrants - Schedule of Equity-Classified Warrants (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details> Note 9 - Warrants - Schedule of Equity-Classified Warrants (Details) Details 44 false false R45.htm 995489- **Disclosure - Note 9 - Warrants - Summary of Outstanding Common Stock Purchase Warrants (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details> Note 9 - Warrants - Summary of Outstanding Common Stock Purchase Warrants (Details) Details 45 false false R46.htm 995490- **Disclosure - Note 11 - Note Payable (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-11-note-payable-details-textual> Note 11 - Note Payable (Details Textual) Details 46 false false R47.htm 995491- **Disclosure - Note 12 - Leases (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-12-leases-details-textual> Note 12 - Leases (Details Textual) Details 47 false false R48.htm 995492- **Disclosure - Note 12 - Leases - Operating Lease Costs and Supplemental Cash Flow Information (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-12-leases-operating-lease-costs-and-supplemental-cash-flow-information-details> Note 12 - Leases - Operating Lease Costs and Supplemental Cash Flow Information (Details) Details 48 false false R49.htm 995493- **Disclosure - Note 12 - Leases - Future Minimum Aggregate Lease Payments (Details) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details> Note 12 - Leases - Future Minimum Aggregate Lease Payments (Details) Details 49 false false R50.htm 995494- **Disclosure - Note 13 - Loss Per Share (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-13-loss-per-share-details-textual> Note 13 - Loss Per Share (Details Textual) Details 50 false false R51.htm 995495- **Disclosure - Note 14 - Income Taxes (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-14-income-taxes-details-textual> Note 14 - Income Taxes (Details Textual) Details 51 false false R52.htm 995496- **Disclosure - Note 15 - Subsequent Events (Details Textual) Sheet** <http://www.cbmdm.com/20241231/role/statement-note-15-subsequent-events-details-textual> Note 15 - Subsequent Events (Details Textual) Details 52 false false All Reports Book All Reports ycbd-20241231-cal.xml ycbd-20241231-def.xml ycbd-20241231-lab.xml ycbd-20241231-pre.xml ycbd-20241231-10q.htm fullproductlineupcatrx25.jpg fullproductlineupcbmd25.jpg fullproductlineupaw2.jpg ycbd-10qimg1.jpg ycbd-10qimg5.jpg <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/dei/2024> <http://xbrl.sec.gov/ecd/2024> true true JSON-74 MetaLinks.json IDEa: XBRL DOCUMENT f "version": "2.2", "instance": f "ycbd20241231-10q.htm", f "nsPrefix": "ycbd", "nsuri": "http://www.cbmdm.com/20241231", "dts": f "schema": f "local": f "ycbd-20241231.xsd" }, f "remote": f "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/ir/role/negated-2009-12-16.xsd", "http://www.xbrl.org/ir/role/net-2009-12-16.xsd", "http://www.xbrl.org/ir/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" }, "calculationLink": f "local": f "ycbd-20241231-cal.xml" }, "definitionLink": f "local": f "ycbd-20241231-def.xml" }, f "labelLink": f "local": f "ycbd-20241231-lab.xml" }, "presentationLink": f "local": f "ycbd-20241231-pre.xml" }, "inline": f "local": f "ycbd-20241231-10q.htm" }, "keyStandard": 209, "keyCustom": 36, "axisStandard": 20, "axisCustom": 0, "memberStandard": 17, "memberCustom": 24, "hidden": f "total": 42, "http://fasb.org/us-gaap/2024", 30, "http://xbrl.sec.gov/ecd/2024", 4, "http://xbrl.sec.gov/dei/2024", 6, "http://www.cbmdm.com/20241231", 2 }, "contextCount": 125, "entityCount": 1, "segmentCount": 44, "elementCount": 376, "unitCount": 6, "baseTaxonomy": f "http://fasb.org/us-gaap/2024", 411, "http://xbrl.sec.gov/dei/2024", 32, "http://xbrl.sec.gov/ecd/2024", 4 }, "report": f "R1": f "role": "http://www.cbmdm.com/20241231/role/statement-document-and-entity-information", "longName": "000-Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": f "contextRef": "d 2024-10-01 2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "b": "p", "div": "body", "html": "1", "reportCount": 1, "baseRef": "ycbd20241231-10q.htm", "first": true, "unique": true }, "uniqueAnchor": f "contextRef": "d 2024-10-01 2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "b": "p", "div": "body", "html": "1", "reportCount": 1, "baseRef": "ycbd20241231-10q.htm", "first": true, "unique": true }, "R2": f "role": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001-Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 2, "firstAnchor": f "contextRef": "f 2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": null, "ancestors": f "td": "tr", "tbody": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "ycbd20241231-10q.htm", "first": true, "unique": true }, "uniqueAnchor": f "INF": "ancestors": f "td": "tr", "tbody": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "ycbd20241231-10q.htm", "first": true, "unique": true }, "uniqueAnchor": f

[illegible]


```

"us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/insiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "23", "firstAnchor": null, "uniqueAnchor": null }, "R24": { "role": "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies-policies", "longName": "995468 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:SignificantAccountingPoliciesTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:SignificantAccountingPoliciesTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R25": { "role": "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "longName": "995469 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:RevenueRecognitionPolicyTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:RevenueRecognitionPolicyTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R26": { "role": "http://www.cbdmd.com/20241231/role/statement-note-3-inventory-tables", "longName": "995470 - Disclosure - Note 3 - Inventory (Tables)", "shortName": "Note 3 - Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:InventoryDisclosureTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:InventoryDisclosureTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R27": { "role": "http://www.cbdmd.com/20241231/role/statement-note-4-property-and-equipment-tables", "longName": "995471 - Disclosure - Note 4 - Property and Equipment (Tables)", "shortName": "Note 4 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R28": { "role": "http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-tables", "longName": "995472 - Disclosure - Note 5 - Intangible Assets (Tables)", "shortName": "Note 5 - Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:IntangibleAssetsDisclosureTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:IntangibleAssetsDisclosureTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R29": { "role": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-tables", "longName": "995473 - Disclosure - Note 8 - Stock Based Compensation (Tables)", "shortName": "Note 8 - Stock Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTableTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTableTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R30": { "role": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-tables", "longName": "995474 - Disclosure - Note 9 - Warrants (Tables)", "shortName": "Note 9 - Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:WarrantsDisclosureTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R31": { "role": "http://www.cbdmd.com/20241231/role/statement-note-12-leases-tables", "longName": "995475 - Disclosure - Note 12 - Leases (Tables)", "shortName": "Note 12 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:LesseeOperatingLeasesTableTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:LesseeOperatingLeasesTableTextBlock", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R32": { "role": "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "longName": "995476 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "d 2024-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:TradeAndOtherAccountsReceivablePolicy", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-12-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:TradeAndOtherAccountsReceivablePolicy", "body": "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "R33": { "role": "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "longName": "995477 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html", "reportCount": 1, "baseRef": "ycbd20241231_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d 2024-10-01 2024-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td", "tr", "tbody", "table", "div", "body", "html", "reportCount": 1, "baseRef": "ycbd20
```


[illegible]

{"label": "Accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."}, {"auth_ref": "r123", "r196", "r584"}, {"us-gaap_AccountsReceivableNetCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": {"http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": {"lang": "en-us", "role": "label", "us-gaap_AccountsReceivableNetCurrent": {"terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."}}, {"auth_ref": "r668"}, {"us-gaap_AccruedLiabilitiesCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0}, {"presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"lang": "en-us", "role": "label", "us-gaap_AccruedLiabilitiesCurrent": {"terseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."}, {"auth_ref": "r41"}, {"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": {"http://www.cbdmd.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details": {"parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0}, {"presentation": {"http://www.cbdmd.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details": {"lang": "en-us", "role": "label", "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {"negatedLabel": "Less accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."}}, {"auth_ref": "r31", "r116", "r459"}, {"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0}, {"presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"lang": "en-us", "role": "label", "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {"terseLabel": "Comprehensive other expense", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."}}, {"auth_ref": "r14", "r15", "r58", "r124", "r454", "r473", "r474"}, {"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": {"lang": "en-us", "role": "label", "AOIAttributableToParentMember": {"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."}}, {"auth_ref": "r1", "r8", "r15", "r377", "r380", "r420", "r469", "r470", "r649", "r650", "r651", "r657", "r658", "r659", "r660"}, {"us-gaap_AdditionalPaidInCapital": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0}, {"presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"lang": "en-us", "role": "label", "Additional paid in capital": {"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."}}, {"auth_ref": "r50", "r615", "r714"}, {"us-gaap_AdditionalPaidInCapitalMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": {"lang": "en-us", "role": "label", "Additional Paid-In CapitalMember": {"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."}}, {"auth_ref": "r488", "r657", "r658", "r659", "r660", "r690", "r715"}, {"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": {"lang": "en-us", "role": "label", "Adjustments to reconcile net loss to net cash used by operating activities": {"auth_ref": "r5", "us-gaap_AllowanceForDoubtfulAccountsReceivable": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": {"http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": {"lang": "en-us", "role": "label", "us-gaap_AllowanceForDoubtfulAccountsReceivable": {"terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable."}}, {"auth_ref": "r125", "r197", "r203", "r204", "r205", "r712"}, {"dei_AmendmentFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": {"http://www.cbdmd.com/20241231/role/statement-document-and-entity-information": {"lang": "en-us", "role": "label", "Amendment Flag": {"documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission."}}, {"auth_ref": "r1", "us-gaap_AmortizationOfIntangibleAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": {"parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": 1.0, "order": 8.0}, {"presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": {"http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-details-textual": {"lang": "en-us", "role": "label", "Intangibles amortization": {"terseLabel": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."}}, {"auth_ref": "r5", "r212", "r219", "r594"}, {"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": {"http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share-details-textual": {"lang": "en-us", "role": "label", "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."}}, {"auth_ref": "r177"}, {"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": {"http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share": {"http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share-details-textual": {"lang": "en-us", "role": "label", "Antidilutive Securities Axis": {"documentation": "Information by type of antidilutive security."}}, {"auth_ref": "r23"}, {"us-gaap_AntidilutiveSecuritiesNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": {"http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share": {"http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share-details-textual": {"lang": "en-us", "role": "label", "Antidilutive Securities, Name Domain": {"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."}}, {"auth_ref": "r23"}, {"us-gaap_Assets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"parentTag": null, "weight": null, "order": null, "root": true}, {"presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"lang": "en-us", "role": "label", "us-gaap_Assets": {"totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit."}}, {"auth_ref": "r82", "r93", "r119", "r150", "r182", "r186", "r190", "r191", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r372", "r374", "r396", "r449", "r522", "r591", "r592", "r615", "r629", "r684", "r685", "r701"}, {"us-gaap_AssetsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0}, {"presentation": {"http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": {"lang": "en-us", "role": "label", "us-gaap_AssetsCurrent": {"totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."}}, {"auth_ref": "r111", "r128", "r150", "r200", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r372", "r374", "r396", "r6

"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "en-us", "role": "label", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }, "auth_ref": "r18", "r65", "r146" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentFlag": null, "weight": null, "order": null, "root": true }, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "en-us", "role": "label", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }, "auth_ref": "r0", "r65" }, "ycbd_CbdMdLimintedMarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "CbdMdLimintedMarkMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details", "lang": "en-us", "role": "label", "CBD MD Liminted Mark [Member]", "documentation": "Represents CBD MD Liminted Mark." }, "auth_ref": null, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": "http://www.cbdmd.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "City Area Code", "documentation": "Area code of city" }, "auth_ref": null, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": "http://www.cbdmd.com/20241231/role/statement-document-and-entity-information", "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity", "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual", "lang": "en-us", "role": "label", "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." }, "auth_ref": "r107", "r120", "r121", "r122", "r150", "r170", "r174", "r176", "r184", "r185", "r200", "r242", "r244", "r245", "r246", "r248", "r250", "r270", "r279", "r281", "r284", "r290", "r396", "r479", "r480", "r481", "r482", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r510", "r531", "r551", "r568", "r569", "r570", "r571", "r572", "r638", "r654", "r661" }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details", "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-tables", "lang": "en-us", "role": "label", "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." }, "auth_ref": "r33" }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details", "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-tables", "lang": "en-us", "role": "label", "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightExercisable", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details", "lang": "en-us", "role": "label", "Exercisable, warrants (in shares)", "documentation": "Number of warrants or rights that are exercisable." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details", "lang": "en-us", "role": "label", "Exercisable, warrant, weighted average exercise price (in dollars per share)", "documentation": "Weighted average exercise price of warrants or rights that are exercisable." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightExercisesInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightExercisesInPeriod", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "ycbd_ClassOfWarrantOrRightExercisesInPeriod", "negatedLabel": "Exercised, warrants (in shares)", "documentation": "Number of warrants or rights exercised during the current period." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightExercisesInPeriodWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "Exercised, warrant, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which warrant holders acquired warrants or right." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightForfeituresInPeriod", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "ClassOfWarrantOrRightForfeituresInPeriod", "negatedLabel": "Forfeited, warrants (in shares)", "documentation": "The number of warrant or right forfeitures in period." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightForfeituresInPeriodWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "Forfeited, warrant, weighted average exercise price (in dollars per share)", "documentation": "The number of grants made during the period on warrant or right." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "Granted, warrant, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire warrant or right." }, "auth_ref": null, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "us-gaap_ClassOfWarrantOrRightOutstanding", "periodStartLabel": "Outstanding, warrants (in shares)", "periodEndLabel": "Number of warrants or rights outstanding", "documentation": "Outstanding, warrants (in shares)", "documentation": "The number of warrant or right forfeitures in period." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm", "xbrltype": "durationItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "Outstanding, warrant, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, warrant, weighted average exercise price (in dollars per share)", "documentation": "Weighted average exercise price of warrants or rights outstanding." }, "auth_ref": null, "ycbd_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": "en-us", "role": "label", "Outstanding, warrant, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, warrant, weighted average exercise price (in dollars per share)", "documentation": "Weighted average exercise price of warrants or rights outstanding." }, "auth_ref": null, "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "CollectionOnDiscontinuedOperationsAccountsReceivable", "crdr": "debit", "calculation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentFlag": null, "weight": 1.0, "order": 2.0 }, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "en-us", "role": "label", "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "totalLabel": "Net cash flows from operating activities", "documentation": "Represents the amount of accounts receivable collected from discontinued operations." }, "auth_ref": null, "ycbd_CommitmentSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "CommitmentSharesMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share", "http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share-details-textual", "lang": "en-us", "role": "label", "Commitment Shares [Member]", "documentation": "Represents commitment shares." }, "auth_ref": null, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "parentFlag": null, "weight": 1.0, "order": 0.0 }, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "lang": "en-us", "role": "label", "Commitments and Contingencies (Note 10)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." }, "auth_ref": "r46", "r85", "r451", "r509" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-10-commitments-and-contingencies", "lang": "en-us", "role": "label", "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." }, "auth_ref": "r73", "r234", "r235", "r575", "r678", "r683" }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.cbdmd.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." }, "auth_ref": "r619", "r620", "r621", "r623", "r624", "r625", "r626", "r657", "r658", "r660", "r690", "r713", "r715" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual", "lang": "en-us", "role": "label", "Common Stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." }, "auth_ref": "r49" }, "ycbd_CommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "CommonStockPurchaseWarrantsMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-tables", "lang": "en-us", "role": "label", "Common Stock Purchase Warrants [Member]", "documentation": "Represents common stock purchase warrants." }, "auth_ref": null, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"

parentheticals", "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "Common Stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r49": { "r510" } }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "Common Stock, issued (in shares)", "terseLabel": "Common Stock, Shares Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r49": { "r49" } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "Common Stock, shares outstanding (in shares)", "terseLabel": "Common Stock, Shares Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r9": { "r49": { "r510": { "r528": { "r715": { "r716" } } } } } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" |, "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r49": { "r453": { "r615" } } } }, "ycbd_ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments": { "xbrltype": "monetaryItem", "nsuri": "http://www.cbmdm.com/20241231", "localname": "ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited" |, "lang": { "en-us": { "role": { "label": "ycbd-ComprehensiveIncomeLossNetOfTaxAttributableToParentBeforeIncomeAdjustments", "totalLabel": "Comprehensive Income (loss)", "documentation": "Amount after tax before income adjustments of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r1": { "us-gaap-ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited" |, "lang": { "en-us": { "role": { "label": "us-gaap-ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive Loss attributable to cbmMD, Inc. common shareholders", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r16": { "r131": { "r133": { "r139": { "r441": { "r464": { "r465" } } } } } } }, "ycbd-ComputersFurnitureAndEquipmentMember": { "xbrltype": "domainItem", "nsuri": "http://www.cbmdm.com/20241231", "localname": "ComputersFurnitureAndEquipmentMember", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details" |, "lang": { "en-us": { "role": { "label": "Computers, Furniture, and Equipment [Member]", "documentation": "Represents Computers, furniture, equipment." } } }, "auth_ref": { "r1": { "us-gaap-ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": { "r25": { "r26": { "r36": { "r37": { "r194": { "r476": { "r574" } } } } } } }, "us-gaap-ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": { "r25": { "r26": { "r36": { "r37": { "r194": { "r476": { "r574" } } } } } } }, "us-gaap-ConcentrationRiskByTypeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employee, supplier, lender." } } }, "auth_ref": { "r25": { "r26": { "r36": { "r37": { "r194": { "r476": { "r574" } } } } } } }, "us-gaap-ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Concentration Risk Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": { "r38": { "r100" } } }, "us-gaap-ConcentrationRiskPercentage1": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "us-gaap-ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the 'benchmark' (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": { "r25": { "r26": { "r36": { "r37": { "r194" } } } } }, "us-gaap-ConcentrationRiskTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employee, supplier, lender) of the concentration." } } }, "auth_ref": { "r25": { "r26": { "r36": { "r37": { "r194": { "r476": { "r574" } } } } } } }, "us-gaap-ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": { "r35": { "r585" } } }, "ycbd-ConsultantMember": { "xbrltype": "domainItem", "nsuri": "http://www.cbmdm.com/20241231", "localname": "ConsultantMember", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity", "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "Consultant [Member]", "documentation": "Represents the consultant." } } }, "auth_ref": { "r1": { "us-gaap-ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" |, "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": { "r292": { "r293": { "r296" } } } }, "us-gaap-ContractWithCustomerSalesChannelAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelAxis", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Contract with Customer, Sales Channel [Axis]", "documentation": "Information by sales channel for delivery of good or service in contract with customer." } } }, "auth_ref": { "r601": { "r687" } } }, "us-gaap-ContractWithCustomerSalesChannelDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerSalesChannelDomain", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details" |, "lang": { "en-us": { "role": { "label": "Contract with Customer, Sales Channel [Domain]", "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary." } } }, "auth_ref": { "r601": { "r687" } } }, "ycbd-ConversionOfNotesIntoCommonStockMember": { "xbrltype": "domainItem", "nsuri": "http://www.cbmdm.com/20241231", "localname": "ConversionOfNotesIntoCommonStockMember", "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.cbmdm.com/20241231/role/statement-note-15-subsequent-events", "http://www.cbmdm.com/20241231/role/statement-note-15-subsequent-events-details-textual", "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity", "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "Conversion of Notes into Common Stock [Member]", "documentation": "Represents conversion of notes into common stock." } } }, "auth_ref": { "r1": { "us-gaap-ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": { "r20": { "r21": { "r22" } } } }, "us-gaap-ConversionOfStockNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockNameDomain", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": { "r20": { "r21": { "r22" } } } }, "us-gaap-ConversionOfStockSharesIssued1": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued1", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual" |, "lang": { "en-us": { "role": { "label": "us-gaap-ConversionOfStockSharesIssued1", "terseLabel": "Conversion of Stock, Shares Issued (in shares)", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": { "r20": { "r21": { "r22" } } } }, "us-gaap-ConvertibleDebt": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details" |, "lang": { "en-us": { "role": { "label": "us-gaap-ConvertibleDebt", "periodStartLabel": "Balance at September 30, 2024", "periodEndLabel": "Balance at December 31, 2024", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": { "r12": { "r84": { "r710" } } } }, "us-gaap-ConvertibleDebtCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" |, "lang": { "en-us": { "role": { "label": "Convertible notes,

at fair value", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": "r40" } } }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtTableTextBlock", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": { "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": { "r1": "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "lang": { "en-us": { "role": { "label": "Cost of sales", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": { "r61": "r150", "r200": "r242", "r243": "r244", "r245": "r246", "r247": "r248", "r249": "r250", "r396": "r591", "r684": "r1", "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": { "http://www.cbddmd.com/20241231/role/statement-significant-accounting-policies": { "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": { "r642": { "dei_CurrentFiscalYearEndDate": { "xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.cbddmd.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD--." } } }, "auth_ref": { "r1": "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": { "r68": "r194", "r1", "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "http://www.cbddmd.com/20241231/role/statement-note-15-subsequent-events": { "http://www.cbddmd.com/20241231/role/statement-note-15-subsequent-events-details-textual": { "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": { "r20": "r22", "r1", "us-gaap_DebtConversionConvertedInstrumentSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-15-subsequent-events-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": { "r20": "r22", "r1, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionNameDomain", "presentation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "http://www.cbddmd.com/20241231/role/statement-note-15-subsequent-events": { "http://www.cbddmd.com/20241231/role/statement-note-15-subsequent-events-details-textual": { "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": { "r20": "r22", "r1, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable": { "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": { "r74": "r148", "r229": "r230", "r231": "r232", "r233": "r240", "r241": "r251", "r257": "r258", "r259": "r260", "r261": "r262", "r267": "r274", "r275": "r276", "r404": "r1", "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": { "r12": "r40", "r41": "r83", "r84": "r152", "r252": "r253", "r254": "r255", "r256": "r258", "r263": "r264", "r265": "r266", "r268": "r269", "r270": "r271", "r272": "r273", "r595": "r596", "r597": "r598", "r599": "r613", "r655": "r679", "r680", "r681", "r695", "r696": { "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": { "r75": "r254", "r1, "ycbd_DebtInstrumentDiscountedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.cbddmd.com/20241231", "localname": "DebtInstrumentDiscountedPercentage", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "ycbd_DebtInstrumentDiscountedPercentage", "terseLabel": "Debt Instrument Discounted Percentage", "documentation": "Represents the percent of discount convertible promissory note issued to investors." } } }, "auth_ref": { "r1": "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": { "r252": "r404", "r405": "r596", "r597": "r613", "r1, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": { "r43": "r253", "r1, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r12": "r152", "r252": "r253", "r254": "r255", "r256": "r258", "r263": "r264", "r265": "r266", "r268": "r269", "r270": "r271", "r272": "r273", "r595": "r596", "r597": "r598", "r599": "r613", "r655": "r679", "r680", "r681", "r695": "r696": { "us-gaap_DebtPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtPolicyTextBlock", "presentation": { "http://www.cbddmd.com/20241231/role/statement-significant-accounting-policies": { "lang": { "en-us": { "role": { "label": "Debt, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt." } } }, "auth_ref": { "r71": "ycbd_DecreaseInAPICIssuanceOfStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cbddmd.com/20241231", "localname": "DecreaseInAPICIssuanceOfStock", "crdr": "debit", "presentation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "ycbd_DecreaseInAPICIssuanceOfStock", "negatedTerseLabel": "Issuance of stock", "documentation": "Represents the decrease in APIC related to be issuance of common stock." } } }, "auth_ref": { "r1": "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-14-income-taxes-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "terseLabel": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": { "r689": { "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Deposits for facilities", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": { "r645": { "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.cbddmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r5": "r30", "r1, "us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationExcludingLessorAssetUnderOperatingLease", "crdr": "debit", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-4-property-and-equipment-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_DepreciationExcludingLessorAssetUnderOperatingLease", "terseLabel": "Depreciation, Excluding Lessor Asset under Operating Lease", "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease of depreciation expense." } } }, "auth_ref": { "r228": "r419", "r1, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": { "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r687": { "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-8-stock-based-compensation": { "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r306": "r307", "r337": "r338", "r340": "r606": { "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": { "http://www.cbddmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": { "http://www.cbddmd.com/20241231/role/statement-note-10-commitments-and-contingencies": { "http://www.cbddmd.com/20241231/role/statement-note-11-note-payable": { "http://www.cbddmd.com/20241231/role/statement-note-12-leases": { "http://www.cbddmd.com/20241231/role/statement-note-7-shareholders-equity": { "http://www.cbddmd.com/20241231/role/statement-note-8-stock-based-compensation": { "http://www.cbddmd.com/20241231/role/statement-note-15-subsequent-events": { "http://www.cbddmd.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities": { "http://www.cbddmd.com/20241231/role/statement-note-3-inventory": { "http://www.cbddmd.com/20241231/role/statement-note-4-property-and-equipment": { "http://www.cbddmd.com/20241231/role/statement-note-5-intangible-assets": { "http://www.cbddmd.com/20241231/role/statement-note-6-related-party-transactions": { "http://www.cbddmd.com/20241231/role/statement-note-9-warrants": { "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to

Financial Statements } } } , "auth_ref": "I", "us-gaap:DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crd": { "credit": "calculation", "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Accrued dividends", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "auth_ref": "I", "r41": "I", "us-gaap:DividendsPreferredStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPreferredStockCash", "crd": { "debit": "presentation", "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap:DividendsPreferredStockCash", "negatedLabel": "Preferred dividend declared, not paid", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.", "auth_ref": "I", "r2": "r77" } } } , "dei:DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "auth_ref": "I", "dei:DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "auth_ref": "I", "dei:DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "I", "dei:DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information Table", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "auth_ref": "I", "dei:DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "auth_ref": "I", "dei:DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "auth_ref": "I", "dei:DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report.", "auth_ref": "I", "r634": "I", "dei:DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type or the word 'Other'.", "auth_ref": "I", "us-gaap:EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "lang": { "en-us": { "role": { "label": "Net Loss per share.", "auth_ref": "I", "us-gaap:EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "lang": { "en-us": { "role": { "label": "Basic and Diluted earnings per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "auth_ref": "I", "r140": "r150", "r159", "r160", "r161", "r162", "r163", "r168", "r170", "r174", "r175", "r176", "r181", "r367", "r371", "r384", "r385", "r442", "r466", "r588" } } } , "us-gaap:EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://www.cbdm.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "auth_ref": "I", "r23", "r24", "r178" } } } , "us-gaap:EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.cbdm.com/20241231/role/statement-note-13-loss-per-share": { "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share.", "auth_ref": "I", "r167", "r177", "r179", "r180" } } } , "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition", "presentation": { "http://www.cbdm.com/20241231/role/statement-note-8-stock-based-compensation-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "auth_ref": "I", "r339" } } } , "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crd": { "debit": "presentation", "http://www.cbdm.com/20241231/role/statement-note-8-stock-based-compensation-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "auth_ref": "I", "r688" } } } , "us-gaap:EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "http://www.cbdm.com/20241231/role/statement-note-8-stock-based-compensation": { "http://www.cbdm.com/20241231/role/statement-note-8-stock-based-compensation-details-textual": { "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "auth_ref": "I", "dei:EntityAddressAddressLine": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "auth_ref": "I", "dei:EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town", "auth_ref": "I", "dei:EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code", "auth_ref": "I", "dei:EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province.", "auth_ref": "I", "dei:EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "auth_ref": "I", "r631" } } } , "dei:EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "auth_ref": "I", "dei:EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "auth_ref": "I", "dei:EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parent-heticals": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited": { "http://www.cbdm.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "http://www.cbdm.com/20241231/role/statement-document-and-entity-information": { "http://www.cbdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": { "http://www.cbdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details": { "http://www.cbdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details": { "http://www.cbdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": { "http://www.cbdm.com/20241231/role/statement-note-10-commitments-and-contingencies": { "http://www.cbdm.com/20241231/role/statement-note-11-note-payable": { "http://www.cbdm.com/20241231/role/statement-note-11-note-payable-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-12-leases": { "http://www.cbdm.com/20241231/role/statement-note-12-leases-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "http://www.cbdm.com/20241231/role/statement-note-12-leases-operating-lease-costs-and-supplemental-cash-flow-information-details": { "http://www.cbdm.com/20241231/role/statement-note-12-leases-tables": { "http://www.cbdm.com/20241231/role/statement-note-13-loss-per-share": { "http://www.cbdm.com/20241231/role/statement-note-13-loss-per-share-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-14-income-taxes": { "http://www.cbdm.com/20241231/role/statement-note-14-income-taxes-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-15-subsequent-events": { "http://www.cbdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities": { "http://www.cbdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-3-inventory": { "http://www.cbdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "http://www.cbdm.com/20241231/role/statement-note-3-inventory-tables": { "http://www.cbdm.com/20241231/role/statement-note-4-property-and-equipment": { "http://www.cbdm.com/20241231/role/statement-note-4-property-and-equipment-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details": { "http://www.cbdm.com/20241231/role/statement-note-4-property-and-equipment-tables": { "http://www.cbdm.com/20241231/role/statement-note-5-intangible-assets": { "http://www.cbdm.com/20241231/role/statement-note-5-intangible-assets-details-textual": { "http://www.cbdm.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": { "http://www.cbdm.com/20241231/role/statement-note-5-

cbddm-assets-tables", "http://www.cbddm.com/20241231/role/statement-note-6-related-party-transaction", "http://www.cbddm.com/20241231/role/statement-note-7-shareholders-equity", "http://www.cbddm.com/20241231/role/statement-note-7-shareholders-equity-details-textual", "http://www.cbddm.com/20241231/role/statement-note-8-stock-based-compensation", "http://www.cbddm.com/20241231/role/statement-note-8-stock-based-compensation-details-textual", "http://www.cbddm.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "http://www.cbddm.com/20241231/role/statement-note-8-stock-based-compensation-tables", "http://www.cbddm.com/20241231/role/statement-note-9-warrants", "http://www.cbddm.com/20241231/role/statement-note-9-warrants-schedule-of-equity-classified-warrants-details", "http://www.cbddm.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details", "http://www.cbddm.com/20241231/role/statement-note-9-warrants-tables", "http://www.cbddm.com/20241231/role/statement-significant-accounting-policies-policies", "lang": "en-us", "role": "label", "EntityIDomain": "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": "r631", "dei_EntityFileNumber": "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntityFileNumber": "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": "r631", "dei_EntityFilerCategory": "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntityFilerCategory": "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": "r631", "dei_EntityIncorporationStateCountryCode": "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntityIncorporationStateCountryCode": "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": "r631", "dei_EntityInteractiveDataCurrent": "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntityInteractiveDataCurrent": "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": "r637", "dei_EntityRegistrantName": "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntityRegistrantName": "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": "r631", "dei_EntityShellCompany": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntityShellCompany": "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": "r631", "dei_EntitySmallBusiness": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntitySmallBusiness": "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": "r631", "dei_EntityTaxIdentificationNumber": "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": "http://www.cbddm.com/20241231/role/statement-document-and-entity-information", "lang": "en-us", "role": "label", "EntityTaxIdentificationNumber": "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": "r631", "ycbd_EquipmentSoldValue": "xbrltype": "monetaryItemType", "nsuri": "http://www.cbddm.com/20241231", "localname": "EquipmentSoldValue", "crdr": "debit", "presentation": "http://www.cbddm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual", "lang": "en-us", "role": "label", "ycbd_EquipmentSoldValue": "terseLabel": "Equipment Sold Value", "documentation": "The total value of equipment sold." } } }, "auth_ref": "r631", "ycbd_EquityClassifiedWarrantsMember": "xbrltype": "domainItemType", "nsuri": "http://www.cbddm.com/20241231", "localname": "EquityClassifiedWarrantsMember", "presentation": "http://www.cbddm.com/20241231/role/statement-note-9-warrants-tables", "lang": "en-us", "role": "label", "EquityClassifiedWarrantsMember": "documentation": "Represents equity classified warrants." } } }, "auth_ref": "r631", "us-gaap_EquityComponentDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": "http://www.cbddm.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "lang": "en-us", "role": "label", "EquityComponentDomain": "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": "r109", "r135", "r136", "r137", "r153", "r154", "r155", "r157", "r162", "r164", "r166", "r183", "r201", "r202", "r227", "r291", "r358", "r359", "r364", "r365", "r366", "r368", "r370", "r371", "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r397", "r398", "r399", "r400", "r401", "r402", "r406", "r408", "r420", "r463", "r469", "r470", "r471", "r480", "r551", "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": "http://www.cbddm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual", "lang": "en-us", "role": "label", "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": "terseLabel": "Equity Method Investment Other than Temporary Impairment", "documentation": "Amount of other than temporary decline in value that has been recognized against investment accounted for under equity method of accounting." } } }, "auth_ref": "r672", "ycbd_FairValueAdjustmentOfDebt": "xbrltype": "monetaryItemType", "nsuri": "http://www.cbddm.com/20241231", "localname": "FairValueAdjustmentOfDebt", "crdr": "credit", "calculation": "http://www.cbddm.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": "1.0", "order": "2.0", "http://www.cbddm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "10.0", "presentation": "http://www.cbddm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "http://www.cbddm.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.cbddm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details", "lang": "en-us", "role": "label", "Decrease (increase) in fair value of convertible debt": "negatedLabel": "Increase (decrease) in fair value of convertible debt", "documentation": "Amount of addition (reduction) to the amount of debt." } } }, "auth_ref": "r631", "us-gaap_FairValueByFairValueHierarchyLevelAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": "http://www.cbddm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details", "lang": "en-us", "role": "label", "Fair Value Hierarchy and NAV Axis": "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": "r265", "r298", "r299", "r300", "r301", "r302", "r303", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r430", "r431", "r432", "r596", "r597", "r602", "r603", "r604", "r608", "r609", "us-gaap_FairValueInputsLevel1Member": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": "http://www.cbddm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details", "lang": "en-us", "role": "label", "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": "r265", "r298", "r303", "r387", "r388", "r392", "r431", "r596", "r597", "r602", "r603", "us-gaap_FairValueInputsLevel2Member": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": "http://www.cbddm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details", "lang": "en-us", "role": "label", "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": "r265", "r298", "r303", "r387", "r388", "r392", "r431", "r596", "r597", "r602", "r603", "us-gaap_FairValueInputsLevel3Member": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": "http://www.cbddm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details", "lang": "en-us", "role": "label", "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": "r265", "r298", "r299", "r300", "r301", "r302", "r303", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r430", "r431", "r432", "r596", "r597", "r602", "r603", "r


```

http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details", "lang": "f", "en-us": "f", "role": "f", "label": "f", "ycbd_FiniteLivedIntangibleAssetsAccumulatedImpairment", "negatedLabel": "Impairment of intangible assets", "documentation": "Amount of accumulated impairment of finite-lived intangible assets.", "auth_ref": "f", "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies-policies", "lang": "f", "en-us": "f", "role": "f", "label": "f", "ycbd_GSSAgreementMember", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "auth_ref": "f", "r210", "r224", "r226", "us-gaap_GrossProfit", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "parentTag": "us-gaap_OperatingIncomeLoss", "weight": "1.0", "order": "0.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "us-gaap_GrossProfit", "totalLabel": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "auth_ref": "f59", "r61", "r92", "r150", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r396", "r590", "r591", "r662", "r663", "r664", "r665", "r666", "r684", "ycbd_GSSAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "GSSAgreementMember", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "GSS Agreement [Member]", "documentation": "Represents GSS Agreement.", "auth_ref": "f", "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "parentTag": "us-gaap_NetIncomeLoss", "weight": "1.0", "order": "0.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Income (loss) before provision for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest.", "auth_ref": "f60", "r87", "r92", "r443", "r461", "r590", "r591", "r662", "r663", "r664", "r665", "r666", "us-gaap_IncomeStatementAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": "f", "en-us": "f", "role": "f", "label": "f", "Income Statement [Abstract]", "auth_ref": "f", "us-gaap_IncomeTaxDisclosureTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-note-14-income-taxes", "lang": "f", "en-us": "f", "role": "f", "label": "f", "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax.", "auth_ref": "f151", "r346", "r349", "r350", "r351", "r352", "r353", "r356", "r360", "r361", "r362", "r363", "r484", "r607", "us-gaap_IncomeTaxPolicyTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies-policies", "lang": "f", "en-us": "f", "role": "f", "label": "f", "Income Tax Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "auth_ref": "f134", "r347", "r348", "r353", "r354", "r355", "r357", "r478", "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "1.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "auth_ref": "f4", "us-gaap_IncreaseDecreaseInAccountsReceivable", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "12.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "auth_ref": "f4", "us-gaap_IncreaseDecreaseInDeferredRevenue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "4.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "Deferred revenue / customer deposits", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "auth_ref": "f580", "us-gaap_IncreaseDecreaseInDepositOtherAssets", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "13.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "us-gaap_IncreaseDecreaseInDepositOtherAssets", "negatedLabel": "Deposits", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "auth_ref": "f4", "us-gaap_IncreaseDecreaseInInventories", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "14.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "auth_ref": "f4", "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "Changes in operating assets and liabilities.", "auth_ref": "f", "us-gaap_IncreaseDecreaseInOperatingLeaseLiability", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "3.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease.", "auth_ref": "f641", "r652", "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "0.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "f", "en-us": "f", "role": "f", "label": "f", "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "auth_ref": "f4", "ycbd_IncreaseDecreaseInPrepaidInventoryTotal", "xbrltype": "monetaryItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "IncreaseDecreaseInPrepaidInventoryTotal", "crdr": "credit", "calculation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": "1.0", "order": "15.0", "presentation": "f", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows
```


Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r142": "r144", "r145" } }, "us-gaap_InventoriesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesDisclosureTextBlock", "presentation": "http://www.cbmdm.com/20241231/role/statement-note-3-inventory", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r206" } }, "us-gaap_InventoriesFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesFinishedGoods", "crdr": "debit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "parentTag": "us-gaap_InventoriesNet", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "lang": { "en-us": { "role": { "label": "Finished Goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": { "r646" } }, "us-gaap_InventoriesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesGross", "crdr": "debit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap_InventoriesGross", "terseLabel": "Inventory", "documentation": "Gross amount as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r647" } }, "us-gaap_InventoriesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesNet", "crdr": "debit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "lang": { "en-us": { "role": { "label": "us-gaap_InventoriesNet", "totalLabel": "Total Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r127", "r583", "r615" } }, "us-gaap_InventoriesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesPolicyTextBlock", "presentation": { "http://www.cbmdm.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Inventory Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": { "r97", "r113", "r126", "r206", "r207", "r208", "r436", "r586" } }, "us-gaap_InventoriesRawMaterialsAndSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesRawMaterialsAndSupplies", "crdr": "debit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "parentTag": "us-gaap_InventoriesNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "lang": { "en-us": { "role": { "label": "Inventory Components", "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed." } } }, "auth_ref": { "r647" } }, "us-gaap_InventoriesValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesValuationReserves", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "parentTag": "us-gaap_InventoriesNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "lang": { "en-us": { "role": { "label": "us-gaap_InventoriesValuationReserves", "negatedLabel": "Inventory Reserve", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": { "r70", "r647" } }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_Investments", "terseLabel": "Investments, Total", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": { "r445", "r447", "r617", "r618" } }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities": { "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": { "r89", "r108", "r198", "r199", "r394", "r395", "r709" } }, "ycbd_Investors8SeniorSecuredOriginalIssue20DiscountConvertiblePromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbmdm.com/20241231", "localname": "Investors8SeniorSecuredOriginalIssue20DiscountConvertiblePromissoryNoteMember", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-11-note-payable": { "http://www.cbmdm.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "Investors 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note [Member]", "documentation": "Represents the Investors 8% Senior Secured Original Issue and the 20% Discount Convertible Promissory Note." } } }, "auth_ref": { "r5" } }, "ycbd_IssuanceOfSharesForConversionOfDebtAndAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cbmdm.com/20241231", "localname": "IssuanceOfSharesForConversionOfDebtAndAccruedInterest", "crdr": "credit", "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "ycbd_IssuanceOfSharesForConversionOfDebtAndAccruedInterest", "terseLabel": "Issuance of shares for conversion of debt and accrued interest", "documentation": "The proceeds from the issuance of shares for the conversion of debt and accrued interest." } } }, "auth_ref": { "r5" } }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Issuance of stock for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": { "r5" } }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-tables": { "lang": { "en-us": { "role": { "label": "Lease Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": { "r697" } }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details": { "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": { "r72", "r419" } }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-comprehensive-income-loss-unaudited": { "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-operations-unaudited": { "http://www.cbmdm.com/20241231/role/statement-document-and-entity-information": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details": { "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": { "http://www.cbmdm.com/20241231/role/statement-note-10-commitments-and-contingencies": { "http://www.cbmdm.com/20241231/role/statement-note-11-note-payable": { "http://www.cbmdm.com/20241231/role/statement-note-11-note-payable-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-operating-lease-costs-and-supplemental-cash-flow-information-details": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-tables": { "http://www.cbmdm.com/20241231/role/statement-note-13-loss-per-share": { "http://www.cbmdm.com/20241231/role/statement-note-13-loss-per-share-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-14-income-taxes": { "http://www.cbmdm.com/20241231/role/statement-note-14-income-taxes-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-15-subsequent-events": { "http://www.cbmdm.com/20241231/role/statement-note-15-subsequent-events-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities": { "http://www.cbmdm.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details": { "http://www.cbmdm.com/20241231/role/statement-note-3-inventory-tables": { "http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment": { "http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details": { "http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-tables": { "http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets": { "http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": { "http://www.cbmdm.com/20241231/role/statement-note-5-intangible-assets-tables": { "http://www.cbmdm.com/20241231/role/statement-note-6-related-party-transactions": { "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity": { "http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation": { "http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation-details-textual": { "http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details": { "http://www.cbmdm.com/20241231/role/statement-note-8-stock-based-compensation-tables": { "http://www.cbmdm.com/20241231/role/statement-note-9-warrants": { "http://www.cbmdm.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details": { "http://www.cbmdm.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details": { "http://www.cbmdm.com/20241231/role/statement-note-9-warrants-tables": { "http://www.cbmdm.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { "r5" } }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-tables": { "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": { "r698" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total future lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": { "r417" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r417" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOffiscalYear", "crdr": "credit", "calculation": { "http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": {


```
"http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "lang": "en-us"; "role": "label"; "2025"; "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } }, "auth_ref": "r698" }, {"us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": "http://www.cbmdm.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "lang": "en-us"; "role": "label"; "us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": "negatedLabel": "Less interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } }, "auth_ref": "r417" }, {"us-gaap-LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": "http://www.cbmdm.com/20241231/role/statement-note-12-leases": { "lang": "en-us"; "role": "label"; "Lessee Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } }, "auth_ref": "r407" }, {"us-gaap-Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": "en-us"; "role": "label"; "us-gaap-Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } }, "auth_ref": "r12", "r40", "r41", "r42", "r44", "r45", "r46", "r47", "r150", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r373", "r374", "r375", "r396", "r508", "r589", "r629", "r684", "r701", "r702" }, {"us-gaap-LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": "en-us"; "role": "label"; "us-gaap-LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } }, "auth_ref": "r54", "r86", "r456", "r615", "r656", "r673", "r694" }, {"us-gaap-LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 0.0 }, "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": "en-us"; "role": "label"; "us-gaap-LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } }, "auth_ref": "r42", "r112", "r150", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r373", "r374", "r375", "r396", "r615", "r684", "r701", "r702" }, {"us-gaap-LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": "en-us"; "role": "label"; "Current liabilities:" } }, "auth_ref": "r11", {"us-gaap-LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": "en-us"; "role": "label"; "us-gaap-LiabilitiesNoncurrent", "totalLabel": "Total long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } }, "auth_ref": "r12", "r44", "r45", "r46", "r47", "r150", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r373", "r374", "r375", "r396", "r615", "r684", "r701", "r702" }, {"us-gaap-LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": "en-us"; "role": "label"; "Long-term liabilities:" } }, "auth_ref": "r11", {"ycbd-LiquidityAndGoingConcernConsiderationsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cbmdm.com/20241231", "localname": "LiquidityAndGoingConcernConsiderationsPolicyPolicyTextBlock", "presentation": "http://www.cbmdm.com/20241231/role/statement-significant-accounting-policies": { "lang": "en-us"; "role": "label"; "Liquidity and Going Concern Considerations, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for liquidity and going concern considerations." } }, "auth_ref": "r11", {"dei-LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": "http://www.cbmdm.com/20241231/role/statement-document-and-entity-information": { "lang": "en-us"; "role": "label"; "Local Phone Number", "documentation": "Local phone number for entity." } }, "auth_ref": "r11", {"ycbd-ManufacturingEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbmdm.com/20241231", "localname": "ManufacturingEquipmentMember", "presentation": "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-textual": { "lang": "en-us"; "role": "label"; "Maximum [Member]" } }, "auth_ref": "r236", "r237", "r238", "r239", "r305", "r345", "r390", "r435", "r467", "r468", "r475", "r500", "r501", "r559", "r561", "r564", "r565", "r566", "r576", "r577", "r593", "r600", "r605", "r609", "r610", "r611", "r612", "r616", "r686", "r703", "r704", "r705", "r706", "r707", "r708" }, {"ycbd-MerchantReceivableAndReservePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cbmdm.com/20241231", "localname": "MerchantReceivableAndReservePolicyTextBlock", "presentation": "http://www.cbmdm.com/20241231/role/statement-significant-accounting-policies": { "lang": "en-us"; "role": "label"; "Merchant Receivable and Reserve [Policy Text Block]", "documentation": "Disclosure of accounting policy for merchant receivables and reserve." } }, "auth_ref": "r11", {"ycbd-MerchantProcessingFee": { "xbrltype": "percentItemType", "nsuri": "http://www.cbmdm.com/20241231", "localname": "MerchantProcessingFee", "presentation": "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-textual": { "lang": "en-us"; "role": "label"; "ycbd_MerchantProcessingFee", "documentation": "Represents agreed percentage for merchant processing fees." } }, "auth_ref": "r11", {"srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies": "http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-textual": { "lang": "en-us"; "role": "label"; "Minimum [Member]" } }, "auth_ref": "r236", "r237", "r238", "r239", "r305", "r345", "r390", "r435", "r467", "r468", "r475", "r500", "r501", "r559", "r561", "r564", "r565", "r566", "r576", "r577", "r593", "r600", "r605", "r609", "r610", "r611", "r616", "r686", "r703", "r704", "r705", "r706", "r707", "r708" }, {"ecd-MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": "en-us"; "role": "label"; "Material Terms of Trading Arrangement [Text Block]" } }, "auth_ref": "r636" }, {"us-gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": "en-us"; "role": "label"; "us-gaap-NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net Cash flows from financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } }, "auth_ref": "r143" }, {"us-gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 0.0 }, "presentation": "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": "en-us"; "role": "label"; "us-gaap-NetCashProvidedByUsedInvestingActivities", "totalLabel": "Net Cash flows from investing activities", "documentation": "
```


"localname": "NonRule10b51ArrTrmndFlag", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmndFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "r636" } }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Non-cash financing/investing activities:" } } }, "auth_ref": { "ycbd_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": { "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_NotesPayable", "terseLabel": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": { "r12", "r84", "r710", "r711" } } }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-11-note-payable-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_NotesPayableFairValueDisclosure", "terseLabel": "Notes Payable, Fair Value Disclosure", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": { "r12", "r40", "r41", "r691", "r693" } } }, "ycbd_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": { "ycbd_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "NumberOfMajorCustomers", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual": { "lang": { "en-us": { "role": { "label": "ycbd_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers", "documentation": "Represents number of major customers." } } }, "auth_ref": { "ycbd_OperatingExpensesExcludingImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "OperatingExpensesExcludingImpairment", "crdr": "debit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "lang": { "en-us": { "role": { "label": "Operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Excludes impairment of assets." } } }, "auth_ref": { "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r92", "r590", "r662", "r663", "r664", "r665", "r666" } } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-12-leases-operating-lease-costs-and-supplemental-cash-flow-information-details": { "lang": { "en-us": { "role": { "label": "Total Operating Lease Costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": { "r412", "r614" } } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details": { "lang": { "en-us": { "role": { "label": "Total lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r410" } } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Operating leases - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r410" } } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Operating leases - long term portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r410" } } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-12-leases-operating-lease-costs-and-supplemental-cash-flow-information-details": { "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": { "r411", "r413" } } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Operating lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r409" } } }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "parentTag": "ycbd_CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": 1.0, "order": 11.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Amortization of operating lease asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": { "r653" } } }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-12-leases-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r416", "r614" } } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-12-leases-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnInFnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r415", "r614" } } }, "ycbd_OptionsRSUsAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "OptionsRSUsAndWarrantsMember", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share": { "parentTag": "http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share-details-textual": { "lang": { "en-us": { "role": { "label": "Options, RSUs and Warrants [Member]", "documentation": "Represents Options, RSUs and Warrants." } } }, "auth_ref": { "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap_OtherAssets", "totalLabel": "Total other assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": { "r81", "r118", "r440", "r592", "r629" } } }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Other assets:" } } }, "auth_ref": { "ycbd_OtherComprehensiveIncomeLossChangesInFairValueOfDebtRelatedToCreditRisk": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "OtherComprehensiveIncomeLossChangesInFairValueOfDebtRelatedToCreditRisk", "crdr": "debit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "ycbd_OtherComprehensiveIncomeLossChangesInFairValueOfDebtRelatedToCreditRisk", "negatedLabel": "Change in fair value of debt related to credit risk", "documentation": "Amount of equity impact on other comprehensive income loss due to changes in fair value of debt related to credit risk." } } }, "auth_ref": { "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited": { "lang": { "en-us": { "role": { "label": "Other Comprehensive income", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": { "r3", "r8", "r80", "r130", "r133", "r162" } } }, "us-gaap_OtherLongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermInvestments", "crdr": "debit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "Investment in other securities, noncurrent", "documentation": "Amount of long-term investments classified as other." } } }, "auth_ref": { "r445", "r446", "r443" } } }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDividends", "terseLabel": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": { "r64" } } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r63" } } }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": { "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": { "ycbd_PreferredDividendsAccruedNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "PreferredDividendsAccruedNotYetPaid", "crdr": "credit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Preferred dividends accrued but not paid", "documentation": "Represents the value of dividends accrued but not paid for the period." } } }, "auth_ref": { "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendRatePercentage", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual": { "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockDividendRatePercentage", "terseLabel": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": { "r279", "r560", "r562", "r563", "r567" } } }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-

[NetIncomeLossAvailableToCommonStockholdersBasic](#), "weight": -1.0, "order": 1.0, "http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited"-{"parentTag":"us-gaap-ComprehensiveIncomeNetOfTax","weight":-1.0,"order":2.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited"},"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited"}}, {"lang":{"en-us":{"role":{"label":"Preferred dividends","negatedLabel":"Preferred dividends","documentation":"The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."}},"auth_ref":{"r619","r620","r623","r624","r625","r626","r713","r715"}}}, {"us-gaap-PreferredStockParOrStatedValuePerShare":{"xbrltype":"perShareItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"PreferredStockParOrStatedValuePerShare","presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parenteticals"},"http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual"}}, {"lang":{"en-us":{"role":{"label":"Preferred Stock, Par or Stated Value Per Share (in dollars per share)","terseLabel":"Preferred Stock, Par or Stated Value Per Share (in dollars per share)","documentation":"Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."}},"auth_ref":{"r48","r278"}}}, {"us-gaap-PreferredStockSharesAuthorized":{"xbrltype":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"PreferredStockSharesAuthorized","presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parenteticals"},"http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual"}}, {"lang":{"en-us":{"role":{"label":"Preferred Stock, Shares Authorized (in shares)","terseLabel":"Preferred Stock, Shares Authorized (in shares)","documentation":"The maximum number of nonredeemable preferred shares for preferred stock redeemable solely at the option of the issuer permitted to be issued by an entity's charter and bylaws."}},"auth_ref":{"r48","r510"}}}, {"us-gaap-PreferredStockSharesIssued":{"xbrltype":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"PreferredStockSharesIssued","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual"}}, {"lang":{"en-us":{"role":{"label":"Preferred Stock, Shares Issued (in shares)","terseLabel":"Preferred Stock, Shares Issued (in shares)","documentation":"Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at the option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."}},"auth_ref":{"r48","r278"}}}, {"us-gaap-PreferredStockSharesOutstanding":{"xbrltype":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"PreferredStockSharesOutstanding","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-7-shareholders-equity-details-textual"}}, {"lang":{"en-us":{"role":{"label":"Preferred Stock, Shares Outstanding, Ending Balance (in shares)","terseLabel":"Preferred Stock, Shares Outstanding (in shares)","documentation":"Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."}},"auth_ref":{"r48","r510","r528","r715","r716"}}}, {"us-gaap-PreferredStockValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"PreferredStockValue","crdr":"credit","calculation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"},"parentTag":"us-gaap-StockholdersEquity","weight":1.0,"order":3.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"}}, {"lang":{"en-us":{"role":{"label":"Preferred Stock","documentation":"Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."}},"auth_ref":{"r48","r452","r615"}}}, {"us-gaap-PrepaidExpenseAndOtherAssetsCurrent":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"PrepaidExpenseAndOtherAssetsCurrent","crdr":"debit","calculation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"},"parentTag":"us-gaap-AssetsCurrent","weight":1.0,"order":1.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"}}, {"lang":{"en-us":{"role":{"label":"Prepaid expenses and other current assets","documentation":"Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."}},"auth_ref":{"r648"}}}, {"ycbd-PrepaidInventory":{"xbrltype":"monetaryItemType","nsuri":"http://www.cbmdm.com/20241231","localname":"PrepaidInventory","crdr":"debit","calculation":{"http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details"},"parentTag":"us-gaap-InventoryNet","weight":1.0,"order":3.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"},"parentTag":"us-gaap-AssetsCurrent","weight":1.0,"order":5.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-note-3-inventory-schedule-of-inventory-details"}}, {"lang":{"en-us":{"role":{"label":"Inventory prepaid","documentation":"Amount of consideration paid in advance for inventory that provide economic benefits within a future period of one year or the normal operating cycle, if longer."}},"auth_ref":{"r717}}}, {"us-gaap-PrepaidSponsorship":{"xbrltype":"monetaryItemType","nsuri":"http://www.cbmdm.com/20241231","localname":"PrepaidSponsorship","crdr":"debit","calculation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"},"parentTag":"us-gaap-AssetsCurrent","weight":1.0,"order":0.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"}}, {"lang":{"en-us":{"role":{"label":"Prepaid sponsorship","documentation":"Amount of consideration paid in advance for sponsorships."}},"auth_ref":{"r717}}}, {"ycbd-PrincipleAdjustmentsOfDebt":{"xbrltype":"monetaryItemType","nsuri":"http://www.cbmdm.com/20241231","localname":"PrincipleAdjustmentsOfDebt","crdr":"credit","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-11-note-payable-details-textual"}}, {"lang":{"en-us":{"role":{"label":"Principle Adjustments Of Debt","terseLabel":"Principle Adjustments of Debt","documentation":"The change in the principle value of debt."}},"auth_ref":{"r717}}}, {"us-gaap-ProceedsFromConvertibleDebt":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ProceedsFromConvertibleDebt","crdr":"debit","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"},"http://www.cbmdm.com/20241231/role/statement-note-11-note-payable-details-textual"}}, {"lang":{"en-us":{"role":{"label":"us-gaap-Proceeds From Convertible Debt","terseLabel":"Proceeds from Convertible Debt","documentation":"The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."}},"auth_ref":{"r717}}}, {"us-gaap-ProceedsFromRepaymentsOfNotesPayable":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ProceedsFromRepaymentsOfNotesPayable","crdr":"debit","calculation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited"},"parentTag":"us-gaap-NetCashProvidedByUsedInFinancingActivities","weight":1.0,"order":0.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited"}}, {"lang":{"en-us":{"role":{"label":"us-gaap-Proceeds From Repayments Of Notes Payable","terseLabel":"Note payable","documentation":"Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation."}},"auth_ref":{"r717}}}, {"us-gaap-PropertyPlantAndEquipmentByTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"PropertyPlantAndEquipmentByTypeAxis","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies"},"http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"},"http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details"},"parentTag":"us-gaap-PropertyPlantAndEquipmentNet","weight":1.0,"order":0.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details"},"parentTag":"us-gaap-PropertyPlantAndEquipmentTextBlock","xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"PropertyPlantAndEquipmentDisclosureTextBlock","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment"},"parentTag":"us-gaap-PropertyPlantAndEquipmentGross","xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"PropertyPlantAndEquipmentGross","crdr":"debit","calculation":{"http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details"},"parentTag":"us-gaap-PropertyPlantAndEquipmentNet","weight":1.0,"order":0.0},"presentation":{"http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details"},"parentTag":"us-gaap-PropertyPlantAndEquipmentTextBlock","xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Property Plant and Equipment Disclosure [Text Block]","documentation":"The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."}},"auth_ref":{"r71","r101","r105","r106"}}}, {"us-gaap-PropertyPlantAndEquipmentPolicyTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Property Plant and Equipment Policy Text Block","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-4-property-and-equipment-major-classes-of-property-and-equipment-details"},"parentTag":"us-gaap-PropertyPlantAndEquipmentTextBlock","xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Property Plant and Equipment Useful Life","presentation":{"http://www.cbmdm.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"},"parentTag":"us-gaap-PropertyPlantAndEquipmentTextBlock","xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Property Plant and Equipment Useful Life (Year)","documentation":"Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. In PnYnMnDfnHnMns format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."}},"auth_ref":{"r72","r418"}}}, {"us-gaap-PropertyPlantAndEquipmentUsefulLife":{"xbrltype":"durationItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Property Plant and Equipment Useful Life (Year)","documentation":"Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. In PnYnMnDfnHnMns format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."}},"auth_ref":{"r72","r418","r435","r436","r437","r438","r439","r440","r441","r442","r443","r444","r445","r446","r447","r448","r449","r450","r451","r452","r453","r454","r455","r456","r457","r458","r459","r460","r461","r462","r463","r464","r465","r466","r467","r468","r469","r470","r471","r472","r473","r474","r475","r476","r477","r478","r479","r480","r481","r482","r483","r484","r485","r486","r487","r488","r489","r490","r491","r492","r493","r494","r495","r496","r497","r498","r499","r500","r501","r502","r503","r504","r505","r506","r507","r508","r509","r510","r511","r512","r513","r514","r515","r516","r517","

RangeMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.cbdmd.com/20241231/role/statement-note-11-note-payable", "http://www.cbdmd.com/20241231/role/statement-note-11-note-payable-details-textual", "lang": "en-us", "role": "label", "Statistical Measurement", "Domain": "auth_ref": "r236", "r237", "r238", "r239", "r297", "r305", "r333", "r334", "r335", "r345", "r390", "r433", "r434", "r435", "r467", "r468", "r475", "r500", "r501", "r559", "r561", "r564", "r565", "r566", "r576", "r577", "r593", "r600", "r605", "r609", "r610", "r611", "r612", "r616", "r621", "r682", "r686", "r692", "r704", "r705", "r706", "r707", "r708", "us-gaap-RelatedPartyDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities", "http://www.cbdmd.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual", "lang": "en-us", "role": "label", "Related and Nonrelated Parties", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest.", "auth_ref": "r195", "r304", "r424", "r425", "r450", "r457", "r503", "r504", "r505", "r506", "r507", "r527", "r529", "r558", "us-gaap-RelatedPartyTransactionsByRelatedPartyAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities", "http://www.cbdmd.com/20241231/role/statement-note-2-marketable-securities-and-investment-other-securities-details-textual", "lang": "en-us", "role": "label", "Related and Nonrelated Parties", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest.", "auth_ref": "r195", "r304", "r424", "r425", "r450", "r457", "r503", "r504", "r505", "r506", "r507", "r527", "r529", "r558", "r700", "us-gaap-RelatedPartyTransactionsDisclosureTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-6-related-party-transactions", "lang": "en-us", "role": "label", "Related Party Transactions Disclosure", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates.", "auth_ref": "r421", "r422", "r423", "r425", "r426", "r485", "r486", "r487", "r534", "r535", "r536", "r555", "r557", "us-gaap-RestrictedStockExpense": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockExpense", "crdr": "debit", "calculation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "parentTag": "ycb CollectionOnDiscontinuedOperationsAccountsReceivable", "weight": 1.0, "order": 6.0, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "en-us", "role": "label", "Restricted stock expense", "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.", "auth_ref": "r5", "us-gaap-RetainedEarningsAccumulatedDeficit": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "lang": "en-us", "role": "label", "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit).", "auth_ref": "r51", "r77", "r455", "r472", "r474", "r483", "r511", "r615", "us-gaap-RetainedEarningsMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "lang": "en-us", "role": "label", "Retained Earnings", "documentation": "Accumulated undistributed earnings (deficit).", "auth_ref": "r109", "r153", "r154", "r155", "r157", "r162", "r164", "r166", "r201", "r202", "r227", "r358", "r359", "r364", "r365", "r366", "r368", "r370", "r371", "r376", "r378", "r379", "r381", "r383", "r406", "r408", "r469", "r471", "r488", "r715", "us-gaap-RevenueFromContractWithCustomerIncludingAssessedTax": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "parentTag": "us-gaap-Revenues", "weight": 1.0, "order": 0.0, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "lang": "en-us", "role": "label", "Gross Sales", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "auth_ref": "r90", "r91", "r182", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r294", "r295", "r437", "us-gaap-RevenueRecognitionPolicyTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies", "lang": "en-us", "role": "label", "Revenue", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "auth_ref": "r532", "r581", "r587", "us-gaap-RevenueRemainingPerformanceObligation": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "lang": "en-us", "role": "label", "us-gaap-RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "auth_ref": "r104", "us-gaap-Revenues": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "parentTag": "us-gaap-GrossProfit", "weight": 1.0, "order": 0.0, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "lang": "en-us", "role": "label", "us-gaap-Revenues", "totalLabel": "Total Net Sales", "terseLabel": "Revenues, Total", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "auth_ref": "r90", "r91", "r138", "r150", "r182", "r187", "r188", "r189", "r191", "r192", "r193", "r194", "r200", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r396", "r443", "r591", "r684", "us-gaap-RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "lang": "en-us", "role": "label", "Change in lease asset", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "auth_ref": "r414", "r614", "ecd-Rule10b51ArrAdoptedFlag": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "ecd-Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted", "auth_ref": "r636", "ecd-Rule10b51ArrTrmtdFlag": "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "label", "ecd-Rule10b51ArrTrmtdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated", "auth_ref": "r636", "us-gaap-SaleOfStockNameOfTransactionDomain": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "lang": "en-us", "role": "label", "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "auth_ref": "ycb-SalesAllowances": "xbrltype": "monetaryItemType", "nsuri": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "parentTag": "us-gaap-Revenues", "weight": 1.0, "order": 1.0, "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "lang": "en-us", "role": "label", "ycb-SalesAllowances", "negatedLabel": "Allowances", "documentation": "Amount of sales allowance.", "auth_ref": "us-gaap-SalesChannelDirectlyToConsumerMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesChannelDirectlyToConsumerMember", "presentation": "http://www.cbdmd.com/20241231

"ycbd_SeriesACumulativeConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "SeriesACumulativeConvertiblePreferredStockMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-document-and-entity-information", "http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share": "http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share-details-textual", "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity": "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual" }, { "lang": { "en-us": { "role": { "label": "Series A Cumulative Convertible Preferred Stock [Member]", "documentation": "Represents Series A Cumulative Convertible Preferred Stock." } }, "auth_ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "terseLabel": "Exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": { "r314" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": { "r314" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": { "r318" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Outstanding (in shares)", "periodEndLabel": "Outstanding (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": { "r312", "r313" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": { "r312", "r313" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation", "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-schedule-of-equityclassified-warrants-details", "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r308", "r309", "r310", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r332", "r333", "r334", "r335", "r336" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": { "r317" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Forfeited, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": { "r318" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": { "r316" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": { "r306", "r311", "r330", "r331", "r332", "r333", "r336", "r341", "r342", "r343", "r344" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "terseLabel": "Exercisable (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnInMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r34" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "terseLabel": "Outstanding, weighted average remaining contractual term (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnInMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r79" }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": { "r1", "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r67", "r147" }, "ycbd_SoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "SoftwareMember", "presentation": "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "lang": { "en-us": { "role": { "label": "Software [Member]", "documentation": "Represents software." } } }, "auth_ref": { "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": "http://www.cbdmd.com/20241231/role/statement-document-and-entity-information", "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity": "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual", "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r107", "r120", "r121", "r122", "r150", "r170", "r171", "r174", "r176", "r184", "r185", "r200", "r242", "r244", "r245", "r246", "r249", "r250", "r278", "r279", "r281", "r284", "r290", "r396", "r479", "r480", "r481", "r482", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r510", "r531", "r551", "r568", "r569", "r570", "r571", "r572", "r638", "r654", "r661" }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r9", "r49", "r52", "r53", "r109", "r135", "r136", "r137", "r153", "r154", "r155", "r157", "r162", "r164", "r166", "r183", "r201", "r202", "r227", "r291", "r358", "r359", "r364", "r365", "r366", "r368", "r370", "r371", "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r397", "r398", "r399", "r400", "r401", "r402", "r406", "r408", "r420", "r463", "r469", "r470", "r471", "r488", "r551" }, "us-gaap_StatementLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parenteticals", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-comprehensive-income-loss-unaudited", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited", "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-disaggregation-of-revenue-details", "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-summary-of-convertible-notes-details", "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.cbdmd.com/20241231/role/statement-note-10-commitments-and-contingencies", "http://www.cbdmd.com/20241231/role/statement-note-11-note-payable", "http://www.cbdmd.com/20241231/role/statement-note-12-leases-details-textual", "http://www.cbdmd.com/20241231/role/statement-note-12-leases-future-minimum-aggregate-lease-payments-details", "http://www.cbdmd.com/20241231/role/statement-note-12-leases-operating-lease-costs-and-supplemental-cash-flow-information-details", "http://www.cbdmd.com/20241231/role/statement-note-12-leases-tables", "http://www.cbdmd.com/20241231/role/statement-note-13-loss-per-share" }

[illegible]


```
under share-based payment arrangement." } } }, "auth_ref": { "r5": "1", "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total cbdMD, Inc. shareholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r49": "r52", "r53": "r69", "r512": "r528", "r552": "r553", "r615": "r629", "r656": "r673", "r694": "r715" } }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "lang": { "en-us": { "role": { "label": "cbdMD, Inc. shareholders' equity" } } }, "auth_ref": { "1": "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity": { "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r76": "r149", "r277": "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r382", "r554", "r556", "r573" } } }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-15-subsequent-events": { "http://www.cbdmd.com/20241231/role/statement-note-15-subsequent-events-details-textual": { "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r403": "r428" } } }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.cbdmd.com/20241231/role/statement-note-15-subsequent-events", "documentation": "Information by type of stock-based compensation tables." } } }, "auth_ref": { "r403": "r428" } } }, "us-gaap_SubsequentEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventDomain", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-15-subsequent-events": { "http://www.cbdmd.com/20241231/role/statement-note-15-subsequent-events-details-textual": { "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r403": "r428" } } } }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-15-subsequent-events": { "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": { "r427": "r429" } } } }, "us-gaap_SubsidarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidarySaleOfStockAxis", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": { "1": "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statement-of-cash-flows-unaudited": { "lang": { "en-us": { "role": { "label": "Cash Payments for:" } } }, "auth_ref": { "1": "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": { "http://www.cbdmd.com/20241231/role/statement-note-12-leases-tables": { "http://www.cbdmd.com/20241231/role/statement-note-3-inventory-tables": { "http://www.cbdmd.com/20241231/role/statement-note-4-property-and-equipment-tables": { "http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-tables": { "http://www.cbdmd.com/20241231/role/statement-note-8-stock-based-compensation-tables": { "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-tables": { "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": { "ycbd_TechnologyReliefFromRoyaltyRelatedToDirectCBDOnlineComMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "TechnologyReliefFromRoyaltyRelatedToDirectCBDOnlineComMember", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": { "lang": { "en-us": { "role": { "label": "Technology Relief From Royalty Related To Direct C B D Online Com Member", "documentation": "Represents Technology Relief From Royalty Related To Direct C B D Online Com." } } }, "auth_ref": { "1": "srt_TitleOffIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOffIndividualAxis", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity": { "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual": { "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": { "r667": "r699" } } }, "srt_TitleOffIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOffIndividualWithRelationshipToEntityDomain", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity": { "http://www.cbdmd.com/20241231/role/statement-note-7-shareholders-equity-details-textual": { "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": { "1": "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": { "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": { "r94": "r95", "r96": "r669", "r670", "r671" } } }, "ycbd_TrademarkRelatedToCbdmdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "TrademarkRelatedToCbdmdMember", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": { "lang": { "en-us": { "role": { "label": "Trademark Related to cbdMD [Member]", "documentation": "Represents the trademark \"cbdMD\"." } } }, "auth_ref": { "ycbd_TrademarkRelatedToHempMdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "TrademarkRelatedToHempMdMember", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": { "lang": { "en-us": { "role": { "label": "Trademark Related to Hemp MD [Member]", "documentation": "Represents the trademark \"HempMD\"." } } }, "auth_ref": { "ycbd_TradenameRelatedToDirectCBDOnlineComMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "TradenameRelatedToDirectCBDOnlineComMember", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": { "lang": { "en-us": { "role": { "label": "Tradename Related To Direct C B D Online Com Member", "documentation": "Represents Tradename Related To Direct C B D Online Com." } } }, "auth_ref": { "1": "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { "http://www.cbdmd.com/20241231/role/statement-document-and-entity-information": { "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": { "ycbd_TreasuryStockReissuedAtLowerThanRepurchasePriceConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "TreasuryStockReissuedAtLowerThanRepurchasePriceConversionOfConvertibleSecurities", "crdr": "credit", "presentation": { "http://www.cbdmd.com/20241231/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited": { "lang": { "en-us": { "role": { "label": "Issuance of Common Stock, Convertible Notes", "terseLabel": "Issuance of Common Stock, Convertible Notes", "documentation": "Represents the amount of treasury stock that is reissued at a lower than repurchase price due to the conversion of convertible securities." } } }, "auth_ref": { "1": "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { "http://www.cbdmd.com/20241231/role/statement-significant-accounting-policies-policies": { "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": { "r27": "r28", "r29": "r98", "r99", "r102", "r103" } } }, "ycbd_WarrantsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "WarrantsDisclosureTextBlock", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-9-warrants": { "lang": { "en-us": { "role": { "label": "Warrants Disclosure [Text Block]", "documentation": "The entire disclosure for warrants." } } }, "auth_ref": { "ycbd_WarrantsExpiringJanuary2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "WarrantsExpiringJanuary2025Member", "presentation": { "http://www.cbdmd.com/20241231/role/statement-note-9-warrants-summary-of-outstanding-common-stock-purchase-warrants-details": { "lang": { "en-us": { "role": { "label": "Warrants Expiring January 2025 [Member]", "documentation": "Represents warrants expiring January 2025." } } }, "auth_ref": { "ycbd_WarrantsExpiringMay2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cbdmd.com/20241231", "localname": "WarrantsExpiringMay2024Member", "presentation": { "http://www.cbdmd.com
```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

02.1F2.1A.B9(D7Y.DGHI1.M5A>L=Z201+1.WDN.K0 \$-U=F=H(29/6.PKFI(24%N)H00.X6+1=+SH.MJ"3=W.UWVHX.FX?UP8.YZ>Z&F5U\$120/>+H/U7./DUOZQZQ%)91F
3-M<2R<E15?T=P=UF8I2DQ05OE?E1%?KB;C1Y17<=,USU0#>R20@?F=ML.H:8MAILY?>6&L2>;B2N<>U4X.ZB1S0V17VNF".EJW+ATZV2V1W/BHK.MM.P+VEVL?>L12?
@O7RL.B"=1L6F50S=J1.R#>R2?1U?>\$.46@G/KIQR9D?@>J1.LL%1=1.0IRP.D1VLZFP+>M.B.63%5Y+ADD@>?W%V=18V1+1?PKOBGL14/>+V4A1XYZQ0299%FYCZB3I
XN?D1B020.YB2C>+IYX.N?D>GCYR.YL5H0I9J.1?1\$WQH0?>A1P.OH<=>A06Q0EDF.MD.00.E+>5?<1.0/3+>5S.FZBC?Q0S<=>GGRUYV6.FRFK07H?Y0K2?Q.0"8"CAIX@N3I.M1S%
(46VCLN0Q)SIUY.MDXL<RG5U?H1.XF72F1E%.ZW7.O26VJ?>8A1.=1+@+INF.A?>11N<S2&XZ028CBUH>+>X2.OUEK#K.OMWQ9NAINMHY13XK41Z.B>J9I.M<+MYFLRH
(5<^OV6L.03=6=IUKIN?ZP4Y17F?>POH.5R>3IVPVUJON<M7L.8L1\$31\$+YPL.#.RNR.HL>+>(C7&D#>+FB.C83P09C<=162)U<^>508#
MXP15FKH33C@QB88?P.C<+>Z6?HLH1Y+99C+3K#.NBGC<+>L1UE16F+V.MGCBX6UE6D>NAGPP-BNKF10Q6905/<^C<2T>+I<XU3JH1?JY.M:A?7=K+W.JMUJ
6183Z.2F=4L.P%F2PX%HO?6DGJ616P16J1X.H.B1#R=MJ?7<^>N.0#>#.G.3F27QRR<+>69FSX?OB/A>=H<+>#1N8+QR3&+>=K6D1#
#@M1L68H.D61>+J1C1X1\$1>3>@K?>2.W.K.M.PC01>HU.MTQ1D1@<R@>VS=J+1+869Z.MQ071"11?7H.H.WY192.5BMFI<W@<E4.Y.R.R%5Y.MQ1.
12.5G=P10J1Y4U4PWL1X146A.53?>V18K<8ZWDRCR3101?#M=N+M3P7.3.P"R0UB?ZVQV=JZB3&V@>.07F7YFR?21=>4.FX>9?STG531?/MMI"2U%>HZZ?10I>B.JGP.
1#W1#>NAGEDNOAIR.#8.2?Q?>07A3N13A1.P1.MT.KT=1E=SW57Q1V?>Z02D.D051L+5&5879L2?E5.Q0Y16L6R+V1+>?P3.E.M@>3?
N.01#A871G9Z1?>#9P?KJCIGK.4ZXR8C2.5(A%N)3G1V.R+W0O.KH&A&D4.MISNEVL.M9F&S.B.3FCR.<+>M4=A6?CXC?OKUYEPST&P/PS6=>=QM4M?QYIDB.79<M.
1X3N.ZG4.BVJNTW?1<G>+>H5XQIE@R7.052RU.O.BTAYD.@D8T?>1J9.MZX+&FGYOA1#>13+>+>M8@>F7MZ\$P12FL1Y?P&+>V7C8BOGSKIK+I=U.ML<60P>A5M?>+>
O20NX1>M6W<=>G0>+>P1+>3@>P1%>@>15N&U@>Q5&E.X8XBGH2?F1L2B>T5E1(OZ.J1332)>@>19C9<C952.C?1>LH%>?>(72P
M42K#K+>0FR4T4ABUPTU.V.N5S.LU<+>18>5K9L6GNM1?>51HAKH1U1N(M<H=+>X1Y1I(NPZAMBS/L12:JDS)#>=>OBVX64>3>+>I<UN."1\$>A.0\$>Z
M2C?6(EKHNNY56NB10113Q)=<+>110IAQMZ?>F?06P1A1Y+HJH.KY.8?>M5H(A=5.5VY2Y?>AU@>K7CA15.EK+>F.M.#B14C>006D?H176V&5(C&L91.M.H
LZIKPE9J).J.V.#WB>J1TK3EJHXQKQ6J.#C.6724Q039.OBJHW=6CM3K6.MWTM7W=7&DGE9YH1F@>F?Z.HN=>6G%5NBIX.MT.0C.M303?8?DK919
ML.DVT<@>(N3Y12?)9OYX-QSHGCI.O0NX".9D5L5N8TJ1+>@HK%4DF1\$>\$.M.T-RBC<9J36O9L75K<1<^9SPTN@+Y68.XG>+>U1BD?1MHT)"X*N=O<^&
(HJYICPV1\$+>?F1=MC&2M.IQ5R18GA.M.M.6ZT55F1?>W-MP4>371?>A9+>0W&2QW\$X.WU71>98C<T?Q.#K)Y+>U2L2Z0#>7H1.MEQ5<1=>M<Z6.V>?>.T1?>PVRT?>
O1UD.#1LK=>G092\$149B.UY.LY1?>C7&Z1?>14#K.MW3?>+>MTG2.TIVMSI.ZB.7=LCK?>+>9TN.OGE9N08<H.O3.RL15.FT40RL1?>MAHF<2+>2Q06<Q/<
H>=UY@O372?>MRYM<6RL<DL2H?>+>G1R<BVA.NK71L1M0+>#D=>+>3LGVUW+A9&5?>+>8SUL.T9E80#G1=>\$.9V62V0<N6G1Q2D.WX01+>1MTMFW7Q12.M0+>
R66V1NPOQ61U2?>+>U.A.22D.FU1YKX.NM.YDU+>IKE.68?>4K?>M+>O5%>BKL01TVG26EAAWC0?>5.Z4Y42\$V6H16N3YU@>Q6%PEH13&Y2.
MW3P#>HCL@>NYU@>9?J03G<1.L1S/Z@>E010XTT<XSY3Y1\$=>12M&>6WY.MF<=>V<+>7=E1AXL%<B7%Y0A2O3G?0LUV#>=>FRCV<=>IRIRGI<UD<?B?>M-H
MGNS#>2<D?S1Q?XGLF1Y061@>Q?>E@>A18&5\$.M@>Y?01?>F.T.G?X.A.U.G.M01?Q1U;H.L?7?22C.744?>J.M08BUW1M1?>JW:U.WS1KNT1?>T?>F+>%=>Q.M7CJH1?>(UR=G1.61+
IUMG.S.>@>TZHF<KOR1FF6AG09F98.1J5POEBET41H1.M2V1?>XJY.HQRO.HW0@>Q?>#H1#>+>A2TT251Y0.>13%>2-10F.125YLV&XLD4.9PR96IQZB?>
M.MG?>V1L3&BTRFKU1#>WD176.4=>0@>1=>+>OZIG4149>1AUP.M5#>+>M.D1S1U+>20L1T?>2(H0Z&G1?>0=>U8X261D.NU1X.F1Y#N2>1?>MTPR&H&=>1FT?>W=>#2B?
ATXZ.OG612.0PG<4?>H?Q?>W61.O6Y1@>CIW?>3?>X.M*G.633XK3?>O1W12B1CF1?>3FTXMF0?>E?>MG3V?>=C1%1C1?>7660D?>S.M4Q10?>4?>81COV.Z1=>+>O61Q#>7D\$NKG
MYD=>1.F1N0.\$S@>(6IKJHW6)=>K<3?U49MVA5?>TTN?>0D3I6@>+>?OD.G.2U.M.C2#B=2@>6?>9Q9N>OGS?>291<6H3D1?>RGLN@>@>ROB9T.O0E#>F19(3I2OH
M9KZL82F+13LP.?2TV#1YH<3A?>ZPL+SDI+>3<=>K0ZXRIQ0Y?>MNN2C3BC(3RA.ZUX31.JH9MUH1+ZNU3.>@>GCY36.C1C=60X<?>WCCY?>F.LH1MSZ?>=>NKOVCJKU(03BL31A-
6"(\$S2ZC.95.MK1X18D/SX1UHA?24Z1?>XWXY13NQY918-4B.66?>F1ZWTN4+1&2?>M82?>X.>@>1OT+>K0.Q1(OR5A90TUQ?>Y49FH1H1Y1.<1?>ZC.Z?>+>FC.ZC
M.WOXE.P@>W.A14U/K;UY1B0.V9\$14X0V51#>.G.%18L1T->DOS.U3-A?>M+>C>K.00Y1#1K1N029P?>#?>@1TAS1X1H6.4G10VX.M?>H&RQ.N=>12<=6.34Y0<H1?>
X.W%VY?>12.L3S3X?>SHS1CN.VU1H1.MK136H16P1Q.9(L1TF<=>0=>G0AOW1#>N91.Q1.GULH.ZEIRY.M@>AROUU1.U1#A1?>1*59CEA12+FU(H12<=>HE.FE.2+1)M@>N2&L
RM8F7.I2NT(21.M)N-8SD#E5FHS?>C0?>7@>J60V5%>W5H0EL10L65Y?>Y(7-5)14>YZ>ZNM.M2WE275W10?>H.TA.0U

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f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n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

[illegible]

[illegible]

[illegible]

S:0'Q'@9D1M#Q#S>UCDIFACU'U'4Y9V%#9B&N>ZlF05>HV(64)*#Z7=PTD53+1+Q.22U% M'L@'T'C20'IAEI<E2@<#6Y5IK029B SN2)EF+ FZ KY5<S'%"AD RP
 MIF@Q/R50)8XW#%#P27V%S CYQ9A7J\$#<@VX0.TUWSEUW\$#40ATB2BN M8R49.TP1V1A:Q(O6TCSD57B&N365R1P=OWTN.#C#FZ>Z(B6 M6Q1Y6+@4=..<102N8<3%>
 00QHN?P'@9VZB910>53OP1C2 OON4C M P124AG5L@R<3'4QIR<B F68IGT9 31Z2Y5A3/SP>+R0=(R0L)PNC' MC<^>9W'KQ.TP'JHOH19T9TA R&AA X6YB=<C=Z
 ZLV703%DI&IPM=VQ0%PTJIS<^>@R1X15B7.56GW24H1V>35'P-MT>DDO=>IP9AWOQKV>K.WHJH'UGK1XLOL.P'#\$R87268S&62X1(6GUO7 MHLR?<
 QJOTFTD1(1%87.0>1TCP<Z1D@>L@TJH5B&X\$S\$2' T71KDA9O U'G.>+V2.KIKFZP(W@07HVP3YVG\$9M UJZ3C1M@HLL'PVLDS2B8DYD(X<+ MGY<S1.WX<>
 <"R5<S5_#B7NHZ(9DG5G8W223+)<+>YJN6CATPANO4M'2:GAE.07G9Z(0Q16\$XDYO' 723.#45B-%K\$G#UEQ7+FI@<4L U05)D' D.M.>91"=AA'(-6/9)PFAJ+C12IA>
 F=JL YD0VY@=<8W'=>+E1X H977>G9S&X M'2'@<LIS:5'4'3>8'YES#36G18S77E'Q:U:7I2N>.>HJ7U>U@I@%2=91 MRZYHZ.4)XOEMYTF7X8@R.O.
 1(2FBFPR(MU129:9H@=BDYF.AXW1&X M7T1222CRB:1SR.OP#H81<3DG67C1=MQSX228EXC2.ZHFHOLO@=UHCUV6 MV=NQ00=71+Y73 ASQO'Q%E2I7(L151V77?
 U=>L.NGK7Z1W3M3JRN8R MBIDKQHLU7YR72A1D.OMWV5E1 B71U'YGC13%L(F1'>X'8F7.E.C+M)A8E1XU(ST=<I&KAX<+100'U'P.B.O CF M'Q'F97S'ZL)S1_9C1<
 =5K.Y'Y%LD@VGS73B9E1K5K8'F6A+K0G17YX&6 1./=W'QB@O'U'Z:HY1R5 M>37'UR1.OO.#\$1'Y<+MIQOO=MX37+#+<CYQX'Z:SG61'Q:LGTO>J0A@>61GWJG<50R
 5'N8W+16P1.M1.YV7@167'MJAZ.92XMHZM'CM1J53H16R.J5 CA07+92YMF.M1.UZ2%#/SP+1BDT5.654Z08LQ1E)IPV8Z.M#06+<1VR=01.'NEXFM.PH.=I
 M.EW6LIEQY.LQ1\$UF<F.L'H2YD9L'CMVXR3Q8BF1HUVWV'T3U6T(OR=2<M.G6'Q O RM'1QR=<84'Q96FH1H9V8O1ACC.U@U'(\$1R61<2VIE)AU<3 MV
 1.SGXS1L'<+<71'U'F7L'3'AB71A'K (W51TK&V7A6(AZ530W400A<U'1)B8400' MWG5<0'4Q50H2L' OS5?< J H8N094YH.K@TID_#118&1P9)Z9D>1M0 50Y M-U'*(NFDI
 F#C#S24R(G7E1H#'+2+U5A4H)EHK<7P5Y7YFZ@K5F)M+M&QW&PNGNIVT21L=4H1PKL7'<39D'8&C1JAL.E5W<1'ADT0IS MQ.
 9E%<CZ6G(FE1H1+<#7CEU'QJ(D1'1H1S'M'YZ3&55U+V+ MA>1'1QK1K&K<+JH8PBDS1Y19ZBBS(HO:QOQ1&Y&V(S591Z MP@)DRI ZHWKWOBJHJ<
 >373<2NNFNP01+ZUF81?>E2=6W0T81)2B<T M0XY C% 0%'FE:GX>ARB+BQ31 CC=>E Q:IG.'TA2+FH'Z1G.QCS3 OH<@ M%F.LWBS7Y'P'P'SD0+<1J7U=5FQZ3 S
 4L BN1Y<#0.XL M0A:IF.'VY<O'0H'X'F3C2DR<@>5A)K'N.C3B83ZY.C@H+E06.81(OH7 M1U'W#0F8'08=<+<4+4R3'D)H1J3?E=J3 M4.HJ\$+<VY?2
 PYP)BN)R8.TDB1'5D@E#.#KJ#<'F7E)F3>R8CM61.0T MP&AT7P 9XE<.<12B5+H GKCP'..DWB<+1.(61A0.LZ+J.SA&GA0A1A 6M<51*99%8.40=>6.5P3<8Y.ML#.#(S
 1(O830R3M20P'<#>VPW5'N1.H03'S'FEN.JH&71A)J5W4<1>T.MR1L.W.O1WL<1&E 2+Q6'6<+.0)Q5N1.06NF 2.H1+J.N.YW=<1S3>
 MY2E<2'<CV1'EXN0U'Y=<G1U'>5=7'F+7+4G11.6V1JYVTSR<5VY>'Z4'G1VZMD1'U'FOHDI0A5<'OK'U1+U MFJ5J1H5Y7TUL'L.B#:/<S8U%NBNW
 MYY1DK.F.S'<1J6C'14V1'P'06W2>.(CHRA14E@2%LH1EMDT'K<01.ME5T(9T'F'<'YB4.WA'6C/>=>HCG7M1.F&P.LZ0R=>Q2G0M1H5P'P4.A(60 M8A)H>.<
 1LGS19SH3<4EB+Y61<E8 GH0<9UKMSH1H'@M<'SPS)H1.MMC Y9B.WR7&S'<C2'8'<.59DHPH@=>3L<1L00U5Y.W1LO1H M.G8D'P9.Y66DY&+LA+1 M1L.<S\$
 (81A>2'D1(Z1#.(5FMS5WUHP1VDT1XA R'@G3'5VA5'17U)8L.MZ69QFWE'BH'<S&C1)F1S5CJR+2+1-8ON1<@73901H'X/L+X1MB+W3\$)M81P
 M471Y4ABA9P/5Z/U'<9.S_7#K2KNS_K3SRR17H2=<=>7E1L<'R8T1A1=GL<1'26V.F63.<#78#<+150436ZD@H31C1)C37' MU'M1GD1TCYNH91#>
 (FEN.XN&NPSK1LQRF9?>0&@< SN1H@<1 J S#E.MA=<F02N78MGRKE@G/CNH# B831#..C74G.Y2P1MN'W'J1(C<=>1935'A M2U29QZ2P'PLYP2?<4'<@LAX.OX
 GQ/66@1REH02U'F7<8CZ)D3.2EC M2368>+Q=>Y%DE.N=<#>WXS5>G6G10W6M5'WJBW.VG=G=<+>WTF.HS<X8 M'LN5A5G006'Y>6FP2B3.
 WB8?7Q'<V%#91P273C-WC 4.W1.X9K1X1A'W1M'XVPH1LEN155ZM'P2G6366H.2C1Z5B.M.IM11<+<S'<VKSRS01E.O=<E'F72 TLNM0.K4CMBAM1=<K1R.G1\$1 M1X'J-
 R1-RA2L1-@OUTG#S0VY0/O'R:7CKXD9L1DWG<=>'C-1'B1LS M(WW1SVF??>.IK-3JMOW#.#@S46>M.R1X7&O1YHGR<.<.<3W1J'<V19DSO.4R'..#>4F1D(6ZQ51/03017&+
 M1AAKYZ<41'Q&1A2Y1)PA'AN(GA1'Q1X'ZS'R81N(WBWXK7G%#>8+X'742 M7(B21P.6E1FM@3ZW7VYV<31TG45XDGXNSP/MK92 UQ.OGM1EY4A M7E#>
 XJ(51<@235681H8>=>45CRNH1H'TS6 Q1J5Y87N.D1D'<@KK FQ# M65&MCM'8#<CPG=<#1B&E&S1JZM4V<+5% M1J3B70AT'52P2BZ@75FMM1U'V.Z>1=<4.O.Q+X<E
 E9S2VYF.N1AQ0'<=<#>B9702>=>8.55PN54PBJ1'<W1K1 MX>A'K'Q30Z1W'&N'UJ35AV90M(WK1M1290HU50<K&T61+1M=<M& MZ1'5J+0LOO&KH Y8-
 11T3B)1'E1X\$S1012+1KP0REP31(O1HMD)WGA<=>MP.V.#1K<FV-2'WQ626'1HNO.VK&2H<3R'0>LE-3Y)2NTBB46132Z'F0 M15&H7J.HF&K7O1@R&N16?<
 5=<+10@H6HJG 7WBZIK%Q8F67W1VRE'Y&?Q M1H0@OY9VBOWY\$WY1'71P)?>O1M9)WG1U# Y40'D1XQFO54WNHH1)>4/6?<# M1F.CVTC=>W15KIG-5-HBBB%)MBFS?
 DE375EY&N48AY&C#R9>Z1BC-M70HD51YE1H140XZQ1B22L15'<#9+<#>05\$#<P>P.JH1KVGYT13'>LW M5.9.R3L4SL+P.S'<6X7N2K1SN9E14075CK>1.25E3K
 NM.O&L1/162F1' MMK<1'Q'EC2K%<2&G101)HHBB2+4HLG1+4GVG90>9EN.<RRM78HD5P89J1D4 MHR@R1T'S)V.@PS.E04N1H1+P.S'<6X7N2K1SN9E14075CK>1.25E3K
 M1531JGCVBN39H1'K1Y24D'<B'<14FR

~~XMLEC8FOR;#(T.3(S.5)Q.\$N:'1M4\$!L.A0#%M@<LXl-6CK+50&%\$!\$+(I-Z)+T'EC8F1;3IQ.M:GUG.2YJ<&-02P\$"%-4-"S@;U:\$O54R5H++#\$M@&S@(>-B9%Q.%!;6~~

~~XML76ycbd2024123110q.htm.xmlIDEA:XBREDOCUMENT00016449032024-10-012024-12-310001644903us-gaap:CommonStockMember2024-10-012024-12-31~~

~~0001644903ycbd:SeriesACumulativeConvertiblePreferredStockMember2024-10-012024-12-3100016449032025-02-1200016449032024-12-3100016449032024-09-30~~

~~00016449032023-10-012023-12-3100016449032023-09-3000016449032023-12-310001644903us-gaap:CommonStockMember2024-09-300001644903us-~~

~~gaap:PreferredStockMember2024-09-300001644903us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001644903us-~~

~~gaap:AdditionalPaidInCapitalMember2024-09-300001644903us-gaap:RetainedEarningsMember2024-09-300001644903us-gaap:CommonStockMember2024-10-012024-~~

~~12-310001644903us-gaap:PreferredStockMember2024-10-012024-12-310001644903us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-31~~

~~0001644903us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310001644903us-gaap:RetainedEarningsMember2024-10-012024-12-310001644903~~

~~ycbd:ConversionOfNotesIntoCommonStockMemberus-gaap:CommonStockMember2024-10-012024-12-310001644903ycbd:ConversionOfNotesIntoCommonStockMember~~

~~us-gaap:PreferredStockMember2024-10-012024-12-310001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-~~

~~gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-310001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-~~

~~gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310001644903ycbd:ConversionOfNotesIntoCommonStockMemberus-gaap:RetainedEarningsMember2024-10-01~~

~~2024-12-310001644903ycbd:ConversionOfNotesIntoCommonStockMember2024-10-012024-12-310001644903us-gaap:CommonStockMemberycbd:GssAgreementMember~~

~~2024-10-012024-12-310001644903us-gaap:PreferredStockMemberycbd:GssAgreementMember2024-10-012024-12-310001644903us-~~

~~gaap:AccumulatedOtherComprehensiveIncomeMemberycbd:GssAgreementMember2024-10-012024-12-310001644903us-gaap:AdditionalPaidInCapitalMember~~

~~ycbd:GssAgreementMember2024-10-012024-12-310001644903us-gaap:RetainedEarningsMemberycbd:GssAgreementMember2024-10-012024-12-310001644903~~

~~ycbd:GssAgreementMember2024-10-012024-12-310001644903us-gaap:CommonStockMember2024-12-310001644903us-gaap:PreferredStockMember2024-12-31~~

~~0001644903us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001644903us-gaap:AdditionalPaidInCapitalMember2024-12-310001644903us-~~

~~gaap:RetainedEarningsMember2024-12-310001644903us-gaap:CommonStockMember2023-09-300001644903us-gaap:PreferredStockMember2023-09-300001644903us-~~

~~gaap:AdditionalPaidInCapitalMember2023-09-300001644903us-gaap:RetainedEarningsMember2023-09-300001644903us-gaap:CommonStockMember2023-10-012023-~~

~~12-310001644903us-gaap:PreferredStockMember2023-10-012023-12-310001644903us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310001644903us-~~

~~gaap:RetainedEarningsMember2023-10-012023-12-310001644903us-gaap:EmployeeStockOptionMemberus-gaap:CommonStockMember2023-10-012023-12-31~~

~~0001644903us-gaap:EmployeeStockOptionMemberus-gaap:PreferredStockMember2023-10-012023-12-310001644903us-gaap:EmployeeStockOptionMemberus-~~

~~gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310001644903us-gaap:EmployeeStockOptionMemberus-gaap:RetainedEarningsMember2023-10-012023-12-31~~

~~0001644903us-gaap:EmployeeStockOptionMember2023-10-012023-12-310001644903us-gaap:CommonStockMember2023-12-310001644903us-~~

~~gaap:PreferredStockMember2023-12-310001644903us-gaap:AdditionalPaidInCapitalMember2023-12-310001644903us-gaap:RetainedEarningsMember2023-12-31~~

~~0001644903srt:MinimumMember2024-12-310001644903srt:MaximumMember2024-12-310001644903ycbd:ManufacturingEquipmentMember2024-12-310001644903~~

~~ycbd:SoftwareMember2024-12-310001644903us-gaap:SalesChannelDirectlyToConsumerMember2024-10-012024-12-310001644903us-gaap:SalesRevenueNetMember~~

~~ycbd:SalesChannelMemberus-gaap:SalesChannelDirectlyToConsumerMember2024-10-012024-12-310001644903us-gaap:SalesChannelDirectlyToConsumerMember2023-~~

~~10-012023-12-310001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMemberus-gaap:SalesChannelDirectlyToConsumerMember2023-10-012023-12-31~~

~~0001644903us-gaap:SalesChannelThroughIntermediaryMember2024-10-012024-12-310001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMemberus-~~

~~gaap:SalesChannelThroughIntermediaryMember2024-10-012024-12-310001644903us-gaap:SalesChannelThroughIntermediaryMember2023-10-012023-12-310001644903~~

~~us-gaap:SalesRevenueNetMemberycbd:SalesChannelMemberus-gaap:SalesChannelThroughIntermediaryMember2023-10-012023-12-310001644903us-~~

~~gaap:SalesRevenueNetMemberycbd:SalesChannelMember2024-10-012024-12-310001644903us-gaap:SalesRevenueNetMemberycbd:SalesChannelMember2023-10-01~~

~~2023-12-310001644903us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-10-012024-12-310001644903~~

~~ycbd:Investors8SeniorSecuredOriginalIssue20DiscountConvertiblePromissoryNoteMember2024-01-302024-01-300001644903~~

~~ycbd:Investors8SeniorSecuredOriginalIssue20DiscountConvertiblePromissoryNoteMember2024-01-300001644903us-gaap:FairValueInputsLevel1Member2024-09-30~~

~~0001644903us-gaap:FairValueInputsLevel2Member2024-09-300001644903us-gaap:FairValueInputsLevel3Member2024-09-300001644903us-~~

~~gaap:FairValueInputsLevel1Member2024-10-012024-12-310001644903us-gaap:FairValueInputsLevel2Member2024-10-012024-12-310001644903us-~~

~~gaap:FairValueInputsLevel3Member2024-10-012024-12-310001644903us-gaap:FairValueInputsLevel1Member2024-12-310001644903us-~~

~~gaap:FairValueInputsLevel2Member2024-12-310001644903us-gaap:FairValueInputsLevel3Member2024-12-310001644903ycbd:SteadyStateLicMember2022-04-072022-~~

~~04-070001644903ycbd:SteadyStateLicMember2022-04-070001644903ycbd:SteadyStateLicMember2023-09-300001644903~~

~~ycbd:ComputersFurnitureAndEquipmentMember2024-12-310001644903ycbd:ComputersFurnitureAndEquipmentMember2024-09-300001644903~~

~~ycbd:ManufacturingEquipmentMember2024-09-300001644903us-gaap:LeaseholdImprovementsMember2024-12-310001644903us-gaap:LeaseholdImprovementsMember~~

~~2024-09-300001644903ycbd:TrademarkRelatedToCbmdMdMember2024-12-310001644903ycbd:TrademarkRelatedToCbmdMdMember2024-09-300001644903~~

~~ycbd:TrademarkRelatedToHempMdMember2024-12-310001644903ycbd:TrademarkRelatedToHempMdMember2024-09-300001644903~~

~~ycbd:TechnologyReliefFromRoyaltyRelatedToDirectCBDOnlineComMember2024-12-310001644903~~

~~ycbd:TechnologyReliefFromRoyaltyRelatedToDirectCBDOnlineComMember2024-09-300001644903ycbd:CbdMdLimitedMarkMember2024-12-310001644903~~

~~ycbd:CbdMdLimitedMarkMember2024-09-300001644903ycbd:TradenameRelatedToDirectCBDOnlineComMember2024-12-310001644903~~

~~ycbd:TradenameRelatedToDirectCBDOnlineComMember2024-09-300001644903ycbd:SeriesACumulativeConvertiblePreferredStock~~

New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than <em style="font-inherit:>three months when purchased to be cash equivalents.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Accounts Receivable</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Accounts receivable are stated at cost less an allowance for credit losses. If applicable, Credit is extended to customers after an evaluation of the customer's financial condition, and generally collateral is <em style="font-inherit:>not required as a condition of credit extension. Management's determination of the allowance for credit losses is based on an evaluation of the receivables, past experience, current economic conditions, and other risks inherent in the receivables portfolio. The balance for allowance for credit losses was \$310,712 and \$346,197 <em style="font-inherit:>December 31, 2024 and <em style="font-inherit:>September 30, 2024,respectively.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Merchant Receivable and Reserve</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>The Company primarily sells its products through the internet and has an arrangement to process customer payments with <em style="font-inherit:>third-party payment processors and negotiate the fee based on the market. The arrangement with the payment processors requires that the Company pay a fee between 2.5% and 4.0% of the transaction amounts processed. Pursuant to this agreement, there can be a waiting period between <em style="font-inherit:>2 to <em style="font-inherit:>5 days prior to reimbursement to the Company, as well as a calculated reserve which some payment processors hold back. Fees and reserves can change periodically with notice from the processors. At <em style="font-inherit:>December 31, 2024 and <em style="font-inherit:>September 30, 2024,the receivable from payment processors included approximately \$631,033 and \$621,678 respectively, for the waiting period amount and is recorded as accounts receivable in the accompanying condensed consolidated balance sheet.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Inventory</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and labor portions of which we outsource to <em style="font-inherit:>third-party manufacturers). Write-offs of potentially slow moving or damaged inventory are recorded based on management's analysis of inventory levels, forecasted future sales volume and pricing and through specific identification of obsolete or damaged products. We assess inventory quarterly for slow moving products and potential impairments and at a minimum perform a physical inventory count annually near fiscal year end.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Property and Equipment</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense over the estimated useful lives of the assets using the straight-line method. Generally, the useful lives are five years for manufacturing equipment and automobiles and three years for software, computer, and furniture and equipment. The useful life for leasehold improvements are over the term of the lease, or the remaining economic life of the asset, whichever is shorter. The cost and accumulated depreciation of property are eliminated from the accounts upon disposal, and any resulting gain or loss is included in the consolidated statements of operations for the applicable period. Long-lived assets held and used by the Company are reviewed for impairment whenever changes in circumstance indicate the carrying value of an asset <em style="font-inherit:>may <em style="font-inherit:>not be recoverable.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Fair Value Accounting</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is a market-based measurement, <em style="font-inherit:>not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, fair value accounting standards establish a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels <em style="font-inherit:>1 and <em style="font-inherit:>2 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level <em style="font-inherit:>3 of the hierarchy).</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Level <em style="font-inherit:>1 inputs utilize quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level <em style="font-inherit:>2 inputs are inputs other than quoted prices included in Level <em style="font-inherit:>1 that are directly or indirectly observable for the asset or liability. Level <em style="font-inherit:>2 inputs <em style="font-inherit:>may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability. Level <em style="font-inherit:>3 inputs are unobservable inputs for the asset or liability, which are based on an entity's own assumptions, as there is little, if any, observable market activity. In instances where the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>When the Company records an investment in marketable securities the carrying value is assigned at fair value. Any changes in fair value for marketable securities during a given period will be recorded as an unrealized gain or loss in the consolidated statement of operations. For investment other securities without a readily determinable fair value, the Company <em style="font-inherit:>may elect to estimate its fair value at cost less impairment plus or minus changes resulting from observable price changes.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>ASC <em style="font-inherit:>825 - Fair Value Measurements</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Convertible Notes</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Intangible Assets</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Trademarks</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Property, Plant and Equipment</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Revenue Recognition</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Revenue from Contracts with Customers</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Contract Liabilities</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Other than account receivable, the Company has no material contract assets nor contract liabilities at <em style="font-inherit:>December 31, 2024.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;>Performance Obligations</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text

Cost of Sales

The Company's cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, party providers, and outbound freight for the Company's products sales. For the Company's product sales, cost of sales also includes the cost of refurbishing products returned by customers that will be offered for resale, if any, and the cost of inventory write-downs associated with adjustments of held inventories to their net realizable value. These expenses are reflected in the Company's consolidated statements of operations when the product is sold and net sales revenues are recognized or, in the case of inventory write-downs, when circumstances indicate that the carrying value of inventories is in excess of their net realizable value.

Income Taxes

The Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. CBDE Therapeutics, and Paw CBD are wholly owned subsidiaries and are disregarded entities for tax purposes and their entire share of taxable income or loss is included in the tax return of the Company and as of March 15, 2024, Therapeutics is also a wholly owned subsidiary and is a disregarded entity for tax purposes and its entire share of taxable income or loss is included in the tax return of the Company.

The Company accounts for income taxes pursuant to the provisions of the Accounting for Income Taxes topic of ASC "font: inherit;" 740 which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company uses the inside basis approach to determine deferred tax assets and liabilities associated with its investment in a consolidated pass-through entity. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

Concentrations

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities. The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation ("FDIC") covers \$250,000 for substantially all depository accounts. The Company from time to time may have amounts on deposit in excess of the insured limits.

Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not have any customers that represented a significant amount of our sales for the three months ended December 31, 2024.

Stock-Based Compensation

The Company accounts for its stock compensation under the ASC Compensation - Stock Compensation using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments.

The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock-based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting period. The Company recognizes forfeitures when they occur.

Earnings (Loss) Per Share

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company experienced income of \$15,095 for the three months ended December 31, 2024, resulting in a working capital deficit of \$2,809,100 at December 31, 2024.

While the Company is taking strong action, believes in the viability of its strategy and path to profitability, and in its ability to raise additional funds, there can be no assurances to that effect. The Company's working capital position may or may not be sufficient to support the Company's daily operations for the twelve months subsequent to the issuance of these annual financial statements. The Company's ability to continue as a going concern is dependent upon its ability to improve profitability and the ability to acquire additional funding. These and other factors raise substantial doubt about the Company's ability to continue as a going concern twelve months after the date that the annual financial statements are issued. These financial statements

<em style="font: inherit;">not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that *<em style="font: inherit;">may* result in the Company *<em style="font: inherit;">not* being able to continue as a going concern.

*<p><em style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"></p><p><em style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"></p><div style="background-color: rgb(255, 255, 255);"></div><div style="background-color: rgb(255, 255, 255);"></div>Convertible Notes</div><p style="font-size: 10pt;font-family:"Times New Roman"; margin: 0pt;background-color: rgb(255, 255, 255);"></p><p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;text-align: justify;margin: 0pt;">Effective *<em style="font: inherit;">February 1, 2024,* the Company entered into a Securities Purchase Agreement dated *<em style="font: inherit;">January 30, 2024 (*the "Purchase Agreement") with *<em style="font: inherit;">five* institutional investors (the "Investors") whereby the Investors advanced the Company an aggregate of \$1,250,000 gross proceeds and the Company issued each Investor an 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note, in the aggregate principal amount of \$1,541,666 (the "Notes"). The Company is using the proceeds from the issuance of the Notes for working capital and general corporate purposes. The table below represents the change in fair value of the convertible notes as of*

December 31, 2024,

Markets for

Significant Other

Identical Assets

Observable

Unobservable

Level 1

(Level 2)

Balance at September 30, 2024

Balance at December 31, 2024

The Company adopted ASU

Improvements to Reportable Segment Disclosures Measurement. This standard went into effect for fiscal years beginning after

December 13, 2023

This standard enhances segment reporting under Topic

280 by expanding the breadth and frequency of segment disclosures. The Company is currently evaluating the impacts of this standard on the consolidated financial statements.

Principles of Consolidation

Use of Estimates

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CBDI, Paw CBD, Proline and Therapeutics. All material intercompany transactions and balances have been eliminated in consolidation.

Use of Estimates

The condensed consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying condensed consolidated financial statements include, but are

limited to, allowances for credit losses, inventory valuation reserves, expected sales returns and allowances, certain assumptions related to the valuation of investments other securities, acquired intangibles and long-lived assets and the recoverability of intangible and long-lived assets and income taxes, including deferred tax valuation allowances and reserves for estimated tax liabilities is a material estimate. Actual results could differ from these estimates. The Company continues to monitor macroeconomic conditions to remain flexible and to optimize and evolve its business as appropriate.

Cash and Cash Equivalents

For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three months when purchased to be cash equivalents.

Accounts Receivable

Accounts receivable are stated at cost less an allowance for credit losses, if applicable. Credit is extended to customers after an evaluation of the customer's financial condition, and generally collateral is

required as a condition of credit extension. Management's determination of the allowance for credit losses is based on an evaluation of the receivables, past experience, current economic conditions, and other risks inherent in the receivables portfolio. The balance for allowance for credit losses was \$310,712 and \$346,197

December 31, 2024

September 30, 2024

respectively.

Merchant Receivable and Reserve

Property and Equipment

Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense over the estimated useful lives of the assets using the straight-line method. Generally, the useful lives are

five to three years for software, computer, and furniture and equipment. The useful life for leasehold improvements are over the term of the lease, or the remaining economic life of the asset, whichever is shorter. The cost and accumulated depreciation of property are eliminated from the accounts upon disposal, and any resulting gain or loss is included in the consolidated statements of operations for the applicable period. Long-lived assets held and used by the Company are reviewed for impairment whenever changes in circumstance indicate the carrying value of an asset

may

be recoverable

Fair Value Accounting

The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is a market-based measurement,

an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, fair value accounting standards establish a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels

1

and

2

of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level

3

of the hierarchy).

Level

inputs utilize quoted prices in active markets for identical assets or liabilities that the Company has the

[illegible]

[illegible]

additional funds, there can be *font: inherit; >no assurances to that effect. The Company's working capital position *font: inherit; >may *font: inherit; >not be sufficient to support the Company's daily operations for the *font: inherit; >twelve months subsequent to the issuance of these annual financial statements. The Company's ability to continue as a going concern is dependent upon its ability to improve profitability and the ability to acquire additional funding. These and other factors raise substantial doubt about the Company's ability to continue as a going concern within *font: inherit; >twelve months after the date that the annual financial statements are issued. These financial statements do *font: inherit; >not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that *font: inherit; >may result in the Company *font: inherit; >not being able to continue as a going concern. <p>< p style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; margin: 0pt;"> <p> 15095 -2809100 <div style="background-color: rgb(255, 255, 255);> Convertible Notes</div> <p style="font-size: 10pt; font-family: "Times New Roman"; margin: 0pt; background-color: rgb(255, 255, 255);> <p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> Effective *font: inherit; >February 1, 2024 the Company entered into a Securities Purchase Agreement dated *font: inherit; >January 30, 2024 (the "Purchase Agreement") with *font: inherit; >five institutional investors (the "Investors") whereby the Investors advanced the Company an aggregate of \$1,250,000 gross proceeds and the Company issued each Investor an 8% Senior Secured Original Issue 20% Discount Convertible Promissory Note, in the aggregate principal amount of \$1,541,666 (the "Notes"). The Company is using the proceeds from the issuance of the Notes for working capital and general corporate purposes. The table below represents the change in fair value of the convertible notes as of *font: inherit; >December 31, 2024 <p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: "Times New Roman"; Times, serif; width: 1746px;"> <tbody> <tr> <td style="width: 602px;"> </td> <td style="width: 14px;"> </td> <td style="width: 14px;"> </td> <td style="width: 390px;"> <p style="margin: 0pt; font-family: "Times New Roman"; font-size: 10pt; text-align: center;"> In Active</p> </td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align: center;"> Significant Other</td> <td style="width: 14px;"> </td> <td style="width: 16px;"> </td> <td style="width: 351px; text-align: center;"> Significant</td> <td style="width: 17px; text-align: center;"> Markets for</td> <td style="width: 15px;"> </td> <td style="width: 17px;"> </td> <td style="width: 331px; text-align************

[illegible]

[illegible]

[illegible]

[illegible]

Exercised

Forfeited

Outstanding at December 31, 2024

Exerciseable at December 31, 2024

As of December 31, 2024, there was approximately \$3,925 of total unrecognized compensation cost related to non-vested stock options which vest over a period of approximately 0.75 years.

Restricted Stock Award transactions:

The Company had 8,000 shares of previously issued restricted stock vest during the three months ended December 31, 2024.

Weighted-average exercise price

Weighted-average remaining contractual term (in years)

Number of shares

[illegible]

[illegible]

[illegible]

[illegible]

from the issuance of the Notes for working capital and general corporate purposes.

Each Note bears interest of 8% per annum and matures on July 30, 2025. The Note is convertible into shares of common stock at any time following the date of issuance at the Investor's option at an initial conversion price of \$0.684 per share (the "Conversion Price"), subject to certain adjustments. If calendar days, or 60 calendar days, or 120 calendar days, or 180 calendar days after the effective date of a registration statement registering the shares of common stock issuable upon conversion of the Notes (the "Registration Statement") (the "Adjustment Dates"), the Conversion Price then in effect is higher than the Market Conversion Price then in effect on the Adjustment Date, the Conversion Price shall automatically decrease to the Market Conversion Price (as defined under the Note). The Conversion Price is subject to a \$0.30 floor price. As of the filing date of this report, the effective Conversion Price is \$0.50666.

The Company elected the fair value option under ASC 825 Fair Value Measurements for the Notes. The Notes were initially recognized at a fair value of \$2,702,000 on the balance sheet as of December 31, 2023. All subsequent changes in fair value, excluding the impact of the change in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income (loss).

The overall change in fair value of the Notes during the quarter ended December 31, 2024 was a decrease of \$809,287. The overall change in principal value related to the conversion of Notes to commons stock during the quarter ended December 31, 2024 was a decrease of \$719,911. As of December 31, 2024, total fair value of the Notes is \$362,021 of which \$363,798 represents the total principal outstanding.

NOTE - LEASES

Right-of-use lease assets and corresponding lease liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since the interest rate implicit in our lease arrangements is not readily determinable, the Company determined an incremental borrowing rate for each lease based on the approximate interest rate on a collateralized basis with similar remaining terms and payments as of the lease commencement date to determine the present value of future lease payments. The Company's lease terms may include options to extend or terminate the lease.

In addition to the monthly base amounts in the lease agreements, the Company is required to pay real estate taxes, insurance and common area maintenance expenses during the lease terms.

Lease costs on operating leases are recognized on a straight-line basis over the lease term and included as a selling, general and administrative expense in the condensed consolidated statements of operations.

Components of operating lease costs are summarized as follows:

Total Operating Lease Costs
Cash paid for amounts included in the measurement of operating lease liabilities
Future minimum aggregate lease payments under operating leases as of December 31, 2024

As of December 31, 2024, our operating leases had a weighted average remaining lease term of 2.56 years and a weighted average discount rate of 4.66%.

Future minimum aggregate lease payments under operating leases as of December 31, 2024 are summarized as follows:

December 31, 2024
January 1, 2025
February 1, 2025
March 1, 2025
April 1, 2025
May 1, 2025
June 1, 2025
July 1, 2025
August 1, 2025
September 1, 2025
October 1, 2025
November 1, 2025
December 1, 2025
January 1, 2026
February 1, 2026
March 1, 2026
April 1, 2026
May 1, 2026
June 1, 2026
July 1, 2026
August 1, 2026
September 1, 2026
October 1, 2026
November 1, 2026
December 1, 2026
January 1, 2027
February 1, 2027
March 1, 2027
April 1, 2027
May 1, 2027
June 1, 2027
July 1, 2027
August 1, 2027
September 1, 2027
October 1, 2027
November 1, 2027
December 1, 2027
January 1, 2028
February 1, 2028
March 1, 2028
April 1, 2028
May 1, 2028
June 1, 2028
July 1, 2028
August 1, 2028
September 1, 2028
October 1, 2028
November 1, 2028
December 1, 2028
January 1, 2029
February 1, 2029
March 1, 2029
April 1, 2029
May 1, 2029
June 1, 2029
July 1, 2029
August 1, 2029
September 1, 2029
October 1, 2029
November 1, 2029
December 1, 2029
January 1, 2030
February 1, 2030
March 1, 2030
April 1, 2030
May 1, 2030
June 1, 2030
July 1, 2030
August 1, 2030
September 1, 2030
October 1, 2030
November 1, 2030
December 1, 2030
January 1, 2031
February 1, 2031
March 1, 2031
April 1, 2031
May 1, 2031
June 1, 2031
July 1, 2031
August 1, 2031
September 1, 2031
October 1, 2031
November 1, 2031
December 1, 2031
January 1, 2032
February 1, 2032
March 1, 2032
April 1, 2032
May 1, 2032
June 1, 2032
July 1, 2032
August 1, 2032
September 1, 2032
October 1, 2032
November 1, 2032
December 1, 2032
January 1, 2033
February 1, 2033
March 1, 2033
April 1, 2033
May 1, 2033
June 1, 2033
July 1, 2033
August 1, 2033
September 1, 2033
October 1, 2033
November 1, 2033
December 1, 2033
January 1, 2034
February 1, 2034
March 1, 2034
April 1, 2034
May 1, 2034
June 1, 2034
July 1, 2034
August 1, 2034
September 1, 2034
October 1, 2034
November 1, 2034
December 1, 2034
January 1, 2035
February 1, 2035
March 1, 2035
April 1, 2035
May 1, 2035
June 1, 2035
July 1, 2035
August 1, 2035
September 1, 2035
October 1, 2035
November 1, 2035
December 1, 2035
January 1, 2036
February 1, 2036
March 1, 2036
April 1, 2036
May 1, 2036
June 1, 2036
July 1, 2036
August 1, 2036
September 1, 2036
October 1, 2036
November 1, 2036
December 1, 2036
January 1, 2037
February 1, 2037
March 1, 2037
April 1, 2037
May 1, 2037
June 1, 2037
July 1, 2037
August 1, 2037
September 1, 2037
October 1, 2037
November 1, 2037
December 1, 2037
January 1, 2038
February 1, 2038
March 1, 2038
April 1, 2038
May 1, 2038
June 1, 2038
July 1, 2038
August 1, 2038
September 1, 2038
October 1, 2038
November 1, 2038
December 1, 2038
January 1, 2039
February 1, 2039
March 1, 2039
April 1, 2039
May 1, 2039
June 1, 2039
July 1, 2039
August 1, 2039
September 1, 2039
October 1, 2039

[illegible]

RECYC260A7011H49ZIN<6.6MR8AK1E7E&J%61ZWM>DE:F7>TH9UV7EDM.M6.N6VY%YLB.M.C8LOJWJK5%TNK6H1EX@.EB3&5*5RWT=MRXIV&9IMF.FA.YGDP=PGCY
M7&ZU.G%9NH1.HDZIN<KLEBR7F7R6G7>2.6*BNL#D.C.I+>RUWHUUV7535M(HQVU62*TPDC-WW9VUO.MXJUOGR3VU18VYMC3P&5=2*FW9G&MWZ5V%#87BP(\$P7A*E).H.NSO#
(MIE2-0*4RB*03Y)VHE>G.MVZG.1*U.X.DIKUQ1@.K2.ZS-1+1*H1@EQGT7V.PJAS&9D177B1=1%N0IX-59HJ&V4&S(10.IQ.U0E).M=09=9*MGUC.\$JUV.D*HEE?<
4H<1*HBBH1%>YVAV1+1=5J=6&S.1B.VU.GY.MUW6/3H&BZ=ZL1.BH.1F1D7.7.HS9.C8A2D1+>95\$\$(94UU)XRR02.M=#1K< (H- M3&MV77D?Q#R4BW?<
P.G1+1+>731G@>+174G@<GNOKY.OO%SWZ1E7&TPDJ=1.M41#RHP.3PVC\$P&A>9).>XJ&B9.52F\$XOC6KGR@<0.M#6/6.K1&SYX#&P#X&M.ZAW.66H6.A<C<?<
P#AW71+>+<H20+2\$1%>WTSKER.M+BSF.HX<^>#9G7\$=3EPP>R3J+J+>OBJC(N)=>AX1.N0.M5F\$XOC6KGR@<0.M#6/6.K1&SYX#&P#X&M.ZAW.66H6.A<C<?<
B8A1+>+<P=3\$69B4J9M.NIU@.F.MXYK+TMFL1B5\$01.931\$8U71+1PB=RX31ENH27*8M6J0Q1+>Q3AX@.1Z1.MJ13<+<K75&BC78H7EQR@<0=0
(H5W+1+>41G.M1C=651&W+1+NEYS=V.MOUYX.HH.@J&E<0+>7F+W+ZOM+.Y+KRU..K1&MOR<1+>6V.FE%>SDFC9K1.MH53+>Q2.Z+>QV>SHJN<48&.%S.(G1F)P05\$X(FS?<
LDY+5F1.9Q."MNI9W-M72(I.WWMV=00057.0.27AM.OU7F>33T36V1XU>+1\$H.M1%U8.M.#.@=9M.VE%>XJDP10ASX7E1.40&9672N)12YHXH=+E1H%(H.N.M=B1/3%YXPPD1.
US6MZE2.W4C%P3DMQ=5.5D>Y.RDDP4*U&1LVYFAFR13BDU.MY%<M9U.SP@.5%>H1H@MH76.VG.M#VGG.&L.SJ3G.(%D8HJ7K<8<+<E1F1K1+<1=Z14XU1=2=<3?>5H
MDP983.274W01E1HEDY.EY=180J.N1X.%M&K7.H.30P3R2=1@<9.M#<VXYHM1T88F1+3M5Y19HR0121S6<0<5(=1+>WYRJ02?=>IR0>BB>+>P&V@<
M4Y)ZY7F>19PC/W/N/OQ12C1/I-F%R.B>1+>OP9#>Y.49B1OFSRGG.MH2&2*UF+VZVT&V19379R.7G%9°F@<5T63)OPCD%<T\$>1*W1RYX4=.%Z=.%<OR.R#1/%?<
<P>B1B.M=5<I.NW("MKPBP&SR02@1F6X)>1%RC1@TERH01.U111.MPD5.M41Y2DA1&P5A2R9Y?J&3G/BOY1(YQ.G1)+>+33/E2.0A51FW14H@1J9Y<M31/ZU91(47ZG1505*4
XPN@C@<L1+>B1.CW?41.T.AYDNT&HMI+G<+<P1.MC1#6+B=O2X.33DWPL1+>2.38+U61XF1+>L.L.L.S>QY1V5U0.0.2MH.MC%Q
MR41%>2&31&55\$W&EJ2P21@<KNEU1X.H.B6G1F1+>R31\$3DVO1+>1@<7C2V1ZB76*Y1W.MTV1+>HCE+>6H>+>G.0W49YV1(1*0L91+>+9.K?1MI#>#1.MB1+9M\$<GL5@<M_<
+B1+2&K6G6M&W&UJT7821(X1R12=9.G1+>X>LV.F1V4G71+>1GAY1M1&J.B.K6.G>N0PM\$<12Y1O1.EA."73+R2W1.R1Q71+>XJ&HXS30X35V.7G.M@OTA1/JZA99M=<
+3ICE\$S1VU@=<0<+>N28V5/52U*MCS.MJB>TMILY1AT810.69W76DNOEY-T=3)DEOK1.4%Q00JWY070CZ1Z#1+>#1\$ MG15C>+<60+13Z3EV>+>MT.S%<CZ(6ZV=BG.K<
H3A9>+<P>X1323NMY<27/M7QIN1CQ?FDGU1V72281471V12ZV.M.<13>+>27BF1877MD>+>16V1Z.15WH4M1&A&U157WKB1.MZV1712X1Z.BEHT0.W15Q
&156W1P>T2>HJOT1A1&E<+>5187OZH.FW.MIBN214J1V1ZHXN0T1Q&M2FTE.U.6B9?TR.>C1M.3(S15C86PN>+<AG157UM1XJ50V@P7C@>SZKPTMNBV87C1S6.M#>21?O
MTX6*4)M22D1E1/UK1+A9E.(E+4+>1%<TKT1\$FEE(33.D9X85<C#K1X1OU%MB.MQ@<E.SOO1X1ZS%>H1+>S.H1W.F1A=TAGW1X2*QO>EY0.7W1+>FWSN?T14Z.31Z1
MHQ/O<3&20P21E1>3>G%<+>R82GOUZ6W1+LZ@<+>P4V1+QY&1+>H16665P1@<H.ZOR>7+>0&P1.1?2\$>+>D773<+>K3?H1Z1V1W.22*WS?>MW(E\$>0%<(BON2\$D<+>NWA\$?<
20R.59"Z"DIY&10>+>21HQB7=Z..1WY0.M>+>7BX11".BL"?>W11>R9.C2@<S<+<C1+>D1P1Z1TDV18%CG\$BO(0*M1+N.#R%>V\$14H1F10D3E1S68.SX.VO>1MT\$1VXEZ12(11
9*W&P./P">M1A5G002/ZS1>+>U0F*2PQ1+>1P980213Y9.00>9?7+>K1W1<+<3PH.MZV16@6K\$7624VQXRM&R(C?<S.RKT390H.SP\$1+>N9+>A1+N<+>+YASC.M4*4N/UB1.
Y\$S&X?>P">E1S>1GB@<KDR37%TWT>1+>6R2E1V7H0.L2V161H.M.X(CY)P\$<G.VY5>+>+>IEM010P1VXD78101B.Y17MNA\$0.6\$APROT?9MI?>1ROR@<EL1+MBF>+12
Y5GRN=84.Y1&<+>G1V1%<N1U+1N=9C1M7R.MK1\$1CK1>52ND1+>1P1B4Z>+>V3\$<(RCB.MPR2X3Q2>+>B1\$>5F131OT8<4Z2.G5<+>M11"UD72Z6HEW=8.#X&2.M6\$9G"<
B15<1%<2M1+WUFUB79ZCB731Q?EPR11%100&+>#<P1V@<PKVMKH01+>B1U1X.KZ"U.SR.UR.H%01TH.ME1D1N=1(C%<D1&1%<V15=51X422Q10T1KSSZV=M#>H2#>H1
2%81O1+>H1WGH1X@<NP\$>+>EESVGP.RS#A.<+>H10+>F11&C<C.M1O?>B1YP+>TT08<+>U.H#21(Q19=018.M1(1#>+317\$1SPEPXL.KG.H2YZ.MR1006B&1.M.9(KK
41616P2=NG.%S=RWY.V.MC=94\$16.POTU1.D1Q1E0BB<H1H1+>05<+>C2H1WS&Z=5Z0617CPO1M#(N1S3ZW156\$G12S1B=W@OK?>+>7P1M1(11V1UF21C)F.C1%8#>=>
M1U91POY.4(31P1C@<47JZ1+>C1L1P.P1PPO<+>H1L=3.N2@H4K%3JYB>E.96M1/M0CVQ5.XSL1+>+>D1D1P1MYXZA41.B\$8H1UER21Y>3>ONPMUD01G1C51X1M=NZCG7P%
(DR68.61@>A9R9C.231LS5U7\$13"D=HVE57W317Y9X3F7=>MF1+075.V1M1V7147WARD\$<M1#>7%WBH<+>V1.U/0.SH4T1"NG<GHGX1Y115.9.PHL1B3Y5.%>Y0P.N3.M+>
<91COON7Q1OW1CVP21AWN7S.C5O.Y1=6251L1V6E1\$5=U1G1R11&1.O.M.H1JD1G1+>73.HP+<0&@<81Z13FA931+>15LNZ0W1"1H1ZB1.V131H1+>1.0.F1H1V151
1=DIVL0.&@<B\$P\$31EV.H.EAW.0A.1.6&1FNSZT1@<B1.701V.M1R21B\$0>WG1S1J>HCCMM2V.<H1X1S15PB4@DS1?>H1T6TR019LH1(1J7R1.M21.M1621.2R1T23@.5=WA566K1
1W1X1H7H7F1P.M@A3B1P\$70Q\$QZ5<+<C.W131

W5U+IY.M8OJQ.HW49P.W%SAU"7R*+45L%KRAIT7YU2P:3.7JOY.#H.OXW1WY*8P5VO)U4XVEOS=Q2SR46F.8-8+U-W=4MW&G547.4.%M%MI
IX=056*H=5IP:~C>W5F2U.7RD@JH=+J=MEI-K9LO2D>DIN^WOTQ?V^V^M104110E>/HJH8^P=ROQ6^B^2A4>U{SRIG64\$W^4/4EXNEBBE#9#F79JP/PICNO*+A.I^M7FFC(I
+ZMHO=+1%IG0+Q=QCAQW5BH4D.NSR.O.W.SP^H^CQ.W=C=ZMMR:7=)=0+L1Y+4+M<2675G5N^OR^B^70%K1A5N:GT&X6P/9#E=OKR51299L(4TC2(8Z2
MK1LQO2@C=Q=QB8HBP6275YBTYBOS^>DSOY^>=23X=ZAWX+5+PE#>66Y^M^7.115>2&R7L<R2IAU^A^TOVFT^>+2T5%9MS7^>Y3H0S7.OE6M>S>8NF:
HP030MYJ2IH=CCB.VGG94WOIB^MP^PS&KIB+4XWO^GVLEF.M5^FE^S2^>X^72^3B3Q^85T8TSF>8DHOGTB^>)>6@.N.S@O^FQO.28
M8ZID#^95H:12.EEJ2.Z@R.8L1SSI.R+5^FX/F2B^#W21C^>@=M<M15M.MOW^U(HSWRM.C/33HS^9^>2<4-UP258.GOE(N)66L19^J^I@L1+L1.M7(KZA=
I31.3G+L1.2DTH#45FTX1HJNL\$HCF#7B31^MMF.(QIOBLV^A>L1.32.W>Z^A^1.6Z^>0+H2<HJPRMHO^4DN+>+MP9(GVX6@R90/EI^JMF<+>^>Q^B>
M61.FEBG^EPP51MPG24NOCAA=5WMS^5Y^>07>V-DR.RJ.L6T.FA5KH.H^M^M6^WMNK:N46R^KIHDPP^>9>K.IXON:N>+JXXF^X^ZPA85491AMOGXIFE
MR4WBK5.U@<S^1%MSPOGA2.L0NM1@O^N1TP80=>E=IAH0.MW7H8EW^#H57(QS@>+<I=H1.H^9%P26#1+<L>LOH1JG8^8.712#=-8)=EY^W^S^XSM.V0^<
MLAMTID7OJ^M^M4M2WT^VYU@<3M3&TKNHW@Y^>N^P:3J.IJLWCW^TCL^HUM1^MP.B18UFVN3PDW:3MGQ^O0^18H7^SRN=SMGHT@|L>D>RZ2^Y.91AW.Y8H.
A1H0FN^=6F6G.M.X8Z1N=ON91FEW8ZLX.LP<S^K0A1^NG39%Q3)CDPQDFV^>^G.2.G>P.O7.M.H2H^V(N2VW^M.^FAC.S^7+CBM1>+IMT&F5&S&L9<H^F9&B(OB3\$UC<
M6IP6X3Y:EVL<L.G.6X^G.35MD;M5L1K75H^R8OLKE^G(HK.SA<=<R4^M^1H7=IQ7K.D>K4HNZD1.60+FH1H0^>5%>O>KEI^OY:Z185%3QDL2Y
MM64I^U=SG6^HX<B1RZXI^G^Y9<V.O3.M0^73B14=8)7V4CE<3^>NBM.M=IN1^KM15<=>^S15FS6N^225UNJV1^<SO=64.16\$XG9173GGJZV95>PDKHKCEFWDB
MG(3+K.W1K4^<@SJJ^<@F7F1E>+1J41>?>=R@.M).SFNMZ@>G6ZKM1^7M0E8X12VY8W17T5G.QC&F<OPZ^T+G=MRCT=N8ZVU^M1>+QH.L1.135\$5WMT67^ZLLR2
Z6VVK@>+0^Z^V+FA95WQML7^QJ.MJO.231^>E@01#2&3F845^NTO+D12R(1^>H^MS2^>OYIM+>PIR19^>M41.88Y.M@16N9DV^+WGP_16+T1L5_DR<1EP:>#N=G
M#6JR.JE9.10GW2Q0^Y.2HB0Q1^>W^N^X^Y^GV0(GYH^>^J^>+>^>U2\$1<71KCLEPXF.T2&#P5^YIO4>ZIBHL&8V19J.E=1#4<#R.
M1TQCS&^0D^@/Q-1S9717OKCAY^%O.N4ZZ.V%1^MM^C^J^O2NU1^CXJ914>9BRAE(6A1.9S1NB)(H^M410MBB^A^<MU3^212CYP1^>7H^WW.E=1^M1.1513.(%X+BF1^P06+F#
14F^>+1.P@/5^M.CJH51HKOW+T.M4DFN.W.H33^F%1^>@X%.WMRF^>C6V^>3.IH8E^>Q2NM6^1H.RK@|S&KTFU^PG.MJ^BBYGY072%1931%+
VY@KJH3ZJURJAO01^>DME75R0PFGS^N8Y6.M+K6Z^>QX2KN9BW^GS.DP^>P123<5<1^J7A.OJEE@531YV=^#1.HN^2^K.MAJPRK1H^>A7^>P-273RD51+>2^>(TDSX^>
HWO_616/J3M^R@=(M.G8M51^M47+>1%|B6JNH.XBZ^>X^Y01U916:15OAI6LS1E2F9>DV6.K(412^M^U2^S^U0TM^>8M^OM<+A7W^X^>6G\$5J62135^#O.O(ODS^>
M1X8D188ZIO.N@G@Q^FJR^<Z=RX&XQ.T2^1(XO7451D>7@>QOO&XV.NMD9J.1ADS8TOZ1AH0HUZ^10.EJAJ2XS0^W8O678NN@5FVQOK0(LSP.58HV1^L.M!
GCA1H.VR.^A9C04P^UE@9F^O3K0S.WYR6^#J9JKZ^>XOW8.M2MB1M^>+F^R^>#^>H1^<4L<B+>G12ZDM67A.7X+O@9^>KWXP^JH^>^>A^>+V.MXFS.IOMN^>VVFZ^>Z4-9U.
SX1A.P.EEEL.70@RW7A1Y4F1U4.X^>INZIM.MN1PC4X^>2T^U.P.P7_#63+H>#>^N.MX1DL.T1^>428.1+L.A15G1Q8051^>Y\$K&INI.C<6.P.W(4Y3NKD/G
MFTIRTRF6VH1Z^>A01M7>1<1V^FE.G042W51>BZ^>F0J3K1@>@>N^TX1L.G.M^P2.VIWF^>30H(8<2GL15U4C(=<G%3/69@92^>8RD900.3F&^>V5=9<4^H.ML1H18=<6%2B1^Y.W&
MFTEDWYPPG021E^>=(FW5>R1^M21N56\$LS131^>CBJ.70^>3K1WE1F.DU.4Z49^>T\$H2.YAD31H^>NGL.M3HHS.M.L^>41XJ^>R^>PJBNZ1^>15H102
FPC_6Y=Z^>S^>8^GEW\$K12715>7.BIG1\$^M5R1D0X&A1.U^>A.YBUH.^H1Z1=>3343^1A1^>EUBFIR12PSM>7F=M1QROT<1^>81#^>Y1I09\$>ZLGFZ5.C041Z^>8.84P
M1A#&6^>87D\$>=>IRTEAEGG.7(KYTHJUP@>O^>X&X^>UABER@CMW9&G2H.M^>#N#>1^>D1>ZD>G@>FNT0^>CNB7^>FY3.H+P+169KIS^>C041Z^>IV.M.^>
I^N^>X.3^>F^H^>NFP.B.=>P708^>1@<\$U^>+M1^>G^H1YMH18Y@>N^H1XJ.B1P^>H&U4>#>KQ.MN<=>UJ1^>+1.(KD219>A10>12+HJ1N@>+>4^>F6BN1^>2^>F&9C.^>9W5M7H/6
MMZNRUS.SG1A1^>@>@>E0101^>2\$>AQV4@>+4Y<83+6>JL@NL.P^>XP51H^>6^>X.JAH8=>1^>@>AX9KT+>X^>E.G1>F^>BY^>M=M6X94^>4^K4HKC(INJ)^>PS1LQ072ACIT^>90=31^>IW.
^RMFANZ095.9JPD^>M4JZIESMOV177.A1R1&0VS^>Y^>3G&K.WY^>1^>A31^>OJZ46^>7DF+5C>2+V.MZSLJPSH^>UE4<Z^>H^>61L2RW^>U^>V637%OZ.B^>5QBJOR^>#>87@9#
V^>TSDS4^>M1^>1&^>CHZVY>P02^>LW.F6K2Q^>O.NU18W^>A^KC<K15^>A^>#>#>O.^>U1+P04.M^>^>S@>U1Z^>PZ.0^>=0.Q^>EC0F0M.C.R^>#R.S^>7%>6B+GAM.M.U^>H^>W/D^>+>8=T^>
X^>1S9DJUNRI.FB=8C@RJB.M.ZPBZ12^>7VUOLD^>O6%4<B1P1SA^>W.VHD1^>82B40B^>X^>I/ZL<^>R.RIC.MQ31H^>1^>FXAM^>BR.
^>=>F7^>Y.3N^>+B^>(56=>%>F2LX1^>T5<6^>9^>^>M^>1.J3GZF12V3FJDX97.GARL.F&2%W^>WE^>(DHX\$D4E.OE^>WSS51>8^>I/ZI
MO+Q1^>6AS^>1G1Y>=>S^>11=>O0W5^>X^>UW1^>0^>